User Image Cart Icon 0 Search Image

Stem Cell Therapy

  1. Stem cell therapy in perspective
  2. Adult Stem cell therapy in perspective
  3. Stem cell therapy for human neurodegenerative disorders–how to make it work
  4. Stable benefit of embryonic Stem cell therapy in myocardial infarction
  5. Stem–cell therapy for diabetes mellitus
  6. New prospects for human Stem–cell therapy in the nervous syStem
  7. Neural Stem cell therapy for neurological diseases: dreams and reality
  8. Stem cell therapy in a caprine model of osteoarthritis
  9. Stem cell therapy and gene transfer for regeneration
  10. Adult Stem cell therapy for the heart
  11. Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans
  12. Nonmyeloablative Stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of …
  13. Mesenchymal Stem cell therapy in joint disease
  14. The effect of neural embryonic Stem cell therapy in a rat model of cavernosal nerve injury
  15. Stem–cell therapy for amyotrophic lateral sclerosis
  16. Potential of hematopoietic Stem cell therapy in hepatology: a critical review
  17. Becoming immortal: Combining cloning and Stem–cell therapy
  18. 28. Embryonic and adult Stem cell therapy
  19. Dentin regeneration by dental pulp Stem cell therapy with recombinant human bone morphogenetic protein 2
  20. Stem cell and precursor cell therapy
  21. Stem cell therapy for ischemic heart disease
  22. Intervertebral disc cell therapy for regeneration: mesenchymal Stem cell implantation in rat intervertebral discs
  23. Stem cell therapy for ocular disorders
  24. Potential Stem cell therapy and application in neurotrauma
  25. Stem cell therapy of the liver—fusion or fiction?
  26. Stem cell therapy for diabetes: do we need to make beta cells?
  27. Stem cell therapy for myocardial repair: is it arrhythmogenic?
  28. Neural Stem cell therapy in the aging brain: pitfalls and possibilities
  29. Stem cell therapy for urinary incontinence
  30. Stem–cell therapy for renal diseases
  31. Stem cell therapy forcerebral palsy
  32. Genetically engineered Stem cell therapy for tissue regeneration
  33. Emerging neuroprotective strategies for Alzheimer’s disease: dietary restriction, telomerase activation, and Stem cell therapy
  34. Hematopoietic Stem cell therapy for type 1 diabetes: induction of tolerance and islet cell neogenesis
  35. In utero Stem cell therapy.
  36. Stem cell therapy for Parkinson’s disease: where do we stand?
  37. Stem cell therapy for the infarcted heart (“cellular cardiomyoplasty”)
  38. Monitoring Stem cell therapy in vivo using magnetodendrimers as a new class of cellular MR contrast agents
  39. Stem cell therapy for muscular dystrophy
  40. Stem cell therapy in ischemic heart disease
  41. Adult Stem cell therapy for heart failure
  42. Stem–cell therapy for myocardial diseases
  43. Stem cell therapy for the heart
  44. Stem cell therapy of cardiac disease: an update
  45. Applications of magnetic resonance imaging for cardiac Stem cell therapy
  46. The origin and development of the immune syStem with a view to Stem cell therapy
  47. Stem cell origin of cancer and differentiation therapy
  48. Novel approaches to allogeneic Stem cell therapy
  49. Autologous bone marrow-derived Stem cell therapy in combination with TMLR. A novel therapeutic option for endstage coronary heart disease: report on 2 cases.
  50. Immune ablation and Stem–cell therapy in autoimmune disease-Clinical experience
  51. Stem–cell therapy for amyotrophic lateral sclerosis
  52. Stem cell therapy for neurodegenerative diseases: the issue of transdifferentiation
  53. Hematopoietic Stem cell therapy of autoimmune diseases.
  54. Three-dimensional approach to Stem cell therapy
  55. Editorial Stem cell therapy in human ALS
  56. Stem cell therapy in utero
  57. Human embryonic Stem cell therapy
  58. Stem cell plasticity: the growing potential of cellular therapy
  59. Pancreatic islet and Stem cell transplantation: new strategies in cell therapy of diabetes mellitus.
  60. Cardiovascular disease: potential impact of Stem cell therapy
  61. From Stem cells to beta cells: new strategies in cell therapy of diabetes mellitus
  62. Additional Stem cell therapy for graft failure after allogeneic bone marrow transplantation
  63. Stem cell therapy for ALS: Hope and Reality A discussion paper from the Executive of the European ALS Consortium
  64. Allogeneic cell therapy for patients who relapse after autologous Stem cell transplantation
  65. Stem cell plasticity or fusion: two approaches to targeted cell therapy
  66. Augmentation of virus-specific immunity after hematopoietic Stem cell transplantation by adoptive T-cell therapy
  67. Stem cell therapy for myocardial infarction
  68. Stem cell therapy in acute myocardial infarction
  69. Stem cell therapy for neurological disease and injury.
  70. Correction of ADA-SCID by Stem cell gene therapy combined with nonmyeloablative conditioning
  71. Stem cell therapy for urinary incontinence and pelvic floor disorders: a novel approach
  72. Bone-marrow Stem cells as a source for cell therapy
  73. Stem–cell therapy: what dose should we use?
  74. Stem‐cell plasticity and therapy for injuries of the peripheral nervous syStem
  75. Public Stem cell banks: considerations of justice in Stem cell research and therapy
  76. Hematopoietic Stem cell compartment: acute and late effects of radiation therapy and chemotherapy
  77. Immune ablation and Stem–cell therapy in autoimmune disease: experimental basis for autologous Stem–cell transplantation
  78. Stem cells for cell therapy in Parkinson’s disease
  79. Dendritic-cell therapy after non-myeloablative Stem–cell transplantation for renal-cell carcinoma
  80. Nuclear transplantation, embryonic Stem cells and the potential for cell therapy
  81. Mylotarg™(gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received Stem cell transplantation
  82. cell therapy: Stem cell transplantation, gene therapy, and cellular immunotherapy
  83. Comparison of high-dose therapy and autologous Stem–cell transplantation with conventional therapy for Hodgkin’s disease induction failure: a case-control study
  84. Autologous Stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn’s disease: a new cell-based therapy
  85. Current status and perspectives of Stem cell therapy for the treatment of diabetes mellitus
  86. Neural Stem cells in the developing central nervous syStem: implications for cell therapy through transplantation
  87. Nuclear transplantation, embryonic Stem cells, and the potential for cell therapy
  88. Exogenously regulated Stem cell-mediated gene therapy for bone regeneration
  89. The potential for Stem cell therapy in cystic fibrosis.
  90. High-dose therapy with autologous Stem cell transplantation in patients with peripheral T cell lymphomas
  91. Neuroreplacement therapy and Stem cell biology under disease conditions
  92. Stem cell gene therapy for chronic renal failure
  93. In utero hematopoietic Stem cell therapy
  94. Embryonic Stem cell therapy in experimental stroke: host-dependent malignant transformation
  95. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic Stem–cell transplantation with virus-specific T-cell lines
  96. Prostate Stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate
  97. Influenza infections after hematopoietic Stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy
  98. Music therapy for mood disturbance during hospitalization for autologous Stem cell transplantation: a randomized controlled trial
  99. The potential of marrow stromal cells in Stem cell therapy
  100. cell therapy using human embryonic Stem cells
  101. Impact on survival of high-dose therapy with autologous Stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population …
  102. High-dose therapy and autologous peripheral blood Stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential …
  103. High‐dose therapy with autologous haemopoietic Stem cell support for Waldenström’s macroglobulinaemia
  104. A new concept of Stem cell disorders and their new therapy
  105. … response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic Stem cell transplantation. Myeloma Subcommittee of the …
  106. Autologous peripheral hematopoietic Stem cell transplantation restores hematopoietic function following marrow ablative therapy
  107. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous Stem cell transplantation for relapsed B cell lymphomas
  108. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic Stem cell transplantation
  109. Paradigms of adult Stem cell therapy for type 1 diabetes in mice
  110. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic Stem–cell transplantation
  111. … ablation and Stem–cell therapy in autoimmune disease Immunological reconstitution after high-dose immunosuppression and haematopoietic Stem–cell …
  112. Rituximab and ICE as second-line therapy before autologous Stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma
  113. Heal thyself: Potential applicability of Stem cell therapy in the management of heart disease
  114. Stem cell therapy for autoimmune disease: overview of concepts from the Snowbird 2002 tolerance and tissue regeneration meeting
  115. The graft-versus-tumor potential of allogeneic cell therapy: an update on donor leukocyte infusions and nonmyeloablative allogeneic Stem cell transplantation
  116. High-dose immunosuppressive therapy and autologous peripheral blood Stem cell transplantation for severe multiple sclerosis
  117. … impact of cytomegalovirus serostatus of donor and recipient before hematopoietic Stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy
  118. Innovative approaches of adoptive immune cell therapy in paediatric recipients of haematopoietic Stem cell transplantation
  119. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic Stem cell transplantation: risk factors, correlation with DNA …
  120. Prognostic factors for survival and response after high‐dose therapy and autologous Stem cell transplantation in syStemic AL amyloidosis: a report on 21 patients
  121. Parainfluenza virus infections after hematopoietic Stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome
  122. High-dose therapy and autologous peripheral blood Stem cell transplantation for patients with lymphoma
  123. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy
  124. 486: Stem cell therapy in Treatment of Urinary Incontinence: First Clinical Results
  125. Mesenchymal Stem–cell therapy in a regulated environment
  126. therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous Stem cell transplantation
  127. Stem cell therapy in scleroderma
  128. High-dose therapy and autologous blood Stem cell transplantation in POEMS syndrome
  129. First-line therapy with thalidomide and dexamethasone in preparation for autologous Stem cell transplantation for multiple myeloma
  130. Intensive therapy with peripheral Stem cell transplantation in 16 patients with mantle cell lymphoma
  131. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic Stem cell transplantation: Presented in …
  132. Infectious complications after allogeneic Stem cell transplantation: epidemiology and interventional therapy strategies
  133. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and Stem–cell rescue: results of the Chicago Pilot II Study
  134. Viral interleukin-10–engineered autologous hematopoietic Stem cell therapy: a novel gene therapy approach to prevent graft rejection
  135. The role of cytotoxic therapy with hematopoietic Stem cell transplantation in the therapy of multiple myeloma: an evidence-based review
  136. Thoracic transplantation and Stem cell therapy
  137. High-dose therapy with Stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience
  138. P75. Feasibility of Stem cell therapy for intervertebral disc degeneration
  139. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic Stem cell transplantation: a phase …
  140. Imatinib mesylate therapy for relapse after allogeneic Stem cell transplantation for chronic myelogenous leukemia
  141. High-dose therapy and autologous Stem cell transplantation for multiple myeloma poorly responsive to initial therapy
  142. Prognostic factors for survival after high-dose therapy and autologous Stem cell transplantation for patients with relapsing Hodgkin’s disease: analysis of 280 patients …
  143. Should immunoglobulin therapy be used in allogeneic Stem–cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial
  144. Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood Stem cell support
  145. Relationship between spermatogonial Stem cell survival and testis function after cytotoxic therapy.
  146. High-dose melphalan, etoposide, total-body irradiation, and autologous Stem–cell reconstitution as consolidation therapy for high-risk Ewing’s sarcoma does not …
  147. High-dose therapy and autologous Stem–cell transplantation for adult patients with Hodgkin’s disease who do not enter remission after induction chemotherapy: results …
  148. The role of high-dose therapy and autologous hematopoietic Stem cell transplantation for mantle cell lymphoma
  149. Stem cell strategies for neuroreplacement therapy in Alzheimer’s disease
  150. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic Stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation
  151. High-dose intravenous melphalan and autologous Stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of …
  152. Blood Stem cell transplantation as therapy for primary syStemic amyloidosis (AL)
  153. … dose therapy and autologous Stem–cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients …
  154. Endocrine complications of high‐dose therapy with Stem cell transplantation
  155. A human umbilical cord Stem cell rescue therapy in a murine model of toxic liver injury
  156. High-dose therapy and autologous haematopoietic Stem–cell transplantation for HIV-1-associated lymphoma
  157. Hematopoietic Stem cell transplantation: a new therapy for autoimmune disease
  158. Implications of long-term survival in acute Stem cell leukemia of childhood treated with composite cyclic therapy
  159. … and autologous peripheral-blood Stem–cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy
  160. Pluripotent Stem cells–model of embryonic development, tool for gene targeting, and basis of cell therapy
  161. Sequential chemotherapy regimens followed by high-dose therapy with Stem cell transplantation in mantle cell lymphoma: an update of a prospective study
  162. Adult Burkitt’s and Burkitt-like non-Hodgkin’s lymphoma–outcome for patients treated with high-dose therapy and autologous Stem–cell transplantation in first remission …
  163. Hematopoietic Stem cell gene therapy: selecting only the best
  164. … reconstitution after autologous hematopoietic Stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications
  165. … followed by high-dose therapy with Stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell …
  166. High-dose therapy and autologous Stem–cell support for chemosensitive transformed low-grade follicular non-Hodgkin’s lymphoma: a case-matched study from the …
  167. Hormonal replacement therapy after Stem cell transplantation
  168. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic Stem cell transplantation for relapsed follicular non-Hodgkin …
  169. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and Stem cell rescue
  170. Myeloablative therapy with blood Stem cell transplantation is effective in mantle cell lymphoma.
  171. Temporary corneal Stem cell dysfunction after radiation therapy.
  172. Early autologous Stem–cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin’s lymphoma: an Italian …
  173. Therapeutic Effects of Massage therapy and Healing Touch on Caregivers of Patients Undergoing Autologous Hematopoietic Stem cell Transplant.
  174. Progress toward vector design for hematopoietic Stem cell gene therapy
  175. Embryonic and adult Stem cells as a source for cell therapy in Parkinson’s disease
  176. High-dose therapy followed by autologous hematopoietic Stem–cell infusion for patients with multiple myeloma.
  177. … relapsed or refractory Hodgkin’s disease treated with high-dose chemotherapy and Stem cell rescue at the time of maximal response to conventional salvage therapy …
  178. cell-replacement therapy with Stem cells in neurodegenerative diseases
  179. Retroviral Stem cell gene therapy
  180. Mesenchymal Stem cells: cell biology and potential use in therapy
  181. High-dose therapy followed by autologous peripheral-blood Stem–cell transplantation for patients with Hodgkin’s disease and non-Hodgkin’s lymphoma using …
  182. Human pancreatic Stem cell and diabetes cell therapy
  183. The role of cytotoxic therapy with hematopoietic Stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin’s lymphoma: an evidence …
  184. Current antiviral strategies for controlling cytomegalovirus in hematopoietic Stem cell transplant recipients: prevention and therapy
  185. Risk to the coronary arteries of intracoronary Stem cell infusion and G-CSF cytokine therapy.
  186. High-dose therapy and autologous Stem cell rescue for patients with Hodgkin’s disease in first relapse after chemotherapy: results from the EBMT
  187. Therapeutic cloning and Stem cell therapy
  188. Stem cells in cardiovascular disease: from cell biology to clinical therapy
  189. … emission tomography with [18F] 2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with Stem cell …
  190. … photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic Stem cell …
  191. Haematopoietic Stem cell transplantation and gene therapy in the fetus: ready for clinical use?
  192. High-dose therapy plus autologous hematopoietic Stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV …
  193. … -emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic Stem cell transplantation: a single …
  194. Stem cell transplantation therapy: controversy over ethical issues and clinical relevance.
  195. Adult Stem cell technology-prospects for cell based therapy in regenerative medicine
  196. High-dose chemotherapy followed by autologous Stem cell transplantation as first-line therapy in aggressive non-Hodgkin’s lymphoma: a meta-analysis
  197. Second malignancy following high-dose therapy and autologous Stem cell transplantation: incidence and risk factor analysis
  198. Epstein-Barr virus (EBV) reactivation in allogeneic Stem–cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy
  199. Myeloablative radiochemotherapy followed by autologous peripheral blood Stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of …
  200. High-dose therapy with autologous Stem–cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the …
  201. High-dose corticosteroid therapy for diffuse alveolar hemorrhage in allogeneic bone marrow Stem cell transplant recipients
  202. Hematopoietic Stem cell gene therapy: progress toward therapeutic targets
  203. Stem cell biology and gene therapy
  204. High-dose therapy with autologous Stem cell rescue for pediatric sarcomas
  205. … lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic Stem cell transplantation for severe …
  206. Parainfluenza virus type 3 infections in hematopoetic Stem cell transplant recipients: response to ribavirin therapy
  207. 10 Current status of Stem cell therapy and prospects for gene therapy for the disorders of globin synthesis
  208. Hematopoietic Stem cell gene therapy
  209. Stem cell Gene therapy for the β‐Chain Hemoglobinopathies: Problems and Progressa
  210. Hematopoietic Stem cell depletion by restorative growth factor regimens during repeated high-dose cyclophosphamide therapy [see comments]
  211. High-dose consolidation therapy with autologous Stem cell rescue in stage IV breast cancer.
  212. High-dose therapy/autologous Stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission
  213. Stem cell therapy and research
  214. High-dose immunoablative therapy with hematopoietic Stem cell support in the treatment of severe autoimmune disease: current status and future direction
  215. High-dose chemotherapy (HDC) and autologous hematopoietic Stem cell transplantation (ASCT) as salvage therapy for relapsed osteosarcoma
  216. High-dose consolidation therapy with autologous Stem–cell rescue in stage IV breast cancer: follow-up report.
  217. Toward Epidermal Stem cell-Mediated ex Vivo Gene therapy of Junctional Epidermolysis Bullosa
  218. Mesenchymal Stem cells from the bone marrow stroma: basic biology and potential for cell therapy
  219. High-dose multimodality therapy with autologous Stem–cell support for stage IIIB breast carcinoma.
  220. … load in plasma allows for fast and accurate prediction of response to therapy of Epstein–Barr virus‐associated lymphoproliferative disease after allogeneic Stem cell …
  221. Single agent dexamethasone for pre-Stem cell transplant induction therapy for multiple myeloma
  222. Efficacy of high-dose therapy and autologous hematopoietic Stem cell transplantation for non-Hodgkin’s lymphoma in adults 60 years of age and older
  223. Arsenic Trioxide (Trisenox®) therapy for Acute Promyelocytic Leukemia in the Setting of Hematopoietic Stem cell Transplantation
  224. Pre-emptive oral ribavirin therapy of paramyxovirus infections after haematopoietic Stem cell transplantation: a pilot study
  225. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and Stem cell …
  226. … high-dose cyclophosphamide without Stem cell rescue in paraneoplastic pemphigus: report of a case and review of this new therapy for severe autoimmune disease
  227. High dose therapy and autologous Stem cell transplantation for human immunodeficiency virus‐associated non‐Hodgkin lymphoma in the era of highly active …
  228. Autologous peripheral blood Stem cell transplantation after high dose therapy in patients with advanced lymphomas.
  229. Hematopoietic Stem cell gene therapy: a current overview.
  230. Muscle-derived Stem cells: characterization and potential for cell-mediated therapy
  231. Immunotherapy with rituximab following high-dose therapy and autologous Stem–cell transplantation for mantle cell lymphoma
  232. Improved cerebrovascular patency following therapy in patients with sickle cell disease: initial results in 4 patients who received HLA‐identical hematopoietic Stem cell …
  233. … with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood Stem cell transplantation in elderly …
  234. therapy with imatinib mesylate (Glivec) preceding allogeneic Stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute …
  235. High-activity samarium-153-EDTMP therapy followed by autologous peripheral blood Stem cell support in unresectable osteosarcoma
  236. Benefit of aggressive multimodality therapy with autologous Stem cell support for intra-abdominal desmoplastic small round cell tumor
  237. Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic Stem cell transplantation
  238. Stem–cell therapy for myocardial diseases
  239. Cytokine production during myeloablative and reduced intensity therapy before allogeneic Stem cell transplantation
  240. High risk of therapy-related leukemia after BEAM chemotherapy and autologous Stem cell transplantation for previously treated lymphomas is mainly related to primary …
  241. Diamond-Blackfan anemia in Japan: clinical outcomes of prednisolone therapy and hematopoietic Stem cell transplantation
  242. Results of high-dose therapy and autologous bone marrow/Stem cell transplantation during remission in poor-risk intermediate-and high-grade lymphoma …
  243. Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic Stem cell …
  244. High-dose therapy in lymphomas: a review of the current status of allogeneic and autologous Stem cell transplantation in Hodgkin’s disease and non-Hodgkin’s …
  245. Melphalan-associated pulmonary toxicity following high-dose therapy with autologous hematopoietic Stem cell transplantation
  246. Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous Stem cell transplant
  247. Stem cell gene therapy, position effects and chromatin insulators
  248. Role for high-dose therapy with autologous hematopoietic Stem cell support in Waldenstrom’s macroglobulinemia
  249. The hematopoietic Stem cell therapy for exploration of deep space
  250. … mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic Stem cell transplantation: a prospective …
  251. … determinant (CD) 34+ cell dose on the cost and consequences of peripheral blood Stem cell transplantation for non-Hodgkin’s lymphoma patients in front-line therapy
  252. Sequential high-dose therapy and autologous Stem cell transplantation for treatment of mantle cell lymphoma
  253. High-dose therapy and autologous Stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive …
  254. Adult mesenchymal Stem cells: characterization, differentiation, and application in cell and gene therapy
  255. Evaluation of the risk of therapy-related MDS/AML after autologous Stem cell transplantation
  256. Intensification of therapy using hematopoietic Stem‐cell support for high‐risk neuroblastoma
  257. Strategies for hematopoietic Stem cell gene therapy: insights from computer simulation studies
  258. A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic hematopoietic Stem cell transplantation
  259. Stem cell defects after cytoreductive therapy in man.
  260. … with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or Stem cell rescue therapy
  261. Myeloma cell contamination of peripheral blood Stem cell grafts in patients with multiple myeloma treated by high-dose therapy.
  262. Embryonic Stem cell grafting: the therapy of the future?
  263. Transabdominal first trimester embryofetoscopy as a potential approach to early in utero Stem cell transplantation and gene therapy
  264. Single center experience of a new intensive induction therapy for Ewing’s family of tumors: feasibility, toxicity, and Stem cell mobilization properties
  265. Pre-emptive therapy with rituximab for prevention of Epstein–Barr virus-associated lymphoproliferative disease after hematopoietic Stem cell transplantation
  266. High-dose therapy and autologous Stem cell transplantation in relapsing cutaneous lymphoma
  267. Peripheral blood Stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study
  268. … (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin’s lymphoma after high-dose therapy and autologous peripheral Stem cell …
  269. Where next with Stem–cell-supported high-dose therapy for breast cancer?
  270. Clonotypic CD20+ and CD19+ B cells in peripheral blood of patients with multiple myeloma post high‐dose therapy and peripheral blood Stem cell transplantation
  271. Lymphoid development and function in X-linked severe combined immunodeficiency mice after Stem cell gene therapy
  272. Consolidation therapy with autologous Stem cell transplantation in plasma cell leukemia after VAD, high-dose cyclophosphamide and EDAP courses: a report of three …
  273. Analysis of feasibility of myeloablative therapy and autologous peripheral Stem cell (PBSC) transplantation in the elderly: an interim report
  274. Embryonic Stem cells in vitro-prospects for cell and developmental biology, embryotoxicology and cell therapy
  275. Peripheral blood Stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood …
  276. An update on the role of high-dose therapy with autologous or allogeneic Stem cell transplantation in mantle cell lymphoma
  277. Hematopoietic Stem cell transplantation for cancer therapy
  278. Hematopoietic Stem cell gene therapy leads to marked visceral organ improvements and a delayed onset of neurological abnormalities in the acid …
  279. Hematopoietic Stem cell gene therapy of murine protoporphyria by methylguanine-DNA-methyltransferase-mediated in vivo drug selection
  280. Superiority of double over single autologous Stem cell transplantation as first-line therapy for multiple myeloma.
  281. … (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic Stem cell …
  282. Twelve years experience with high-dose therapy and autologous Stem cell transplantation for high-risk Hodgkin’s disease patients in first remission after MOPP/ABVD …
  283. Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood Stem cell transplantation
  284. The role of autologous Stem cell reconstitution in intensive therapy for resistant neoplasms
  285. Nonmyeloablative therapy and allogeneic hematopoietic Stem cell transplantation
  286. Decitabine with allogeneic peripheral blood Stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study
  287. Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous Stem cell transplantation for salvage therapy in B-NHL
  288. The place of high-dose therapy with haemopoietic Stem cell transplantation in relapsed and refractory Hodgkin’s disease
  289. siRNAs, ribozymes and RNA decoys in modeling Stem cell-based gene therapy for HIV/AIDS.
  290. Clinically‐based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic Stem cell …
  291. Embryonic Stem cell research and therapy: the need for a common European legal framework
  292. … high-dose chemotherapy with granulocyte colony-stimulating factor and autologous Stem–cell transplantation support as first-line therapy in high-risk diffuse large-cell …
  293. Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood Stem cell transplantation …
  294. Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood Stem cell transplantation in children: results of a prospective …
  295. Nutritional support of the patient receiving high-dose therapy with hematopoietic Stem cell support
  296. … Stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with α/β hepatosplenic T-cell …
  297. … boydii) brain abscess during therapy for invasive pulmonary aspergillosis following high‐risk allogeneic hematopoietic Stem cell transplantation. Scedosporiasis and …
  298. Optimization of recombinant human erythropoietin therapy after allogeneic hematopoietic Stem cell transplantation
  299. … long‐term hematologic recovery despite a marked quantitative defect in the Stem cell compartment of patients with aplastic anemia after immunosuppressive therapy
  300. Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic Stem cell transplant …
  301. Potential use of human Stem cell factor as adjunctive therapy for human immunodeficiency virus-related cytopenias
  302. Effectiveness of high‐dose MCNU therapy and hematopoietic Stem cell autografts treatment of childhood acute leukemia/lymphoma with high‐risk features
  303. Interleukin-2 therapy after bone marrow or Stem cell transplantation for hematologic malignancies.
  304. Cytokines: value-added products in hematopoietic Stem cell gene therapy
  305. … of Multiple Myeloma and Breast Cancer cells by TH9402‐mediated Photodynamic therapy: Implication for Clinical Ex Vivo Purging of Autologous Stem cell …
  306. Antimicrobial therapy of febrile complications after high-dose chemo-/radiotherapy and autologous hematopoietic Stem cell transplantation
  307. Autologous Stem cell transplantation for AL amyloidosis: a standard therapy?
  308. A prospective randomized trial of granulocyte colony-stimulating factor therapy after autologous blood Stem cell transplantation in adults
  309. Hematopoietic Stem cell gene therapy: towards clinically significant gene transfer efficiency.
  310. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic Stem cell transplantation in Philadelphia chromosome–positive acute …
  311. Search for a cure for idiopathic pulmonary fibrosis: is Stem cell therapy a light at the end of a long tunnel?
  312. Stem cell Transplantationfor Leukemias Following Myelodysplastic Syndromesor Secondaryto Cytotoxic therapy
  313. Hematopoietic Stem cell–based gene therapy for acquired immunodeficiency syndrome: efficient transduction and expression of RevM10 in myeloid cells in vivo and …
  314. Stem cell therapy (Aastrom Biosciences Inc).
  315. High-dose chemotherapy with Stem cell rescue as initial therapy for anaplastic oligodendroglioma
  316. Directed mobilization of endogenous neural progenitor cells: the intersection of Stem cell biology and gene therapy.
  317. High‐dose intravenous methotrexate followed by autologous Stem cell transplantation as a potentially effective therapy for neurolymphomatosis
  318. 6The role of haematopoietic Stem cell-supported myeloablative therapy for the management of multiple myeloma
  319. Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood Stem cell transplantation
  320. Early intensive therapy with autologous Stem cell transplantation in advanced Hodgkin’s disease: retrospective analysis of 158 cases from the French registry
  321. Ultrasound-guided Stem cell sampling from the early ovine fetus for prenatal ex vivo gene therapy
  322. Hematopoietic Stem cell therapy for multiple sclerosis
  323. The remission status before and the PCR status after high-dose therapy with peripheral blood Stem cell support are prognostic factors for relapse-free survival in …
  324. Hematopoietic Stem cell gene replacement therapy
  325. … by non-myeloablative allogeneic Stem cell transplantation in multiple myeloma: results of a pilot study as salvage therapy after autologous transplantation
  326. Peripheral blood Stem cell transplantation after high-dose therapy in patients with malignant lymphoma: a retrospective comparison with autologous bone marrow …
  327. Stem cell therapy for intervertebral disc diseases in vitro and in vivo feasibility study
  328. The leukemogenic risk of integrating retroviral vectors in hematopoietic Stem cell gene therapy applications.
  329. Functional organization of the hematopoietic Stem cell compartment: implications for cancer and its therapy.
  330. The importance of CD34+/CD33− cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood Stem cell rescue
  331. … suppression and autologous hematopoietic Stem cell transplantation in severe Crohn’s disease refractory to immunosuppressive and immunomodulator therapy
  332. Micro-injection-mediated hematopoietic Stem cell gene therapy.
  333. Early allogeneic blood Stem cell transplantation after modified conditioning therapy during marrow aplasia: stable remission in high-risk acute myeloid …
  334. Fetal immune suppression as adjunctive therapy for in utero hematopoietic Stem cell transplantation in nonhuman primates
  335. Development of a modified selective amplifier gene for hematopoietic Stem cell gene therapy
  336. Embryonic Stem cells: a promising tool for cell replacement therapy
  337. Clinical benefits of granulocyte colony-stimulating factor therapy after hematopoietic Stem cell transplant in children: results of a prospective randomized trial
  338. Value of autologous Stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS …
  339. Late infectious complications after high-dose therapy and autologous blood Stem cell transplantation
  340. Stem cell gene therapy: a breakthrough combination magnified by therapeutic Stem cell homing
  341. Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous Stem cell transplantation
  342. Peripheral blood Stem cell mobilization following CHOP plus rituximab therapy combined with G-CSF in patients with B-cell non-Hodgkin’s lymphoma
  343. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis after Stem cell transplantation: effective monitoring of CMV infection by quantitative …
  344. Highly active antiretroviral therapy corrects hematopoiesis in HIV-1 infected patients: interest for peripheral blood Stem cell-based gene therapy
  345. Feasibility of multidrug resistance (MDR-1) gene transfer in patients undergoing high-dose therapy and peripheral blood Stem cell transplantation for lymphoma
  346. Platelet flow cytometric findings in patients undergoing conditioning therapy for allogeneic hematopoietic Stem cell transplantation
  347. Recombinant human erythropoietin therapy is very effective after an autologous peripheral blood Stem cell transplant when started soon after engraftment
  348. Bone marrow Stem cell gene therapy of arylsulfatase A-deficient mice, using an arylsulfatase A mutant that is hypersecreted from retrovirally transduced donor-type …
  349. Front-line high-dose therapy with autologous Stem cell transplantation for high risk Hodgkin’s disease: comparison with combined-modality therapy
  350. Anti-CD20 monoclonal antibody therapy for autoimmune hemolytic anemia following T cell-depleted, haplo-identical Stem cell transplantation
  351. Plasticity of skeletal muscle differentiation generating Stem cell-like phenotype: Possible application to cell therapy for muscular diseases
  352. The Hematopoietic Stem cell therapy for Exploration of Space
  353. Selective expansion of transduced cells for hematopoietic Stem cell gene therapy
  354. Progress towards hematopoietic Stem cell gene therapy.
  355. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic Stem cell …
  356. When to harvest peripheral-blood Stem cells after mobilization therapy: prediction of CD34-positive cell yield by preceding day CD34-positive concentration in …
  357. Globin gene transfer for the treatment of severe hemoglobinopathies: a paradigm for Stem cell‐based gene therapy
  358. Autologous blood Stem cell transplantation as therapy for autoimmune diseases
  359. High‐dose therapy/Stem cell support: Comparison of mice and humans
  360. High‐dose therapy with Stem cell rescue for pediatric solid tumors: Rationale and results
  361. Transfusion therapy in the patient undergoing hematopoietic Stem cell transplantation
  362. Long-term follow-up on a patient with incomplete POEMS syndrome undergoing high-dose therapy and autologous blood Stem cell transplantation
  363. Intra-muscular vidarabine therapy for polyomavirus-associated hemorrhagic cystitis following allogeneic hemopoietic Stem cell transplantation
  364. Multivalent anti-CCR5 ribozymes for Stem cell-based HIV type 1 gene therapy
  365. Renal dysfunction during high-dose cisplatin therapy and autologous hematopoietic Stem cell transplantation: effect of aminoglycoside therapy
  366. High-dose therapy with Stem–cell transplantation in the malignant lymphomas.
  367. … Stem and progenitor cells from acid sphingomyelinase-deficient mice: implications for Niemann-Pick disease gene therapy and the development of improved Stem cell …
  368. Treatment of mantle-cell lymphomas with the VAD+/− chiorambucil regimen with or without subsequent high-dose therapy and peripheral blood Stem–cell …
  369. … Stem cell transplantation as post-remission therapy in adult acute myelogenous leukemia: does platelet contamination of peripheral blood mobilized Stem cell grafts …
  370. High-dose therapy and autologous peripheral Stem cell transplantation for patients with bone marrow metastases and relapsed lymphoma: an alternative to bone …
  371. … of the tumor load predicts progressive disease in patients with multiple myeloma after high-dose therapy with autologous peripheral blood Stem cell …
  372. Technology evaluation: Stem–cell therapy, Aastrom Biosciences Inc.
  373. … colony stimulating factor for the treatment of delayed engraftment following high dose therapy and autologous hematopoietic Stem cell transplantation for lymphoid …
  374. The present role of bone marrow and Stem cell transplantation in the therapy of children with acute leukemia.
  375. Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H. 82 with autologous Stem cell support and cyclosporin A
  376. Stem cell transplantation and gene therapy for HIV-related lymphomas
  377. High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood Stem cell support in the adjuvant therapy of high-risk breast cancer: a practical …
  378. High-dose therapy and Stem cell transplantation in follicular lymphoma
  379. Allogeneic hematopoietic Stem–cell transplantation: the next generation of therapy for metastatic renal cell cancer
  380. … for cytomegalovirus disease in patients receiving polymerase chain reaction–based preemptive antiviral therapy after allogeneic Stem cell transplantation depends on …
  381. Autologous peripheral blood Stem cell transplantation (PBSCT) mobilized with G-CSF in AML in first complete remission. Role of intensification therapy in outcome
  382. Retroviral vector design studies toward hematopoietic Stem cell gene therapy for mucopolysaccharidosis type I
  383. Adult Stem cells and their importance in cell therapy.
  384. A novel sub-population of bone marrow–derived myocardial Stem cells: potential autologous cell therapy in myocardial infarction
  385. Importance of radiation therapy for breast cancer patients treated with high-dose chemotherapy and Stem cell transplant
  386. Curative therapy of advanced essential thrombocythemia or polycythemia vera by hemopoietic Stem cell transplantation
  387. High dose therapy and autologous Stem cell transplantation in follicular non-Hodgkin’s lymphoma
  388. Multidisciplinary therapy including high-dose chemotherapy followed by peripheral blood Stem cell transplantation for invasive thymoma
  389. High dose therapy and autologous hematopoietic Stem cell transplantation in poor risk solid tumors of childhood.
  390. The role of cytotoxic therapy with hematopoietic Stem cell transplantation in the treatment of diffuse large cell B-cell non-Hodgkin’s lymphoma
  391. Radiation therapy for consolidation of metastatic or recurrent sarcomas in children treated with intensive chemotherapy and Stem cell rescue. A feasibility study
  392. … carboplatin and interleukin-2 (IL-2) activated autologous Stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma–a …
  393. Filgrastim‐induced Stem cell mobilization in chronic myeloid leukaemia patients during imatinib therapy: safety, feasibility and evidence for an efficient in vivo purging
  394. The SCID-hu mouse: an in-vivo model for HIV-1 pathogenesis and Stem cell gene therapy for AIDS
  395. Intensive therapy and autologous Stem cell transplantation for Hodgkin’s disease in first relapse after combination chemotherapy
  396. Stem cell-based gene therapy
  397. Stem–cell depletion and grid therapy
  398. Adult Stem cell therapy: Imagining Futures in cell Biology
  399. Long-term survival in primary plasma cell leukemia after therapy with VAD, autologous blood Stem cell transplantation and interferon-alpha
  400. … of autologous Stem cell transplantation in patients with multiple myeloma who received dexamethasone-based nonmyelosuppressive induction therapy
  401. Consolidation therapy with autologous blood Stem cell transplantation in a patient with primary plasma cell leukaemia
  402. … therapy for remission in myeloma with Intron A following high-dose melphalan and either an autologous bone marrow transplantation or peripheral Stem cell rescue.
  403. Intermediate‐dose melphalan (IDM) combined with G‐CSF (filgrastim) is an effective and safe induction therapy for autologous Stem cell transplantation in multiple …
  404. … therapy for Hodgkin’s disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous Stem …
  405. Stem cell therapy: medical advance or moral challenge?
  406. Experience with liposomal Amphotericin‐B in 60 patients undergoing high‐dose therapy and bone marrow or peripheral blood Stem cell transplantation
  407. In utero hematopoietic Stem cell transplantation: a caprine model for prenatal therapy in inherited metabolic diseases
  408. … non-Hodgkin’s lymphoma after high-dose therapy and autologous peripheral Stem–cell transplantation: changing the natural history with monoclonal antibody therapy
  409. Future cure of hearing disorders? Gene therapy and Stem cell implantation are possible new therapeutic alternatives
  410. Thiotepa and cyclophosphamide with Stem cell rescue for consolidation therapy for children with high-risk neuroblastoma: a phase I/II study of the Pediatric Blood and …
  411. High‐dose therapy and autologous blood Stem cell transplantation in multiple myeloma: Preliminary results of a randomized trial involving 167 patients
  412. Interferon-α therapy following autologous peripheral blood Stem cell transplantation for adult T cell leukemia/lymphoma
  413. Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood Stem–cell support as front-line therapy
  414. Hematopoietic Stem cell gene therapy for Niemann–Pick disease and other lysosomal storage diseases
  415. Neural Stem cells are uniquely suited for cell replacement and gene therapy in the CNS
  416. Stem cell component therapy: supplementation of unmanipulated marrow with CD34 enriched peripheral blood Stem cells
  417. Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood Stem cell support is an effective adjuvant treatment for high-risk primary breast …
  418. Donor chimerism and Stem cell function in a murine congenic transplantation model after low-dose radiation conditioning: effects of a retroviral-mediated gene transfer …
  419. Stem cell therapy for severe autoimmune diseases
  420. … use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic Stem cell transplantation as consolidation therapy for high-risk …
  421. Retroviral transduction of T lymphocytes for suicide gene therapy in allogeneic Stem cell transplantation
  422. … survival of children with advanced neuroblastoma treated by intensified therapy including myeloablative chemotherapy with Stem cell transplantation: a retrospective …
  423. therapy-related myelodysplastic syndrome after autologous Stem cell transplantation for breast cancer
  424. … significance of the detection of tumour cells in peripheral blood Stem cell collections in stage II and III breast cancer patients treated with high-dose therapy
  425. Male germ line Stem cells: from cell biology to cell therapy?
  426. High dose therapy with autologous Stem cell transplantation for solitary bone plasmacytoma complicated by local relapse or isolated distant recurrence
  427. Cytomegalovirus following Stem cell transplantation: from pharmacologic to immunologic therapy
  428. High-dose therapy followed by Stem cell transplantation in partial response after first-line induction therapy for aggressive non-Hodgkin’s lymphoma
  429. High-dose therapy and autologous Stem cell rescue for poor risk and refractory lymphoma: a single centre experience of 123 patients.
  430. The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic Stem cell transplantation for patients with chronic myelogenous …
  431. Antimycotic therapy with liposomal amphotericin-B for patients undergoing bone marrow or peripheral blood Stem cell transplantation
  432. … of ability of ciprofloxacin-rifampin prophylaxis to decrease infection-related morbidity in neutropenic patients given cytotoxic therapy and peripheral blood Stem cell …
  433. High-dose therapy with Stem cell support in solid tumors
  434. cell sources and support programs for Stem cell research and cell-based therapy in the USA
  435. Immune ablation and Stem–cell therapy in autoimmune disease Introduction
  436. Current status in intrauterine fetal Stem cell therapy
  437. … exposure to Merocyanine 540-mediated photodynamic therapy and Edelfosine: implications for the ex vivo purging of autologous haematopoietic Stem cell …
  438. Allogeneic Stem cell–Derived “Repair Unit” therapy and the Barriers to Clinical Deployment
  439. Autologous Stem cell therapy for syStemic vasculitis
  440. Diabetes therapy boosts Stem–cell campaign
  441. Once weekly recombinant human erythropoietin therapy is very efficient after allogeneic peripheral blood Stem cell transplantation when started soon after …
  442. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood Stem cell transplantation as initial therapy for patients with high-risk non …
  443. Stem–cell gene therapy moves toward approval: an NIH advisory committee gives the nod to a new strategy for genetic therapy based on a rare type of blood cell
  444. Dog leukocyte antigen-haploidentical Stem cell allografts after anti-CD44 therapy and reduced-intensity conditioning in a preclinical canine model
  445. The case for and against high-dose therapy with Stem cell rescue for early poor prognosis Hodgkin’s disease in first remission
  446. Lamivudine therapy for a hepatitis B surface antigen (HBsAg)-positive leukemia patient receiving myeloablative chemotherapy and autologous Stem cell …
  447. Neural Stem cells–a versatile tool for cell replacement and gene therapy in the central nervous syStem: Section Editor: Roderick R McInnes e‐mail: mcinnes@ sickkids …
  448. Cidofovir for cytomegalovirus-preemptive therapy in Stem cell transplant recipients
  449. Autologous Stem cell Transplantation as First Line therapy in Peripheral T cell Lymphomas. Update of a Prospective Multicenter Study.
  450. 1432: The Effect of Neural Embryonic Stem cell therapy in a Rat Model of Cavernous Nerve Injury
  451. In vitro T lymphopoiesis: a model syStem for Stem cell gene therapy for AIDS
  452. Immune therapy for EBV infections after hemopoietic Stem–cell transplant
  453. Outcome for patients with leukemia, multiple myeloma and lymphoma who relapse after high dose therapy and autologous Stem cell support
  454. High‐dose therapy with peripheral blood Stem cell transplantation results in a significant reduction of the haemopoietic progenitor cell compartment
  455. … ‐dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood Stem cell …
  456. Autologous Stem cell transplantation as adjuvant treatment vs no further therapy for poor-risk Hodgkin’s disease in first complete remission after MOPP/ABVD
  457. Autologous blood Stem cell transplantation for acute myeloblastic leukemia in first complete remission. Intensification therapy before transplantation does not prolong …
  458. High-dose therapy with peripheral blood Stem cell transplantation for patients with relapsed or refractory Hodgkin’s disease: long-term outcome and prognostic factors
  459. … antitumoral effect of adenovirus-mediated cytosine deaminase gene therapy by induction of antigen-presenting cells through Stem cell factor/granulocyte-macrophage …
  460. A human pluripotent Stem cell in the blood of adults: towards a new cellular therapy for tissue repair
  461. PCR detection of residual Bcl-2/IgH-positive cells after high-dose therapy with autologous Stem cell transplantation is a prognostic factor for event-free survival …
  462. … /nonlymphoid antigen+ acute leukemias: immunologic and karyotypic monitoring during therapy and at relapse suggests the transformation of a bipotential Stem cell.
  463. High dose therapy followed by autologous peripheral blood Stem cell transplantation as a first line treatment for multiple myeloma: a Korean Multicenter Study
  464. Neural Stem cell therapy
  465. Circulating hematopoietic Stem cell populations in human fetuses: implications for fetal gene therapy and alterations with in utero red cell transfusion
  466. … -associated pulmonary alveolar proteinosis as two hereditary diseases of childhood which are potentially curable by Stem cell gene therapy but require different …
  467. … of interferon tolerance after autologous bone marrow or peripheral blood Stem cell transplants for myeloma patients who have responded to induction therapy
  468. … suppression in chronic myeloid leukemia: molecular and cytogenetic studies in patients treated with alpha-2b IFN, high-dose chemotherapy and autologous Stem cell …
  469. Tandem high-dose therapy followed by autologous Stem–cell transplantation for refractory or relapsed high grade non-Hodgkin’s lymphoma with poor prognosis …
  470. Efficacy and toxicity of sequential high-dose therapy with peripheral blood Stem cell support in patients with high-risk breast cancer.
  471. Hematopoietic Stem cell gene therapy: progress and prospects
  472. Purging of contaminating breast cancer cells from hematopoietic Stem cell grafts by adenoviral GAL-TEK gene therapy and magnetic antibody cell separation
  473. … cells as a sensitive method for determination of aneuploid multiple myeloma cells in peripheral blood Stem cell harvests and bone marrow after therapy
  474. Embryonic Stem cell therapy: Progress and Perspectives
  475. High-dose combined alkylating agent therapy with autologous Stem cell support and chest radiotherapy for limited small-cell lung cancer
  476. Allogenic Stem cell transplantation as salvage therapy for patients relapsing after autologous transplantation: experience from a single institution
  477. Development of gene therapy for hematopoietic Stem cell using viral vectors
  478. Stem cell therapy: prospects and
  479. Toxic megacolon: a life-threatening complication of high-dose therapy and autologous Stem cell transplantation among patients with AL amyloidosis
  480. Blood Stem cell transplantation and gene therapy of cancer
  481. MESENCHYMAL Stem cell therapy IN GROWTH PLATE CARTILAGE INJURY
  482. Empiric antimicrobial therapy of febrile neutropenic patients undergoing haematopoietic Stem cell transplantation
  483. Repetitive low-dose radiation therapy for acute Stem–cell leukemia
  484. Modeling human hematopoietic Stem cell gene therapy in nonhuman primates.
  485. The role of high-dose therapy with hematopoietic Stem cell rescue in low-grade non-Hodgkin’s lymphoma
  486. Intensified daunorubicin in induction therapy and autologous peripheral blood Stem cell transplantation in postremission therapy (Double-7 protocol) for adult acute …
  487. Mobilization of peripheral blood Stem cells (PBSCs) after etoposide, adriamycin and cisplatin therapy, and a multimodal cell therapy approach with PBSCs in …
  488. High-dose chemotherapy and autologous Stem cell support followed by post-transplant doxorubicin and taxol as initial therapy for metastatic breast cancer …
  489. Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous Stem cell support in patients …
  490. Survival after high-dose therapy with autologous Stem cell support
  491. Stem–cell researchers offer possible therapy for diabetes
  492. Hematopoietic Stem cell gene therapy for inherited bone marrow disorders: past accomplishments and continued challenges
  493. ESHAP+/− Rituximab as Salvage therapy for Relapsed Lymphoma Prior to Stem cell Transplant: Single Institution Experience.
  494. Stem cell (CFU-S) inhibitory peptides: Biological properties and application of pEEDCK as hemoprotector in cytostatic tumor therapy
  495. High-dose therapy and autologous Stem cell transplantation for high-risk Hodgkin’s lymphoma: a single center experience
  496. Outcome after Second Autologous Stem cell Transplantation as Salvage therapy in Patients with Relapsed Multiple Myeloma.
  497. Complications after high dose therapy and autologous Stem cell transplantation. Retrospective study of an unselected patient sample
  498. Feasibility of using autologous transplantation to evaluate hematopoietic Stem cell-based gene therapy strategies in transgenic mouse models of human …
  499. … in combination with glycopeptide antibiotic is an effective first-line therapy for patients undergoing high-dose therapy with autologous peripheral blood Stem cell …
  500. Pulmonary infiltrates after cytokine therapy for Stem cell transplantation: massive deposition of eosinophil major basic protein detected by immunohistochemistry
  501. Hematopoietic Stem cell therapy.
  502. THE ETHICS OF Stem cell therapy
  503. High-dose therapy with autologous bone marrow Stem cell support in primary and metastatic human breast cancer
  504. Hematopoietic Stem cell autografts in support of myeloablative therapy for multiple myeloma
  505. The third conference on hematopoietic Stem cell gene therapy: biology and technology
  506. Survival Following Etanercept therapy for the Treatment of Idiopathic Pneumonia Syndrome Post Allogeneic Stem cell Transplantation.
  507. Excellent disease eradication by myeloablative therapy and Stem–cell transplantation in patients with acute myelogenous leukemia
  508. Phase I/II trials of autologous peripheral blood Stem cell transplantation in autoimmune diseases resistant to conventional therapy: preliminary results from the …
  509. NOVEL CLINICAL CONCEPTS ON Stem cell therapy: 336
  510. Monoclonal antibody therapy with autologous peripheral blood Stem cell transplantation for non-Hodgkin’s lymphoma
  511. Lamivudine therapy for acute hepatitis B infection following peripheral blood Stem cell transplantation
  512. The addition of topotecan to carboplatin and paclitaxel as first-line therapy for advanced ovarian cancer; is it possible only with peripheral blood Stem cell support?
  513. … high dose therapy and autologous Stem cell transplantation versus conventional therapy for patients with advanced Hodgkin’s disease responding to first line therapy
  514. Results of a Multi-Center Randomized Phase II Trial of Thalidomide and Prednisone Maintenance therapy for Multiple Myeloma Following Autologous Stem cell …
  515. Mesenchymal and nonhematopoietic Stem–cell therapy
  516. Neurosurgical Stem cell therapy
  517. A Stem cell therapy for stroke
  518. Embryonic Stem cell lines for regenerative therapy and pharmaceutical research
  519. Effect of prior therapy and bone marrow metastases on progenitor cell content of blood Stem cell harvests in breast cancer patients
  520. … by campath mab t cell depleted Stem cell allograftP14. Stem cell treatment in inflammatory myopathies: proposals for patient selectionP15. Autologous Stem cell …
  521. ALLOGENEIC Stem cell therapy FOR JOINT DISEASE
  522. … Foundations. Note: A. Hultquist is presently at the Department of Stem cell Biology, Strategic Center for Stem cell Research and Gene therapy, Lund University, S …
  523. High-dose chemotherapy and autologous Stem cell support followed by posttransplantation doxorubicin as initial therapy for metastatic breast cancer.
  524. Early infectious complications after high-dose therapy and autologous blood Stem cell transplantation
  525. High dose therapy and autologous hemopoietic Stem cell transplantation in rheumatoid arthritis–the feasibility of phase III trials.
  526. Adjuvant high-dose therapy with peripheral blood Stem cell support for patients with high-risk breast cancer
  527. High-dose therapy and autologous Stem cell transplantation in relapsed and refractory Hodgkin’s disease: outcome based on a prognostic model
  528. Rituximab given after high dose therapy and autologous Stem cell transplantation induces durable clearance of minimal residual disease in about half of the …
  529. Becoming Immortal: Combining Cloning and Stem‐cell therapy
  530. A Setback for Stem cell therapy?
  531. Safety and efficacy of Stem cell mobilization under imatinib therapy
  532. Stem cell therapy for Ischemic Heart Disease: A Status Report
  533. Repetitive cycles of cytoreductive therapy followed by Stem cell autografting for nonlymphoblastic transformation of chronic granulocytic leukaemia
  534. Intrauterine Stem cell therapy
  535. Embryonic and Adult Stem cell therapy.(Abstracts)
  536. Failure of a single cycle of high dose cyclophosphamide followed by intensive myeloablative therapy and autologous Stem cell transplantation to improve outcome in …
  537. Stem cell therapy in the Mouse Heart
  538. Good manufacturing practice production of human Stem cells for somatic cell and gene therapy
  539. Use of capecitabine as first-line therapy in patients with metastatic breast cancer relapsing after high-dose chemotherapy and autologous Stem cell support
  540. Stem cell therapy for Alzheimer’s Disease
  541. Mobilized versus non-mobilized peripheral Stem cell transplantation after high dose therapy for low grade nonhodgkin lymphoma: Effect on failure-free survival
  542. Cytapheresis—The Next 25 Years: Stem cell therapy
  543. COMBINATION GENE AND Stem cell therapy FOR MS: PROMISE OR FANTASY?
  544. Stem cell therapy for Ischemic Heart Disease: A Status Report
  545. Costs of high-dose salvage therapy and blood Stem cell transplantation for resistant-relapsed malignant lymphomas in a southern Italian hospital
  546. Stem cell therapy for ACS: The Possibility of Myocardial Regeneration
  547. Stem cell biology and gene therapy
  548. One strategy for cell and gene therapy: harnessing the power of adult Stem cells to repair tissues
  549. Stem cell therapy in diabetes mellitus: Dream or reality
  550. Intensified myeloablative therapy and autologous Stem–cell transplantation for patients with AML: single center experience
  551. Adoptive cellular therapy for Cytomegalovirus Following Allogeneic Stem cell Transplantation: Toxicity and Efficacy.
  552. Future treatment options for Parkinsonism: Stem cell therapy
  553. How far away is the Stem cell therapy from the glaucoma management. A ten-year review
  554. High-Dose therapy and Stem cell Transplantation
  555. Potential Use of Stem cell therapy for Traumatic Brain Injury
  556. Reduced Intensity Conditioning therapy Using Campath-1H Is Successful for Stem cell Transplantation in Non-Malignant Disorders.
  557. Adult Mesenchymal Stem cell therapy in Joint Injury and Disease
  558. Autologous Stem cell Transplantation and cell therapy for Acute Leukemia
  559. Stem cell transplantation after salvage therapy with high-dose cytarabine and amsacrine in adults with high-risk leukaemia
  560. Single cell DNA analysis: possibilities, methods, implications in relation to Stem cell therapy
  561. Stem cell transplantation and gene therapy in utero
  562. Early tandem high-dose ifosfamide, carboplatin, etoposide therapy with Stem cell rescue for small-cell lung cancer: brief report on the results of a phase-I/II trial
  563. Twelve cases of malignant hematopathy treated by combined therapy of hematopoietic Stem cell transplantation and Chinese herbal medicine
  564. Ethics of Stem cell therapy and genetic engineering on human tissue
  565. Observation on Stem cell therapy of far advanded skin trauma of guinea pig
  566. Stem cell therapy for diseases in the nervous syStem-A potential for regeneration of inner ear
  567. Understanding endocrine development of the human beta cell: guiding Stem cell therapy for Type 1 Diabetes
  568. Radiation therapy after high-dose chemotherapy with peripheral blood Stem cell support for high-risk breast cancer
  569. Quadruple therapy with CsA, MTX, MMF and ATG for preventing graft-versus-host disease in unrelated donor hematopoietic Stem cell transplantation
  570. RELAPSE AFTER AUTOLOGOUS Stem cell therapy (ASCT) IN A PATIENT WITH SYStemIC LUPUS ERYTHEMATOSUS (SLE)
  571. High dose therapy with Stem cell support for breast cancer: the jury is still out
  572. cell therapy: Stem cell transplantation, gene therapy, and cellular immunotherapy: Edited by George Mortsyn and Wiliam Sheridan (New York: Cambridge University …
  573. Allogeneic cell therapy (act) after relapse from autologous Stem cell transplantation (autosct)
  574. Ceftazidime and ciprofloxacin as empiric therapy in febrile neutropenic patients undergoing hematopoietic Stem cell transplantation
  575. Muscle derived Stem cell-based cell therapy in urology
  576. … Stem cell harvests have no impact on 5 year outcomes for breast cancer patients with 4–9 positive nodes treated with adjuvant high-dose therapy and Stem …
  577. Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood Stem cells with a low CD34+ cell content
  578. Research for corresponding dental therapy for patients undergoing bone marrow and peripheral blood Stem–cell transplantation.
  579. Autologous Stem cell transplantation (ASCT) as consolidation therapy for patients with low-intermediate (LI) risk diffuse large B-cell lymphoma (DLBCL) and …
  580. … with seven-drug induction therapy and intensive consolidation with or without autologous Stem cell transplantation followed by maintenance therapy. Experience of a …
  581. Disease‐or therapy‐related bone marrow damage cannot be overcome by changes in Stem cell source or dose in allogeneic transplantation
  582. The effects of Stem cell factor and granulocyte colony stimulating factor therapy on the activity of the neutrophil NADPH oxidase enzyme syStem.
  583. Idarubicin or Mitoxantrone, VP-16, and Cytarabine for Induction/Consolidation therapy Followed by Autologous Stem cell Transplantation in Elderly Patients with …
  584. Mending a broken heart: animal studies helped lay the groundwork for Stem cell therapy.(Hot Papers)
  585. Neoadjuvant therapy with high dose chemotherapy via isolated pelvic intra-abdominal perfusion with bone marrow Stem cell support for advanced endometrial cancer
  586. Current Trends and Prospect of cell therapy using Hematopoietic Stem cells
  587. Willenbacher W, et al.: Somatic Risk Factors for Intermediate and Long-Term Sequelae after Hematological Stem cell therapy Predictive for Feasibility of a …
  588. therapy of highly malignant non-Hodgkin lymphoma with high-dose chemotherapy and Stem cell transplantation
  589. Establishment of juvenile and tolerant immune syStems in patients with autoimmune diseases treated with immunoablation and autologous Stem cell therapy
  590. Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal Stem cells for cell and gene therapy
  591. Stem cell therapy for treatment of central nervous syStem pathology in α-mannosidosis guinea pigs.
  592. Early and late toxicity of involved-field radiation therapy in conjunction with high-dose chemotherapy and Stem cell rescue
  593. Sequential High‐Dose Alkylating therapy and Stem cell Support for High‐Risk Stage III Breast Cancer
  594. Adoptive therapy with monocyte‐derived macrophages in the setting of high‐dose chemotherapy and peripheral blood Stem cell transplantation
  595. Catheter Interventions in Congenital Heart Disease—Part I Guest Editor, Horst Sievert Applications of Magnetic Resonance Imaging for Cardiac Stem cell therapy.
  596. Sequential high-dose therapy of adult acute lymphoblastic leukemia: role of maintenance chemotherapy after peripheral blood Stem cell transplantation in first …
  597. Hematologic toxic reaction to radiation therapy adjuvant to autologous peripheral blood Stem cell transplantation for recurrent or refractory Hodgkin disease
  598. … therapy with UVADEX® for the Prevention of Acute GVHD in Patients Undergoing Standard Myeloablative Conditioning and Allogeneic Hematopoietic Stem cell …
  599. High-dose therapy of cancer with CD34 positive cells as Stem cell support
  600. Hematopoietic chimerism following immunoablative therapy for non-malignant disorders-out-patient Stem cell transplantation
  601. Prospective Multicenter Trial Comparing Repeated Immunosuppressive therapy (IST) with Stem cell Transplantation (SCT) from an Alternative Donor as a Second …
  602. Autologus Stem cell transplantation as postremission therapy for acute myeloid leukemia. Risk factors at diagnosis can predict the outcome
  603. Myeloablative Chemotherapy and Peripheral Blood Stem cell Transplantation vs. Consolidation therapy of Acute Myelogenous Leukemia in First Remission
  604. … Heart Function after the Combined Treatment of Patients Undergoing Coronary Artery Bypass Grafting through Stem cell therapy and Transmyocardial Laser …
  605. Treatment of non-Hodgkin’s lymphoma with high-dose therapy and hematopoietic Stem cell support.
  606. KINETIC MODELING OF THE MOLECULAR PROBE 18F-FHBG FOR IMPROVED PET REPORTER GENE IMAGING OF Stem cell therapy
  607. Feasibility of a Stem cell Gene therapy Approach with Nonmyeloablative Conditioning in Patients with HIV-1 Infection.
  608. High-dose therapy with peripheral blood Stem cell (PBSC) support using an innovative mobilization regimen in patients with high-risk primary or chemoresponsive …
  609. Rituximab, Fludarabin and Cyclophosphamide Followed by High Dose therapy with Autologous Stem cell Rescue Leads to High Molecular Remission Rate …
  610. High dosage therapy with Stem cell transplantation in neuroendocrine carcinoma
  611. High dose chemotherapy and Stem cell support for poor risk and recurrent nonseminomatous germ cell cancer: initial experience with sequential therapy
  612. Hepatocyte growth factor modified human umbilical cord mesenchymal Stem cell therapy promotes remyelination after intracerebral hemorrhage in rats
  613. Wednesday, September 22, 2004: Plenary Session PL1: Stem cell therapy
  614. High-dose melphalan with Stem cell support is now an established myeloma therapy. Treatment of myeloma from a 30-year perspective
  615. High dosage therapy and autologous peripheral Stem cell transplantation in breast carcinoma
  616. 710. Stem cell Gene therapy: Synergizing Improved Gene Repair/Modification & Targeted Integration of Transgenes to Transient In Vivo Topical Minigene …
  617. The effect of preemptive therapy with intravenous ganciclovir followed by oral ganciclovir against cytomegalovirus infection after allogeneic peripheral blood Stem cell …
  618. Current trends in Stem cell biology and cell replacement therapy
  619. Dose-intensive therapy with autologous Stem cell transplantation for patients with multiple myeloma
  620. Current trends of Stem cell-mediated gene therapy
  621. Stem cell Biology and Gene therapy.: Quesenberry PJ, Stein GS, eds.(£ 65.00.) Wiley, 1998. ISBN 0 47114 656 0.
  622. Expansion Of Muscle-Derived Stem cells: Implications of cell therapy For Muscle Regeneration
  623. HEMATOPOIETIC Stem cell GENE therapy
  624. High-dose therapy and autologous Stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK …
  625. Transplantation of hepatic Stem cells and potential applications for cell therapy
  626. 160 Importance of radiation therapy for high-risk breast cancer patients treated with high-dose chemotherapy and Stem cell transplant
  627. Scientific, logistical, and ethical issues related to creation of a Stem cell repository for use in experimental trials of gene therapy for AIDS
  628. Basic Studies Toward Hematopoietic Stem cell Gene therapy
  629. Integrating vector and Stem cell-based strategies for gene therapy of Duchenne muscular dystrophy
  630. … ANBL0032: a phase III randomized trial of chimeric anti-GD2 and GM-CSF/IL2 in high risk neuroblastoma following myeloablative therapy and autologous Stem cell …
  631. Human Stem cell Gene therapy
  632. … onset invasive pulmonary zygomycosis following allogeneic peripheral blood Stem cell transplantation in a patient with therapy-related myelodysplastic syndrome
  633. High-dose busulfan, VP-16 and ACNU therapy with Stem cell transplantation for the treatment of children with acute leukemia
  634. Delivery of a vector with vascular endothelial growth factor gene to the pluripotent Stem cell for gene therapy
  635. Diabetes therapy boosts Stem–cell campaign
  636. … -dose therapy and autologous Stem–cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy …
  637. cellular therapy by Non-Myeloablative Stem cell Transplantation and Immunotherapy of Minimal Residual Disease
  638. Pioneering Stem cell/Gene therapy Trials
  639. Hematopoietic Stem cell Transplantation. An Established therapy
  640. High Dose therapy (HDCT) with Autologous Stem cell Transplantation (ASCT) for Non-Hodgkin Lymphoma in the Elderly: Feasibility of a Patient-Tailored Treatment …
  641. Human embryonic Stem cells: possibilities for future cell transplantation therapy
  642. Cost of antibiotic therapy in neutropenic patients undergoing peripheral blood Stem cell transplantation for breast cancer
  643. Advances in Hematopoietic Stem cell Transplantation and Molecular therapy
  644. The Biology of the Stem cell and Its Environment in the Role of Effective Gene therapy
  645. Evaluation of leukemic contamination in peripheral blood Stem cell leukaphereses vs bone marrow after consolidation therapy in acute myeloid leukemia: not a …
  646. Hematopoietic Stem cell Gene therapy
  647. Hematopoietic Stem cell gene therapy
  648. Cord blood Stem and progenitor cell therapy for immunodeficiency and other disorders
  649. High dose therapy with autologous Stem cell support–finally a progress in myelomatosis
  650. High-dose therapy and peripheral blood Stem cell transplantation for patients with aggressive non-Hodgkin’s lymphoma remaining in initial remission: results of a …
  651. High-dose chemotherapy and autologous Stem cell transplantation for refractory and relapsing Hodgkin’s disease as first-line therapy–studies at Sheba Medical …
  652. Autologous hematopoietic Stem cell transplantation (AHSCT) as consolidation therapy for childhood acute myelogenous leukemia in 1st complete remission
  653. Prognostic factors for survival and response after high-dose therapy and autologous Stem cell transplantation in syStemic AL amyloidosis: a report on 21 patients
  654. Stem–cell gene therapy: problems and solutions
  655. Stem cell GENE therapy OR GENETIC DISEASES
  656. High dose therapy and autologous Stem cell transplantation (ASCT) for lymphoblastic lymphoma in adults: Results from the European Group for Bone Marrow …
  657. Aggressive neoplastic plasma cell growth with MLL gene rearrangement after high-dose therapy with autologous Stem cell support for multiple myeloma
  658. Stem cell GENE therapy OR GENETIC DISEASES
  659. A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with Stem cell transplantation
  660. Stem cell GENE therapy OR GENETIC DISEASES
  661. Stem cell and gene therapy approaches for skeletal disorders
  662. High-dose therapy and autologous hematopoietic Stem–cell transplantation for recurrent or refractory pediatric hodgkin’s disease: analysis of the stanford university …
  663. … Trial of Short-Course Preemptive Ganciclovir Compared with Conventional Ganciclovir therapy To Prevent Cytomegalovirus Infection after Allogeneic Stem cell …
  664. therapy-related acute myeloid leukemia following double autologous peripheral blood Stem cell transplantation for non-Hodgkin’s lymphoma
  665. Human hematopoietic Stem cell gene therapy
  666. Excessive Weight Gain during Mobilization Increases First Year Mortality Following High Dose therapy and Stem cell Transplantation in Patients with Primary …
  667. Contamination with minimal residual disease in autologous peripheral Stem cell collected from Non-Hodgkin’s lymphoma patients treated with high-dose therapy
  668. Leukocyte Depleted Blood Transfusion in Hematopoietic Stem cell Reconstitution therapy
  669. … therapy with Autologous Blood Stem cell Transplantation (Asct) for Relapsed, Follicular Lymphoma (FL) vs. De Novo, Diffuse Large B-cell (dnDLBL) vs. Transformed …
  670. Evaluation of human hemopoietic Stem cell assays for transplantation and gene therapy
  671. Stem cell gene therapy–second conference. Biology and technology. 31 May-3 June 1998, Orcas Island, WA, USA.
  672. High-dose therapy with peripheral Stem cell support in patients with lymphomas and breast cancer
  673. Supportive therapy in patients with autologous hemopoietic Stem cell transplantation
  674. … Predictor of Survival for Refractory and Relapsed HIV-Associated Lymphoma Enrolled in a Program of High Dose therapy and Autologous Peripheral Blood Stem cell …
  675. The biologic character of cancer Stem cell and targeted therapy
  676. CD34-positive cells as Stem cell support after high dose therapy
  677. … infusions is safe and effective therapy for a subgroup of relapsed acute myeloid leukaemia and myelodysplastic syndrome following allogeneic haemopoietic Stem cell …
  678. … (Gemcitabine, Dexamethasone, Cisplatin) Salvage therapy Results in Superior Progression Free Survival Compared to Mini-Beam Prior to Autologous Stem cell …
  679. Application of mesenchymal Stem cells for the regeneration of cardiomyocyte and its use for cell transplantation therapy
  680. Modulation of the Hematopoietic Stem cell Phenotype: Implications For Regenerative Medicine and Gene therapy
  681. Studies Add to Debate on High-Dose therapy & Stem cell Transplantation for NHL
  682. Surgical therapy for corneal epithelial Stem cell deficiency
  683. High dose therapy with autologous Stem cell support in malignant disorders; Hoeydosebehandling med autolog stamcellestoette ved maligne lidelser
  684. Studies of hematopoietic-human-Stem–cell viability in-vitro and of celocentesis in non-human primates for in-utero Stem cell gene therapy
  685. Mesenchymanl Stem cell Based Intradiscal Gene therapy: Therapeutic Implication in Degenerative Disc Disease
  686. Correction of mouse models of sickle cell disease and β-thalassemia using Stem cell and genetic-based therapy
  687. An investigation of murine trachea cellular kinetics: implications for Stem cell gene therapy
  688. … ARTHRITIS (JIA) ON LONG-TERM therapy WITH METHOTREXATEP172. THE POSITION OF AUTOLOGOUS Stem cell TRANSPLANTATION (ASTA) IN …
  689. Electronic data processing-assisted high dosage therapy with Stem cell transplantation at the Donauspital
  690. Twelve Cases of Malignant Hematopathy Treated by Combined therapy of Hematopoietic Stem cell Transplantation andChinese Herbal Medicine
  691. A Novel Stem cell Derived Gene therapy for HIV/AIDS
  692. Development of selective amplifier genes for hematopoietic Stem cell gene therapy
  693. Application of Risk-Adapted therapy for Acute Myeloid Leukemia to a Population. Effects of Stem cell Transplantation on Outcome.
  694. Correction of ADA-SCID by Stem cell gene therapy combined with nonmyeloablative conditioning
  695. Nonmyeloablative Allogeneic Peripheral Blood Hematopoietic Stem cell Transplantation for therapy of Hematologic Diseases
  696. Stem cells and cell therapy. Contribution to the ethical debate
  697. Stem cell Transplantation: Successful therapy for the Substitution of Unfunctional Hemato-Lymphoid SyStem
  698. Optimizing recovery from aplasia after high-dose therapy and hematopoietic Stem cell transplantation
  699. High-dose therapy with autologous Stem cell support in malignant lymphoma and breast cancer. Experiences with hematopoietic Stem cells isolate from blood
  700. ABCG2: A new target for cancer therapy and new marker for Stem cell screening
  701. Renal transplantation and immunosuppressive therapy do not contraindicate Stem–cell donation for bone-marrow transplantation
  702. 15-year follow-up of myeloma patients receiving 140 MG/M2 melphalan without hematopoietic Stem cell or growth factor support as initial therapy
  703. Twelve cases of malignant hematopathy treated by combined therapy of hematopoietic Stem cell transplantation and Chinese herbal medicine
  704. High-dose therapy followed by autologous haematopoietic Stem cell transplantation in multiple myeloma.
  705. Thirteenth Annual Meeting of Society for Biological therapy, 454 interleukin-2 expression, CTL against renal cell carcinoma, 170 CD8 T cell activity, 307 Stem cell …
  706. Use of Cord Blood Stem cells in cell therapy
  707. … phase II study of maintenance chemotherapy versus high-dose chemotherapy with autologous peripheral blood Stem cell transplantation as postremission therapy of …
  708. High-dose immunosuppressive therapy with Stem cell transplantation for the treatment of autoimmune disease
  709. High dose therapy with autologous Stem cell support in malignant disorders. Excerpt from the statement by the advisory group of the State Health Services
  710. Application of real-time quantitative PCR for guidance therapy of cytomegalovirus infection after allohematopoietic Stem cell transplantation
  711. Myeloablative therapy, Stem cell rescue and gene transfer in advanced ewing tumors (AET)
  712. Gene therapy for Human Immunodeficiency Virus Infection Using Stem cell Transplantation
  713. … -non-identical peripheral blood Stem cell transplantation (total body irradiation, etoposide, thiotepa) and interleukin 2-based experimental therapy for poor prognosis …
  714. cellular therapy for intensification in oncology and hematology: manipulation of peripheral blood Stem–cell products
  715. High-dose chemotherapy with peripheral blood Stem cell transplantation as adjuvant therapy for primary breast cancer
  716. 225. Phenotypic Correction of ALD Mouse after Hematopoietic cell Transplantation and Evaluation of Hematopoietic Stem cell Gene therapy with a Lentivirus Vector
  717. Autologous blood Stem cell transplantation as intensive consolidation therapy in hematological malignancies.
  718. Bone Stem cell mediated gene therapy and tissue engineering
  719. Dose-Intensive therapy with Autologous Blood Stem cell or Bone Marrow Transplantation for Treatment of Breast Cancer
  720. Etarnercept therapy for Idiopathic Pneumonia Sydrome After Allogeneic Hematopoietic Stem cell Transplantation in an Adul
  721. # 649 The feasibility of outpatient high dose multiagent cytoreductive rpeparative therapy (CPT) in patients undergoin autologous Stem cell transplantation (SCT) for …
  722. Autologous Stem cell harvesting after high dosage chemo-and/or growth factor therapy
  723. 1004. Integration Analyses in ADA-Deficient SCID Patients Successfully Treated with Stem cell Gene therapy
  724. Isolation of human mesenchymal Stem cell-like fibroblast from adipose tissue for reconstructive therapy
  725. … Targeted Integration of Minigenes: T Integration of Minigenes: Toward Improved Ex V oward Improved Ex V oward Improved Ex Vivo/In Vivo Stem–cell Gene-therapy
  726. High dose chemotherapy and autologous Stem cell transplantation as adjuvant therapy for primary breast cancer pa…
  727. 51. A Novel Approach to Stem cell Gene therapy: Controlling Stem cell ifferentiation with Engineered Zinc-Finger Protein Transcription Factors
  728. Dose intensive therapy and myeloablative chemotherapy with haematopoietic Stem cell rescue in childhood poor prognosis Ewing’s sarcoma
  729. Stem–cell engraftment as delayed therapy to repair organophosphate-induced brain damage
  730. predicts relapse of malignant lymphoma after high-dose therapy with Stem cell transplantation
  731. Oral valganciclovir is safe and effective as preemptive therapy for CMV infection in allogeneic hematopoietic Stem cell transplantation
  732. High-dose chemotherapy with peripheral blood Stem cell transplantation as adjuvant therapy for primary breast cancer with extensive lymph node involvement
  733. High-dose therapy and autologous peripheral blood Stem cell transplantation in patients with relapsed lymphoma
  734. 1125 High-dose therapy with hemopoietic Stem cell support for high risk breast cancer. A pilot study in 31 patients
  735. Role of Chemokine Receptor, CXCR4, Expression in Directing Neural Stem cell Vectors in Brain Tumor therapy
  736. Imatinib therapy for Chronic Myeloid Leukemia Patients Who Relapse after Allogeneic Stem cell Transplantation: A Molecular Analysis.
  737. Role of music therapy-based relaxation vs. expressive reading interventions in blood marrow Stem cell transplantation
  738. The Impact of Immunosuppressive therapy on an Early Quantitative Reconstitution of NK cells after Allogeneic Hematopoietic Stem cell Transplantation.
  739. Allogenic Peripheral Blood Stem cell Transplant Utilizing Rabbit Anti-Thymocyte Globulin as a Part of Non-Myeloablative Conditioning therapy.
  740. Engineered human mesenchymal Stem cells: a novel platform for skeletal cell mediated gene therapy
  741. 1162. Correction of the Immune and Metabolic Defect of ADA-SCID by Stem cell Gene therapy Combined with Nonmyeloablative Conditioning
  742. The HGFIN Gene Mediates cell Cycle Quiescence of CD34+/CD38-: Implications for Hematopoietic Stem cell Expansion and Gene therapy.
  743. Adenovirus-Mediated Targeted Gene therapy for Breast Cancer and for Purging Hematopoietic Stem–cell Sources
  744. … RESTORES THYMIC FUNCTION AND ENHANCES HEMOPOIESIS AND LYMPHOPOIESIS FOLLOWING ALLOGE-NEIC AND AUTOLOGOUS Stem cell …
  745. High Dose therapy with Autologous Blood Stem cell Transplantation (ASCT) for Follicular Lymphoma: Long-Term Outcome According to Histologic Grade.
  746. Intracerebral Mesenchymal Stem cell Gene therapy in the Niemann-Pick Disease Mouse
  747. First Line therapy with Reduced Intensity Conditioning Allogeneic Stem cell Transplantation for Patients with Acute Myeloblastic Leukemia in First Complete …
  748. … Intensity Induction therapy Followed by Early High Dose Chemotherapy (HDT) and Autologous Hematopoietic Stem cell Transplantation (AHSCT) for Mantle cell …
  749. GMP Compliant Expansion of Hematopoietic Stem cells (CD34+) Selected from Cord Blood for a Phase I cell therapy Trial
  750. Sex streoid ablation therapy restores thymic function and enhances hemopoiesis and lymphopoiesis following allogeneic and autologous Stem cell transplantation
  751. … RESISTANT TO CONVENTIONAL THERAPEUTIC REGIMENSV4. 2. 18 CHILDREN AFTER AUTOLOGOUS Stem cell TRANSPLANTATION FOR REFRACTORY …
  752. Autologous Stem cell transplantation following induction therapy with an anthracycline-based regimen including interferon-alpha for low-grade non-Hodgkin’s …
  753. Development of hemopoietic Stem cell gene therapy for Niemann-Pick disease using the acid sphingomyelinase knock-out mouse model
  754. BCCA Protocol Summary for Myeloablative Conditioning therapy Prior to Autologous and Allogeneic Hematopoietic Stem cell Transplantation for Myeloid …
  755. # 703 High dose mobilization chemotherapy followed by myeloblative therapy with Stem cell support for the treatment of small, round, blue cell tumors
  756. … blood Stem cell transplantation (allo-pbsct): changing patterns and low dose short course (ldsc) gancyclovir (gcv) as an effective nontoxic presumtive therapy (pt) …
  757. Intensified induction followed by high-dose therapy with autologous peripheral blood Stem cell support in poor-prognosis aggressive non-Hodgkin’s lymphoma …
  758. 12 Multiple courses of high-dose alkylating therapy with autologous Stem cell support
  759. … Followed by High-Dose therapy with Autologous Peripheral Blood Stem cell Transplantation for Advanced-Stage Follicular Lymphoma as First-Line therapy …
  760. Improving dosing precision in busulfan (bu)-based preparative regimens for hematopoietic Stem cell transplantation (HSCT) using parmacokinetics directed therapy …
  761. Gene therapy: Bone Regeneration Using Adenovirus Mediated Bone Morphogenic Protein Engineered Mesenchymal Stem cell
  762. … Stem cell transplantation (PBSCT) for patients with malignant lymphoma–its role in the treatment strategy for non-Hodgkin’s lymphoma, and ESHAP+ PBSCT therapy
  763. The Useful Individualized Assessment of Immunosuppressive therapy with Cyclosporine A (CsA) after Allogeneic Stem cell Transplantation by Simultaneous …
  764. … Patients Undergoing Allogeneic Hematopoietic Stem cell Transplantation: Increased Incidence in Patients Receiving Alemtuzumab (ALEM) as Conditioning therapy …
  765. AUTOLOGOUS Stem cell TRANSPLANTATION (ASCT) FOR THE TREATMENT OF HIV-ASSOCIATED NON-HODGKIN’S LYMPHOMA (NHL) IN THE ERA OF …
  766. Intensified full-dose induction therapy (HD-MACHOP+ radiotherapy) follwed dy consolidation with BAVC regimen and autologous Stem cell transplantation as fron-line …
  767. Symposium 7: Stem cell Research; Application of Endothelial Progenitor cells (EPC) to Vascular Medicine: Mobilized EPC by GM-CSF accelerate …
  768. Intensive antileukemic therapy including Stem cell transplantation (SCT) for high risk MDS and AML following MDS (SAML) in patients< 60 years. a joint study of the …
  769. … Versus Gene Modified Autologous Stem cell Transplantation for Severe Combined Immunodeficiencies (SCID). The Risk/Benefit Balance Is in Favor of Gene therapy …
  770. Denileukin diftitox (ONTAK) as targeted therapy against steroid refractory graft-versus-host disease (GVHD) after allogeneic hematopoietic Stem cell transplantation …
  771. Repetitive High-Dose therapy with Dose Escalated CHOP+ Etoposide Followed by Autologous Stem cell Transplantation (Mega-CHOEP) in Younger Patients with …
  772. … POST TRANSPLANT-Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic Stem cell …
  773. Fludarabine and cytosine arabinoside as salvage therapy in patients with relapsed acute and chronic leukaemia after BMT or allogenic Stem cell transplantation
  774. Post-remission therapy with 4 cycles of intermediate (I) or high-dose (HD) cytarabine (AC) or autologous hematopoietic Stem cell transplantation (ASCT) for acute …
  775. … /Disease Consisting of a Higher Cutoff Point and a Lower Initial Dose of Ganciclovir after Allogeneic Hematopoietic Stem cell Transplantation (HSCT) with an HLA …
  776. cell therapy Using Embryonic Stem cells
  777. … EXPRESSION IN SYStemIC JUVENILE IDIOPATHIC ARTHRITIS IS RESTORED BY AUTOLOGOUS Stem cell TRANSPLANTATION. AUTONOMIC NERVOUS …
  778. … purging of autologous hematopoietic Stem cells using anti-B-cell monoclonal antibody-coated high-density microparticles prior to high-dose therapy for patients with …
  779. A novel sub-population of bone marrow derived myocardial Stem cells: potential autologus cell therapy in myocardial infarction
  780. Human neural Stem and progenitor cells: in vitro and in vivo properties, and potential for gene therapy and cell replacement in the CNS
  781. Autologous mesenchymal Stem cells for articular and bone cell therapy
  782. Potential use of T cell receptor genes to modify hematopoietic Stem cells for the gene therapy of cancer
  783. … of Human Neural Stem cells in a New Primate Model of Motor Neuron Degeneration: An Experimental Study of Potential cell therapy for Amyotrophic Lateral …
  784. Engineering mesenchymal Stem cells with hypoxia-regulated gene syStem: A promising approach for effective cell therapy
  785. Recovery of stromal Stem cells in bone sarcoma patients after chemotherapy: Implication for cell-based therapy in bone defect reconstruction
  786. … of the rate of reduction in platelet counts in recipients of hematopoietic Stem and progenitor cell transplant: clinical implications for platelet transfusion therapy
  787. Mesenchymal Stem cells. Potential use in cell and gene therapy of bone loss caused by aging and osteoporosis
  788. Use of Embryonic Stem cells to Produce Islets in cell Replacement therapy as a Treatment for Type 1 Diabetes
  789. 1417: Mesenchymal Stem cells Alone or Modified with ENOS Restore Erectile Function in the Aged Rat: cell-Based Gene therapy for Erectile Dysfunction
  790. Adult Stem cell therapy in stroke
  791. Potential of mesenchymal Stem cell therapy
  792. Stem cell therapy and the retina
  793. Does mesenchymal Stem cell therapy help multiple sclerosis patients? Report of a pilot study
  794. Role of imaging in cardiac Stem cell therapy
  795. Stem cell therapy enhances electrical viability in myocardial infarction
  796. The potential for Stem cell therapy in diabetes
  797. Stem cell-based cell therapy for spinal cord injury
  798. Comparison of imaging techniques for tracking cardiac Stem cell therapy
  799. cell therapy and the safety of embryonic Stem cell-derived grafts
  800. Adult Stem cell therapy: dream or reality?
  801. Stem cell therapy for autism
  802. Stem cell therapy for vascular disease
  803. The dying Stem cell hypothesis: immune modulation as a novel mechanism for progenitor cell therapy in cardiac muscle
  804. Mesenchymal Stem cell therapy to rebuild cartilage
  805. Stem cell therapy for ischemic heart failure
  806. Stem cell therapy—Present status
  807. Stem cell therapy for neurologic disorders: therapeutic potential of adipose-derived Stem cells
  808. Injectable mesenchymal Stem cell therapy for large cartilage defects—a porcine model
  809. Autologous in vitro expanded mesenchymal Stem cell therapy for human old myocardial infarction
  810. Concise review: prospects of Stem cell therapy for temporal lobe epilepsy
  811. Enhancing Stem cell therapy through genetic modification
  812. Differentiation of mesenchymal Stem cells transplanted to a rabbit degenerative disc model: potential and limitations for Stem cell therapy in disc regeneration
  813. Successful Stem cell therapy using umbilical cord blood‐derived multipotent Stem cells for Buerger’s disease and ischemic limb disease animal model
  814. Stem cell therapy: hope or hype?
  815. Embryonic Stem cell therapy for diabetes mellitus
  816. Stem cell therapy for osteonecrosis of the femoral head
  817. Concise review: scientific and ethical roadblocks to human embryonic Stem cell therapy
  818. Stem cell therapy for human brain disorders
  819. New approach to radiation burn treatment by dosimetry-guided surgery combined with autologous mesenchymal Stem cell therapy
  820. Mesenchymal Stem cell therapy in equine musculoskeletal disease: scientific fact or clinical fiction?
  821. Lost and found: cardiac Stem cell therapy revisited
  822. Stem cell therapy for cardiovascular disease
  823. Cardiac Stem cell therapy: need for optimization of efficacy and safety monitoring
  824. Stem cell therapy for cardiac diseases
  825. Stem cell therapy in bone repair and regeneration
  826. The potential role of mesenchymal Stem cell therapy for intervertebral disc degeneration: a critical overview
  827. Multimodality noninvasive imaging demonstrates in vivo cardiac regeneration after mesenchymal Stem cell therapy
  828. Nonmyeloablative Stem cell therapy enhances microcirculation and tissue regeneration in murine inflammatory bowel disease
  829. Practical issues in Stem cell therapy for Alzheimer’s disease
  830. Towards Stem–cell therapy in the endocrine pancreas
  831. Stem cell therapy for cardiac repair: ready for the next step
  832. Increase in vascular permeability and vasodilation are critical for proangiogenic effects of Stem cell therapy
  833. Stem cell plasticity and issues of Stem cell therapy
  834. Intravenous mesenchymal Stem cell therapy early after reperfused acute myocardial infarction improves left ventricular function and alters electrophysiologic …
  835. Current concepts in adult Stem cell therapy for stroke
  836. Stem cell therapy for joint problems using the horse as a clinically relevant animal model
  837. Stem cell therapy for Parkinson’s disease
  838. Stem cell therapy for urinary stress incontinence
  839. Fetomaternal cell trafficking: a story that begins with prenatal diagnosis and may end with Stem cell therapy
  840. Preimplantation genetics: improving access to Stem cell therapy
  841. Stem cell therapy after myocardial infarction: ready for clinical application?
  842. Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances Stem cell therapy
  843. Stem cell therapy for human liver cirrhosis: a cautious analysis of the results
  844. Adult neural Stem cell therapy: expansion in vitro, tracking in vivo and clinical transplantation
  845. Stem cell therapy in postinfarction chronic coronary heart disease
  846. Hyalomatrix: a temporary epidermal barrier, hyaluronan delivery, and neodermis induction syStem for keratinocyte Stem cell therapy
  847. Stem cell therapy delivery: treading the regulatory tightrope
  848. In situ Stem cell therapy: novel targets, familiar challenges
  849. Nonmyeloablative Stem cell transplantation and cell therapy for malignant and non-malignant diseases
  850. Paracrine and differentiation mechanisms underlying Stem cell therapy for the damaged kidney
  851. Gene and Stem cell therapy
  852. Heparin/poly (L-lysine) nanoparticle-coated polymeric microspheres for Stem–cell therapy
  853. Diabetes mellitus: a potential target for Stem cell therapy
  854. Multipotential mesoangioblast Stem cell therapy in the mdx/utrn-/- mouse model for Duchenne muscular dystrophy
  855. Stem cell therapy for sickle cell disease: transplantation and gene therapy
  856. Stem cell therapy for ischemic heart disease: beginning or end of the road?
  857. Neural Stem cell therapy and gastrointestinal biology
  858. Therapeutic angiogenesis for peripheral artery disease: Stem cell therapy
  859. Stem cell therapy for myelin diseases
  860. The allure of Stem cell therapy for muscular dystrophy
  861. Bone marrow Stem cell therapy for myocardial angiogenesis
  862. Gene and Stem cell therapy for erectile dysfunction
  863. The use of Stem cell therapy for cardiovascular disease
  864. Limbal epithelial Stem cell therapy
  865. Which place for Stem cell therapy in the treatment of acute radiation syndrome?
  866. cellular multiparametric MRI of neural Stem cell therapy in a rat glioma model
  867. Pharmacologic management of ischemic stroke: relevance to Stem cell therapy
  868. Stem cell therapy for myocardial repair
  869. Advances in the understanding of sress urinary incontinence and the promise of Stem–cell therapy
  870. Artificial cells: biotechnology, nanomedicine, regenerative medicine, blood substitutes, bioencapsulation, and cell/Stem cell therapy
  871. Stem cells and their applications in skin-cell therapy
  872. The potential of cardiac Stem cell therapy for heart failure
  873. Contemplating the bright future of Stem cell therapy for cardiovascular disease
  874. Stem cell therapy: a hope for dying hearts
  875. Neural Stem cell therapy for neuropsychiatric disorders
  876. Stem cell therapy or snake oil?
  877. Novel therapies for the treatment of cystic fibrosis: new developments in gene and Stem cell therapy
  878. G‐CSF‐based Stem cell therapy for the heart—unresolved issues part A: Paracrine actions, mobilization, and delivery
  879. Stem cell therapy for the treatment of heart failure
  880. … -colony-stimulating factor mobilization of Stem cells in patients with acute or chronic ischaemic heart disease: a non-invasive alternative for clinical Stem cell therapy?
  881. Mesenchymal Stem cell-based HLA-independent cell therapy for tissue engineering of bone and cartilage
  882. Stem–cell therapy: hope and hype
  883. Gene and Stem cell therapy of the hair follicle
  884. Cardiac Stem cell therapy for myocardial regeneration. A clinical perspective.
  885. Embryonic Stem cell therapy.
  886. Isolation of amniotic Stem cell lines with potential for therapy
  887. … donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and cell therapy
  888. Stem cell therapy in the aging hearts of Fisher 344 rats: synergistic effects on myogenesis and angiogenesis
  889. Sources of cardiomyocytes for Stem cell therapy: an update
  890. The Netherlands bans private Stem cell therapy
  891. Adult Stem cell therapy beyond haemopoietic Stem cell transplantation? An update
  892. Gene therapy and Stem cell therapy for cardiovascular diseases today: a model for translational research
  893. The origin of deoxynucleosides in brain: implications for the study of neurogenesis and Stem cell therapy
  894. Stem cell therapy for central nervous syStem demyelinating disease
  895. Stem cell therapy for cardiac arrhythmias
  896. Cardiac Stem cell therapy: present and future
  897. Cancer Stem cell: target for anti‐cancer therapy
  898. T-cell therapy after hematopoietic Stem cell transplantation
  899. A method for quantitative cell tracking using SPECT for the evaluation of myocardial Stem cell therapy
  900. Umbilical cord Stem cell therapy for cerebral palsy
  901. Stem cell therapy for Parkinson’s disease
  902. Tubular regeneration and the role of bone marrow cells:’Stem cell therapy‘–a panacea?
  903. The promise of Stem cell therapy to restore urethral sphincter function
  904. The role of high-dose therapy and Stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study
  905. Bone-marrow-derived cells for cardiac Stem cell therapy: safe or still under scrutiny?
  906. Cancer Stem cell and cancer Stemloids: from biology to therapy
  907. Clinical applications of Stem cell therapy–the pros and cons of Stem cell sources
  908. … and sustain hematopoietic reconstitution after coculture and cografting in lethally irradiated baboons: is autologous Stem cell therapy in nuclear accident …
  909. Safety of intramyocardial Stem cell therapy for the ischemic myocardium: results of the Rostock trial after 5-year follow-up
  910. Functional considerations of Stem cell transplantation therapy for spinal cord repair
  911. Insertional mutagenesis in gene therapy and Stem cell biology
  912. Bone marrow Stem cell therapy for cardiac repair: challenges and perspectives.
  913. Stem–cell therapy for diabetes cure: how close are we?
  914. Platelet lysates promote mesenchymal Stem cell expansion: A safety substitute for animal serum in cell‐based therapy applications
  915. Stem cell therapy for retinal degeneration: retinal neurons from heterologous sources
  916. How does human Stem cell therapy influence gene expression after liver injury?: Microarray evaluation on a rat model
  917. … leukocyte antigen matching estimations in a hypothetical bank of human embryonic Stem cell lines in the Japanese population for use in cell transplantation therapy
  918. Stem cell‐based therapy for Parkinson’s disease
  919. Stem cell therapy for neuropathic pain treatment
  920. Stem cell therapy-Hope and scope in pediatric surgery
  921. Phenotypic characterization and preclinical production of human lineage‐negative cells for regenerative Stem cell therapy
  922. Stem cell therapy for acute myocardial infarction
  923. Stem cell therapy improves myocardial perfusion and cardiac synchronicity: new application for echocardiography
  924. 50th anniversary of artificial cells: their role in biotechnology, nanomedicine, regenerative medicine, blood substitutes, bioencapsulation, cell/Stem cell therapy …
  925. Stem cell strategies for Alzheimer’s disease therapy.
  926. Stem cell therapy and tissue engineering for cardiovascular repair: from basic research to clinical applications.
  927. Stem cell transplantation: a promising therapy for Parkinson’s disease
  928. The role of noninvasive imaging techniques in the assessment of Stem cell therapy after acute myocardial infarction
  929. From bench to bedside? Biomedical scientists’ expectations of Stem cell science as a future therapy for diabetes
  930. In vivo tracking in cardiac Stem cell-based therapy
  931. Hematopoietic Stem cell therapy for malignant diseases
  932. Gene therapy progress and prospects: Stem cell plasticity
  933. Preemptive therapy of EBV‐related lymphoproliferative disease after pediatric haploidentical Stem cell transplantation
  934. Stem cell therapy-A panacea for all ills?
  935. Bone marrow-derived Stem cell therapy in ischemic heart disease
  936. Survival of the fittest: in vivo selection and Stem cell gene therapy
  937. Cardiovascular MRI for Stem cell therapy
  938. Stem cell therapy for hearing loss: Math1 overexpression in VOT-E36 cells
  939. Impact of lenalidomide therapy on Stem cell mobilization and engraftment post-peripheral blood Stem cell transplantation in patients with newly diagnosed …
  940. REVIEW ARTILCE: cell therapy and Stem cells in animal models of motor neuron disorders
  941. Stem cell therapy for glomerular disease
  942. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic Stem–cell transplantation: an international case-control study
  943. A look to the future: prediction, prevention, and cure including islet transplantation and Stem cell therapy
  944. Remaking the body? Scientists’ genetic discourses and practices as examples of changing expectations on embryonic Stem cell therapy for diabetes
  945. The impact of Stem cell therapy in hematology and oncology
  946. Youthful prospects for human Stem‐cell therapy: In another few decades, revised attitudes towards Stem cells could lead to disease prevention and life extension
  947. A natural Stem cell therapy? How novel findings and biotechnology clarify the ethics of Stem cell research
  948. Dutch clinic is ordered to stop giving Stem cell therapy
  949. Stem cell therapy in stroke: strategies in basic study and clinical application
  950. Hematopoietic Stem cell mobilization therapy accelerates recovery of renal function independent of Stem cell contribution
  951. Evaluation of the functional assessment of cancer therapy cognitive scale with hematopoetic Stem cell transplant patients
  952. Development of human umbilical cord matrix Stem cell-based gene therapy for experimental lung tumors
  953. Celocentesis for in utero Stem cell therapy: where we now stand and future directions
  954. Clinical trials in Stem cell therapy: pitfalls and lessons for the future
  955. Stem cell therapy of acute spinal cord injury in dogs
  956. G‐CSF‐Based Stem cell therapy for the Heart—Unresolved Issues Part B: Stem cells, Engraftment, Transdifferentiation, and Bioengineering
  957. The challenge for Stem cell therapy
  958. … Renal Failure by Stem cell therapy—Paracrine Secretion Versus Transdifferentiation into Resident cells: Administered Mesenchymal Stem cells Protect against …
  959. Nonmyeloablative Stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative …
  960. The role of cytotoxic therapy with hematopoietic Stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review
  961. High-dose therapy and autologous blood Stem–cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term …
  962. Stem cell therapy in patients with multiple sclerosis
  963. Embryonic Stem cells: prospects for developmental biology and cell therapy
  964. Cardiac Stem cell therapy from bench to bedside
  965. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with Stem cell gene therapy
  966. Stem cell and gene-based therapy
  967. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic Stem cell transplantation
  968. Stem cell therapy for diabetes mellitus: progress, prospects and challenges
  969. Infectious complication in 314 patients after high-dose therapy and autologous hematopoietic Stem cell transplantation: risk factors analysis and outcome
  970. Promises and pitfalls of Stem cell therapy for promotion of bone healing
  971. Quantitative assessment of molecular remission after high-dose therapy with autologous Stem cell transplantation predicts long-term remission in mantle cell …
  972. Launching a clinical program of Stem cell therapy for cardiovascular repair
  973. The role of cytotoxic therapy with hematopoietic Stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review
  974. Potential of Stem cell based therapy and tissue engineering in the regeneration of the central nervous syStem
  975. Allogeneic hematopoietic Stem cell transplantation as part of postremission therapy improves survival for adult patients with high‐risk acute lymphoblastic leukemia: a …
  976. … of the left ventricular myocardial contraction with Stem cell therapy: new insights into the therapeutic implication of Stem cell therapy in myocardial infarction
  977. Allogeneic Stem–cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma
  978. Embryonic Stem cells: meeting the needs for cell therapy
  979. Successful reconstitution of immunity in ADA-SCID by Stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning
  980. High-dose therapy followed by autologous purged Stem–cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a …
  981. Stem–cell therapy for hepatobiliary pancreatic disease
  982. Safety and efficacy of enzyme replacement therapy in combination with hematopoietic Stem cell transplantation in Hurler syndrome
  983. Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic Stem–cell transplantation results in favorable outcomes
  984. Stem cell therapy in cardiovascular diseases
  985. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous Stem cell transplantation in untreated patients with …
  986. Mesenchymal Stem cell therapy for multiple sclerosis
  987. The role of cytotoxic therapy with hematopoietic Stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based …
  988. … With Myeloablative Chemotherapy and Autologous Stem–cell Transplantation in Refractory Neuroblastoma: A New Approaches to Neuroblastoma therapy …
  989. High-dose chemotherapy with autologous Stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a …
  990. Autologous Stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis
  991. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic Stem cell transplantation
  992. Stem cell transplantation and gene therapy for hemoglobinopathies.
  993. The effect of first-line imatinib interim therapy on the outcome of allogeneic Stem cell transplantation in adults with newly diagnosed Philadelphia chromosome …
  994. Stem cell therapy in the heart and vasculature
  995. Perspectives of gene therapy in Stem cell tissue engineering
  996. Correction of murine hemophilia A by hematopoietic Stem cell gene therapy
  997. Stem cell therapy
  998. Stem cell migration: a quintessential stepping stone to successful therapy
  999. Dendritic cell therapy for tolerance induction to Stem cell transplants
  1000. Integration of genomics, proteomics, and imaging for cardiac Stem cell therapy
  1001. … in the peripheral blood after allogeneic Stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy
  1002. Induction of neurotrophin expression via human adult mesenchymal Stem cells: implication for cell therapy in neurodegenerative diseases
  1003. … syStem-based comparison between human dental pulp Stem cells (hDPSCs) and human mesenchymal Stem cells (hMSCs) for tissue engineering cell therapy
  1004. Inflammatory response to mucosal barrier injury after myeloablative therapy in allogeneic Stem cell transplant recipients
  1005. Low‐energy laser therapy for prevention of oral mucositis in hematopoietic Stem cell transplantation
  1006. New era of cardiac Stem cell therapy in heart failure
  1007. Cripto as a Target for Improving Embryonic Stem cell–Based therapy in Parkinson’s Disease
  1008. Gene and Stem cell therapy in the treatment of erectile dysfunction and pulmonary hypertension; potential treatments for the common problem of endothelial …
  1009. Stem cell therapy in Iran
  1010. Current practice and future perspectives of myocardial Stem cell therapy
  1011. Current status and concepts of Stem cell therapy
  1012. Rituximab and DHAP followed by intensive therapy with autologous Stem–cell transplantation as first-line therapy for mantle cell lymphoma
  1013. Stem cell therapy in acute myocardial infarction
  1014. Stem cell therapy for myocardial regeneration: creating hype ignoring reality
  1015. The safety of interferon‐γ‐1b therapy for invasive fungal infections after hematopoietic Stem cell transplantation
  1016. Targeting, imaging, and therapy using a humanized antiprostate Stem cell antigen (PSCA) antibody
  1017. Mesenchymal Stem cell therapy of brain ischemic stroke in rats
  1018. Stem cell-based therapy for the treatment of Type 1 diabetes mellitus
  1019. Novel tyrosine kinase inhibitor therapy before allogeneic Stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant …
  1020. Cardiovascular therapeutic aspects of cell therapy and Stem cells
  1021. Neuropsychological function in high-risk breast cancer survivors after Stem–cell supported high-dose therapy versus standard-dose chemotherapy: evaluation …
  1022. Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic Stem–cell transplant
  1023. Effectiveness of prophylactic anti‐HBV therapy in allogeneic hematopoietic Stem cell transplantation with HBsAg positive donors
  1024. … , dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous Stem cell …
  1025. Stem cell therapy in chronic heart failure
  1026. Tumorigenesis and embryonic Stem cell-derived therapy
  1027. Imatinib therapy prior to myeloablative allogeneic Stem cell transplantation
  1028. Stem cell therapy in heart failure: where do we stand and where are we heading?
  1029. Development of hematopoietic Stem cell gene therapy for Wiskott-Aldrich syndrome.
  1030. Neural Stem cells as biological minipumps: a faster route to cell therapy for the CNS?
  1031. High-dose therapy with autologous Stem cell transplantation in first response in mantle cell lymphoma
  1032. Stem cell pharmacogenomics: a reality check on Stem cell therapy.
  1033. cell therapy using allogeneic bone marrow mesenchymal Stem cells prevents tissue damage in collagen‐induced arthritis
  1034. Stem cell research: cloning, therapy and scientific fraud
  1035. Stem cell therapy. Biology of hematopoietic Stem cells
  1036. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic Stem cell …
  1037. Hematopoietic Stem–cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimens
  1038. Myogenic Stem cells: regeneration and cell therapy in human skeletal muscle
  1039. Lessons for the Stem cell discourse from the gene therapy experience
  1040. Targeting the most critical cells: approaching leukemia therapy as a problem in Stem cell biology
  1041. “Stealth immune tolerance” in Stem cell transplantation: potential for “universal donors” in myocardial regenerative therapy
  1042. Ethical legal and social issues in Stem cell research and therapy
  1043. Stem cell therapy for demyelinating disorders
  1044. Hematopoietic Stem cell–targeted neonatal gene therapy reverses lethally progressive osteopetrosis in oc/oc mice
  1045. Stem cells engineering for cell-based therapy
  1046. … veno-occlusive disease in pediatric Stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy
  1047. … conditioning allogeneic Stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and cellular therapy …
  1048. Value of Stem cell therapy for the treatment of stress incontinence. Current status and perspectives
  1049. The role of high-dose therapy and autologous Stem cell transplantation for pediatric bone and soft tissue sarcomas
  1050. … -occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood Stem cell transplantation in multiple …
  1051. Application of liver Stem cells for cell therapy
  1052. Stem cell therapy: a new perspective for the treatment of ischemic heart failure
  1053. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic Stem cell transplantation
  1054. Estrogen-progestin therapy in women after Stem cell transplant: our experience and literature review
  1055. Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic Stem cell recipients
  1056. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic Stem cell transplant recipients
  1057. Mesenchymal Stem cell therapy for the injured heart
  1058. Hematopoietic Stem cell gene therapy: dead or alive?
  1059. The promise of Stem cell therapy for eye disorders
  1060. Towards the generation of patient-specific pluripotent Stem cells for combined gene and cell therapy of hematologic disorders
  1061. Use of bortezomib as induction therapy prior to Stem cell transplantation in frontline treatment of multiple myeloma: impact on Stem cell harvesting and engraftment
  1062. Good manufacturing practice-compliant expansion of marrow-derived Stem and progenitor cells for cell therapy
  1063. Salvage therapy for CLL and the role of Stem cell transplantation
  1064. Chemotherapy with rituximab followed by high‐dose therapy and autologous Stem cell transplantation in patients with mantle cell lymphoma
  1065. Short intensive sequential therapy followed by autologous Stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma
  1066. Haematopoietic Stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma
  1067. Marked recovery of severe renal lesions in POEMS syndrome with high-dose melphalan therapy supported by autologous blood Stem cell transplantation
  1068. Stem cell therapy for intervertebral disc degeneration: In vitro study
  1069. Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load⩾ 10000 copies/ml: a safe and effective strategy for allogeneic Stem cell …
  1070. High-dose therapy and autologous hematopoietic Stem cell transplantation for patients with primary syStemic amyloidosis: a Center for International Blood and Marrow …
  1071. A randomized comparison of empiric or pre-emptive antibiotic therapy after hematopoietic Stem cell transplantation
  1072. Stem cell controversy to stall European tissue and cell therapy rules
  1073. cell therapy, Stem cells and brain repair
  1074. Outcome of hematopoietic Stem cell transplantation for pediatric patients with therapy‐related acute myeloid leukemia or myelodysplastic syndrome
  1075. New strategies of antifungal therapy in hematopoietic Stem cell transplant recipients and patients with hematological malignancies
  1076. Stem cell Transplantation: Biology, Processes, therapy
  1077. Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with Stem cell transplant: review and consensus statement
  1078. therapy of Duchenne muscular dystrophy with umbilical cord blood Stem cell transplantation
  1079. Human embryonic Stem cell therapy for Parkinson’s disease
  1080. Autologous Stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome
  1081. Motor function recovery after adipose tissue derived mesenchymal Stem cell therapy in rats with cerebral infarction
  1082. Efficacy of high‐dose therapy and hematopoietic Stem cell transplantation for mantle cell lymphoma
  1083. Correction of the disease phenotype in canine leukocyte adhesion deficiency using ex vivo hematopoietic Stem cell gene therapy
  1084. High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic Stem cell transplantation
  1085. Pre-mobilization therapy blood CD34+ cell count predicts the likelihood of successful hematopoietic Stem cell mobilization
  1086. Cardiac effects within 3 months of BEAC high‐dose therapy in non‐Hodgkin’s lymphoma patients undergoing autologous Stem cell transplantation
  1087. High dose chemotherapy and autologous Stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes …
  1088. … intensity conditioning and allogeneic Stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non …
  1089. High-dose chemotherapy with Stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up
  1090. Thalidomide salvage therapy following allogeneic Stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du …
  1091. Characterization of an immunodeficient mouse model of mucopolysaccharidosis type I suitable for preclinical testing of human Stem cell and gene therapy
  1092. Hematopoietic Stem cell gene therapy with drug resistance genes: an update
  1093. Stem cell therapy in end-stage ischaemic heart failure: a catheter-based therapeutic strategy targeting myocardial viability
  1094. … therapy with ICE Followed by High Dose therapy and Autologous Stem cell Transplantation for Relapsed/Refractory Peripheral T-cell Lymphomas: Minimal Benefit …
  1095. Preclinical trials for Stem cell therapy
  1096. Complexity of the human acute myeloid leukemia Stem cell compartment: implications for therapy
  1097. Value of surveillance blood culture for early diagnosis of occult bacteremia in patients on corticosteroid therapy following allogeneic hematopoietic Stem cell …
  1098. Catheter-based Stem cell and gene therapy for refractory myocardial ischemia
  1099. Stem cell and Stem cell therapy in Thailand
  1100. Reduced intensity conditioning allows for up-front allogeneic hematopoietic Stem cell transplantation after cytoreductive induction therapy in newly-diagnosed …
  1101. Adoptive precursor cell therapy to enhance immune reconstitution after hematopoietic Stem cell transplantation
  1102. Posaconazole salvage therapy allows successful allogeneic hematopoietic Stem cell transplantation in patients with refractory invasive mold infections
  1103. Characterization of BioSafe SEPAX Manufactured Stem cell Intended for Cardiac cell therapy.
  1104. Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic Stem cell transplantation
  1105. The role of high-dose therapy and autologous Stem cell transplantation in patients with primary refractory Hodgkin’s lymphoma: a report from the Gruppo …
  1106. Diagnostic yield of bronchoalveolar lavage is low in allogeneic hematopoietic Stem cell recipients receiving immunosuppressive therapy or with acute graft …
  1107. Medium-term survival without haematopoietic Stem cell transplantation in a case of IPEX: insights into nutritional and immunosuppressive therapy
  1108. The effect of neural embryonic Stem cell therapy in a rat model of cavernosal nerve injury
  1109. Review: Mesenchymal Stem cells: cell–Based Reconstructive therapy in Orthopedics
  1110. Initial therapy of multiple myeloma patients who are not candidates for Stem cell transplantation
  1111. Mantle cell lymphoma (MCL): induction therapy with HyperCVAD/High-dose methotrexate and cytarabine (MC)(±rituximab) improves results of autologous Stem cell …
  1112. High-dose chemotherapy and autologous hematopoietic Stem cell transplantation for metastatic breast cancer: a therapy whose time has passed
  1113. Melphalan 200 mg/m2 with blood Stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related …
  1114. Human embryonic Stem cell therapy, what is the attitude of the public?
  1115. Progress and clashes in Stem cell therapy research
  1116. The role of Stem–cell transplantation in chronic lympocytic leukemia risk-adapted therapy
  1117. Haematopoietic Stem cell gene therapy to treat autoimmune disease
  1118. Rising antigenemia levels may be misleading in pre-emptive therapy of human cytomegalovirus infection in allogeneic hematopoietic Stem cell transplant recipients
  1119. Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic Stem cell transplantation: a single-center experience in Korea
  1120. … Stem–cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy
  1121. Effect of prior rituximab on high-dose therapy and autologous Stem cell transplantation in follicular lymphoma
  1122. Stem cell therapy in ischemic heart disease
  1123. High-dose therapy and autologous Stem cell transplantation in Korean patients with aggressive T/NK-cell lymphoma
  1124. Stem cell transplantation for patients with Fanconi anemia with low-dose cyclophosphamide and antithymocyte globulins without the use of radiation therapy
  1125. Stem cell therapy for chronic cardiac insufficiency–therapy of the future?
  1126. Outcome of Allogeneic Stem cell Transplantation after Hypomethylating therapy with 2′-Deoxy-5 Azacytidine for Patients with Myelodysplastic Syndrome.
  1127. Rituximab long-term maintenance therapy after autologous Stem cell transplantation in patients with B-cell non-Hodgkin’s lymphoma
  1128. First-line thalidomide–dexamethasone therapy in preparation for autologous Stem cell transplantation in young patients (< 61 years) with symptomatic multiple …
  1129. Long-term event-free survivors after high-dose therapy and autologous Stem–cell transplantation for low-grade follicular lymphoma
  1130. … staging syStems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood Stem cell transplantation as first-line therapy
  1131. Human cordonal Stem cell intraperitoneal injection can represent a rescue therapy after an acute hepatic damage in immunocompetent rats
  1132. Stem cell therapy still not here
  1133. … in a multicenter observational database: relevance for design of a clinical trial for high dose immunosuppressive therapy with autologous hematopoietic Stem cell …
  1134. Collection of fetal blood for Stem cell research and therapy
  1135. Umbilical Cord Stem cell therapy: The Gift of Healing from Healthy Newborns
  1136. Growth hormone (GH) secretion and response to GH therapy after total body irradiation and haematopoietic Stem cell transplantation during childhood
  1137. … therapy for Treatment of Autoimmune Diseases, Basic Science and Clinical Studies, Including New Developments in Hematopoietic and Mesenchymal Stem cell …
  1138. Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic Stem cell transplantation: a molecular analysis
  1139. Current concepts of Stem cell therapy
  1140. Diabetic cardiomyopathy: a “cardiac Stem cell disease” involving p66Shc, an attractive novel molecular target for heart failure therapy
  1141. The yin and yang of Stem cell gene therapy: insights into hematopoiesis, leukemogenesis, and gene therapy safety
  1142. Autologous Stem cell Transplantation as First-Line therapy in Peripheral T-cell Lymphomas. A Prospective Multicenter Study.
  1143. Angiogenetic factors and biochemical markers of bone metabolism in POEMS syndrome treated with high-dose therapy and autologous Stem cell support
  1144. Recent View of Stem cell Plasticity and Stem cell therapy
  1145. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous Stem–cell transplantation as first-line treatment in …
  1146. The therapeutic potential of mesenchymal Stem cells: cell-& tissue-based therapy
  1147. Regulating Stem cell research & therapy
  1148. Embryonic Stem cell-based diabetes therapy—a long road to travel
  1149. Etanercept therapy for late-onset idiopathic pneumonia syndrome after nonmyeloablative allogeneic hematopoietic Stem cell transplantation
  1150. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous Stem cell …
  1151. Caspofungin as second-line therapy for fever of unknown origin or invasive fungal infection following allogeneic Stem cell transplantation
  1152. Stem and progenitor cell–based therapy of the human central nervous syStem
  1153. Immobilization of mesenchymal Stem cells and monocytes in biocompatible microcapsules to cell therapy
  1154. T cell suicide gene therapy to aid haematopoietic Stem cell transplantation
  1155. … therapy between chemotherapeutic cycles and in vivo purging prior to autologous Stem cell transplantation, followed by maintenance therapy is a feasible …
  1156. Suppressive anti-HCV therapy for prevention of donor to recipient transmission in Stem cell transplantation
  1157. Frontline therapy with early intensification and autologous Stem cell transplantation versus conventional chemotherapy in unselected high-risk, aggressive non …
  1158. Mechanistic insights into cardiac Stem cell therapy from a histopathologic perspective
  1159. Modified total body irradiation as a planned second high-dose therapy with Stem cell infusion for patients with bone-based malignancies
  1160. Early Stem cell transplantation for refractory acute leukemia after salvage therapy with high-dose etoposide and cyclophosphamide
  1161. Successful therapy with whole‐lung lavage and autologous peripheral blood Stem cell transplantation for pulmonary alveolar proteinosis complicating acute …
  1162. … during fluconazole prophylaxis followed by breakthrough zygomycosis during caspofungin therapy in a patient with severe aplastic anemia who underwent Stem cell …
  1163. The shady side of embryonic Stem cell therapy
  1164. … of In Vitro Irradiated CD34+ cells in the Presence of SCF, FLT3 Ligand, TPO and IL3: Potential Application to Autologous cell therapy in Accidentally Irradiated …
  1165. The KIDStem European research training network: Developing a Stem cell based therapy to replace nephrons lost through reflux nephropathy
  1166. Peritransplant use of ultraviolet-B irradiation (UV-B) therapy is detrimental to allogeneic Stem cell transplantation outcome
  1167. Adefovir therapy for lamivudine escape and hepatitis B virus reactivation after reduced intensity conditioning allogeneic Stem cell transplantation
  1168. Successful interim therapy with imatinib prior to allogeneic Stem cell transplantation in Philadelphia chromosome‐positive acute myeloid leukemia
  1169. rHuEpo before high-dose therapy allows autologous peripheral Stem–cell transplantation without red blood cell transfusion: a pilot study
  1170. Stem cells, Stem cell therapy, and ethical problems of medicine
  1171. The World of Stem cell therapy: Anonymity is not an Option
  1172. The effect of quantification standards used in real-time CMV PCR assays on guidelines for initiation of therapy in allogeneic Stem cell transplant patients
  1173. Mesenchymal Stem cells characteristics, niches, and applications for cell therapy
  1174. Gene and cell therapy involving hematopoietic Stem cell
  1175. Cardiovascular regeneration and Stem cell therapy
  1176. Autologous Stem cell gene therapy: toward a universal platform for personalized therapy
  1177. Embryonic Stem cell–derived astrocytes: a novel gene therapy vector for brain tumors
  1178. The impact of histologic grade on the outcome of high-dose therapy and autologous Stem cell transplantation for follicular lymphoma
  1179. A novel intensive induction therapy for high‐risk neuroblastoma utilizing sequential peripheral blood Stem cell collection and infusion as hematopoietic support
  1180. Use of iron oxide MR contrast agents for monitoring Stem cell therapy
  1181. Potentials and limitations of Stem cell therapy in myocardial disease
  1182. Stem cell based cell therapy for muscular dystrophy
  1183. Cure of a patient with profoundly chemotherapy-refractory primary mediastinal large B-cell lymphoma: role of rituximab, high-dose therapy, and allogeneic Stem cell …
  1184. High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous Stem cell transplantation
  1185. Efficacy of recombinant human erythropoietin therapy started one month after autologous peripheral blood Stem cell transplantation
  1186. cell transplant and regenerative therapy with Stem cells
  1187. Potential application of embryonic Stem cells in Parkinson’s disease: drug screening and cell therapy
  1188. 328: Transurethral Ultrasound Guided Stem cell therapy of Urinary Incontinence
  1189. … International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin’s lymphomas treated with high-dose BEAM therapy and autologous Stem cell …
  1190. Effect of neurotrophic factor and Stem cell therapy on axonal regeneration after spinal cord injury: Overseas progress in basic and clinical researches
  1191. A randomized, double-blinded, pilot trial of aprepitant added to standard antiemetics during conditioning therapy for hematopoietic Stem cell transplant (HSCT)
  1192. Can Basic Fibroblast Growth Factor Pre-Treatment Enhance Mesenchymal Stem cell therapy in Undecorticated Posterior Spinal Fusion?
  1193. Dog leukocyte antigen-haploidentical Stem cell allografts after anti-CD44 therapy and nonmyeloablative conditioning in a preclinical canine model
  1194. The Impact of Disease Status on the Outcome of High-Dose therapy (HDT) and Autologous Stem cell Transplantation (ASCT) for Peripheral T-cell …
  1195. High‐dose therapy and autologous Stem‐cell transplantation can improve event‐free survival for indolent lymphoma: a study using patients as their own controls
  1196. 230. In Vivo Fluorescence Tracking SyStem for Cardiac Stem cell therapy
  1197. Autologous bone marrow Stem cell or peripheral blood endothelial progenitor cell therapy in patients with peripheral limb ischaemia
  1198. Stem cells and plasticity of skeletal muscle cell differentiation: potential application to cell therapy for degenerative muscular diseases
  1199. Initial therapy of multiple myeloma in patients who are candidates for Stem cell transplantation
  1200. Is combination antifungal therapy for invasive aspergillosis a necessity in hematopoietic Stem–cell transplant recipients?
  1201. The future of allogeneic hematopoietic Stem cell transplantation for metastatic renal cell carcinoma in the era of target-specific therapy
  1202. … therapy for myeloma: Thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high‐dose melphalan with autologous Stem cell …
  1203. Lenalidomide as induction therapy before allogeneic Stem cell transplantation in a patient with proliferative CMML-2 and del (5q) not involving the EGR1 locus
  1204. IMVP-16/Pd followed by high-dose chemotherapy and autologous Stem cell transplantation as a salvage therapy for refractory or relapsed peripheral T-cell …
  1205. Embryo Stem cells from parthenotes and embryos produced by nuclear transfer: the distinction between them and their potential value in cell therapy
  1206. Evaluation of the therapeutic responses of Stem cell therapy after myocardial infarction: Comparison of Thallium-201 gated-SPECT with 18F-FDG metabolism imaging
  1207. cell therapy for heart failure—muscle, bone marrow, blood, and cardiac-derived Stem cells
  1208. Mechanisms and applications of Stem cell gene therapy in autoimmunity
  1209. CD34+ selected haematopoietic Stem cell (HSC) not preceded by any immunosuppressive therapy as effective treatment for graft failure
  1210. … circulation with localized transplantation in situ at the site of tissue/organ damage: a possible strategy to optimize the efficacy of Stem cell transplantation therapy
  1211. Neural Stem cell therapy in lysosomal storage disorders
  1212. Embryonic Stem cell-based therapy for the treatment of diabetes mellitus: a work in progress
  1213. Pre‐Stem cell transplantation enzyme replacement therapy in Hurler syndrome does not lead to significant antibody formation or delayed recovery of the endogenous …
  1214. Triple antifungal therapy for severe syStemic candidiasis allowed performance of allogeneic Stem cell transplantation
  1215. Gene and Stem cell therapy for autoimmune demyelination
  1216. High‐dose therapy and autologous Stem cell transplantation for children with HIV‐associated non‐Hodgkin lymphoma
  1217. Stability of colon Stem cell methylation after neo-adjuvant therapy in a patient with attenuated familial adenomatous polyposis
  1218. Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous Stem cell transplant in multiple myeloma patients
  1219. … recurred hemophagocytic syndrome in remission state of anaplastic large cell lymphoma following high‐dose therapy and autologous peripheral blood Stem cell …
  1220. Successful therapy of patients in therapy-resistant cardiogenic shock with intracoronary, autologous bone marrow Stem cell transplantation
  1221. Salvage therapy of refractory chronic disseminated candidiasis in a patient with acute myeloid leukaemia and secondary prophylaxis during allogeneic Stem cell …
  1222. 568. Ex Vivo Mesenchymal Stem cell therapy with rAAV2 Encoding BMP-2 Enhances Bone Regeneration in Ovariectomized Mouse Model
  1223. Peripheral blood Stem cell mobilization and harvesting after fludarabine therapy for low-grade lymphoma and chronic lymphocytic leukemia
  1224. Molecular imaging is indispensable for the development of Stem cell-based myocardial regenerative therapy
  1225. Cancer Stem cells–new and potentially important targets for the therapy of oral squamous cell carcinoma
  1226. Stem cell therapy of IBD
  1227. The effect of induction therapy with novel agents on Stem cell mobilization in multiple myeloma
  1228. Stem cell therapy: an emerging science
  1229. Stem cell therapy: An Emerging Science
  1230. … amphotericin B and combined syStemic antifungal therapy for the treatment of severe pulmonary aspergillosis after allogeneic hematopoietic Stem cell transplant for a …
  1231. Stem cell therapy ahead
  1232. Autologous bone marrow Stem cell therapy for an ischemic ulcer of the lower limb in a diabetic patient
  1233. Febrile neutropenia in paediatric peripheral blood Stem cell transplantation, in-vitro sensitivity data and clinical response to empirical antibiotic therapy
  1234. … Complete Responses (CR/nCR) after Initial therapy with Bortezomib (Velcade®), Doxil®, and Dexamethasone (VDD) Is Further Increased after Autologous Stem cell …
  1235. Stem cell Biotechnology for cell therapy
  1236. Maintenance therapy by Glivec® and Pegasys® in Patients with Philadelphia Positive Acute Lymphocytic Leukemia Not Eligible for Hematopoietic Stem cell …
  1237. Planning time for peripheral blood Stem cell infusion after high-dose targeted radionuclide therapy using dosimetry
  1238. An International Conversation on Stem cell Gene therapy: 4th Stem cell Conference on Stem cell Gene therapy Thessaloniki, Greece, 13–17 September …
  1239. Hematopoietic Stem cell Gene therapy for Wiskott-Aldrich Syndrome.
  1240. Investigation progress of imaging techniques monitoring Stem cell therapy
  1241. KINETIC CONSIDERATIONS FOR. Stem cell therapy
  1242. cellular therapy can be affected by the sex of the Stem cell used
  1243. Biological modifiers as cytoreductive therapy before Stem cell transplant in previously untreated patientswith multiple myeloma
  1244. Resistance to pretransplant imatinib therapy may adversely affect the outcome of allogeneic Stem cell transplantation in CML
  1245. Stem cell therapy for Liver Disease
  1246. Stem cell therapy for myocardial infarction
  1247. 360. Transmitochondrial Stem cells: Toward Autologous Cybrid Stem cell therapy and Synergistic Transient Regenerative Gene therapy for Mitochondrial (mt) DNA …
  1248. Second Autologous Stem cell Transplant (ASCT) as Salvage therapy in Patients with Relapsed Multiple Myeloma: Improved Outcomes in Patients with Longer …
  1249. Autologous or allogeneic Stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy
  1250. Gene and Stem cell therapy
  1251. Stem cell therapy in heart disease
  1252. Hematopoietic Stem cell Transplantation, StemCells, and Gene therapy
  1253. … Reduces the Cytotoxic Effects of In Vitro Expanded NK cells: Implications for Adoptive NK cell therapy in the Setting of Allogeneic Hematopoietic Stem cell …
  1254. A PETHEMA study of high-dose therapy/Stem cell support (HDT), including tandem transplant, in primary refractory multiple myeloma (MM): Identification of two …
  1255. Nuclear cloning, embryonic Stem cells and cell therapy: Promise, problems, reality
  1256. Stem cell therapy of AD: Which way to go?
  1257. Concerns Regarding Stem cell therapy from the Clinical Perspective
  1258. therapy-related myelodysplastic syndrome following acute promyelocytic leukemia and biphenotypic acute leukemia following Stem cell transplantation in the …
  1259. Durable remissions are rare following high dose therapy with autologous Stem cell transplantation for adults with” paediatric” bone and soft tissue sarcomas
  1260. Neural Stem cells and cell replacement therapy: making the right cells
  1261. Stem cell therapy in Liver Disease
  1262. Stem cell therapy for myocardial infarction
  1263. … Schedule Finding Study of Maintenance therapy with Low-Dose 5-Azacitidine (AZA) after Allogeneic Hematopoietic Stem cell Transplantation (HSCT) for …
  1264. Stem cell therapy: Moving towards reality
  1265. … : ARTIFICIAL cells: Biotechnology, Nanomedicine, Regenerative Medicine, Blood Substitutes, Bioencapsulation, and cell/Stem cell therapy. By Thomas Ming Swi …
  1266. Stem–cell therapy for type 1 diabetes
  1267. The Role of Pet Scan in Stem cell therapy
  1268. Developmental aberrations of permanent teeth after high-dose anticancer therapy in childhood: A study on Stem cell transplant recipients
  1269. Stem cell therapy in Acute Coronary Syndrome
  1270. … PCR detection method for preemptive therapy of cytomegalovirus infection in patients after allogeneic hematopoietic Stem cell transplantation–single-centre …
  1271. Development of Adult Stem cell therapy Products
  1272. Is Regulation of Stem cell therapy and Therapeutic Cloning Needed?
  1273. New developments in Stem cell biology and therapy. meeting report from the working group of the German Society for Hematology and Oncology
  1274. Hope to the cancer therapy: cancer Stem cell
  1275. Stem cell therapy in endocrinology: reality and challenges
  1276. New Approach in Ischemic Stroke Treatment: Stem cell therapy
  1277. Adult Stem cell therapy–an option for the brain?
  1278. Stem cell therapy for Erectile Dysfunction
  1279. The Basics of Pathologic Assessment in Experimental Models of Stem cell therapy
  1280. Understanding the Basics of Clinical Imaging for Assessing Stem cell therapy in the Heart
  1281. Stem cell therapy for Patients with Myocardial Infarction
  1282. Intensive multimodality therapy including paclitaxel and reduced-intensity allogeneic hematopoietic Stem cell transplantation in the treatment of adrenal cancer with …
  1283. Clinical Utilization of Stem cell therapy in Acute Myocardial Infarction
  1284. Stem cell therapy In Endocrinology-Scope And Limitations
  1285. Stem cell transplantation as consolidation therapy for children in first-remission AML: a single-center report
  1286. Second autologous Stem cell transplantation as salvage therapy in patients with relapsed multiple myeloma: Improved outcomes in patients with longer disease free …
  1287. Embryonic Stem cell therapy for diabetes mellitus
  1288. Mechanisms of myocardium repairing by Stem cell therapy
  1289. Stem cell therapy FOR MYOCARDIAL REGENERATION
  1290. Stem cell therapy-role in corneal diseases: mini review
  1291. 1088. Stem cell Gene therapy with No Pre-Conditioning for the ADA-Deficiency Patients Leads to Generalized Detoxification and Delayed, but Steady Hematological …
  1292. Hearing loss treatment through Stem cell therapy
  1293. Exploring Stem cell therapy Potentials: A Q&A with Anthony G. Payne, Ph.D.
  1294. Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic Stem cell transplantation: a single-center experience in Korea
  1295. Current Status of G-CSF Based Stem cell therapy for Patients with Myocardial Infarction
  1296. Future of Stem–cell therapy for neuromuscular diseases
  1297. Long-term remission of paraprotein-induced immunotactoid glomerulopathy after high-dose therapy and autologous blood Stem cell transplantation
  1298. Stem cell therapy for failing hearts: there is something else beyond the cells
  1299. Cardiac Stem cell therapy research in China
  1300. The Role of Non-invasive Imaging and cell Labelling Techniques in the Clinical Assessment of Stem cell therapy
  1301. Bringing cardiac Stem cell therapy into the clinic
  1302. A comparative review of legal and ethical issues arising from Stem cell therapy and therapeutic cloning
  1303. Myocardium repair with Stem cell therapy
  1304. Risk-adapted preemptive therapy for cytomegalovirus diseases after allogeneic hematopoietic Stem cell transplantation
  1305. Guided cardiogenesis for safe Stem cell‐based therapy
  1306. Stem cell therapy of Intractable Human Diseases; Potentials and Pitfalls
  1307. Efficacy of High-Dose therapy and Autologous Stem cell Transplantation for Chemoresistant Hodgkin’s Lymphoma.
  1308. Stem cell therapy jumps another ethical hurdle
  1309. Adult neural Stem cell therapy for the brain
  1310. Stem cell therapy using Umbilical Cord Blood in Liver Disease
  1311. Pre-Transplant Rituximab therapy Is Associated with Improved Progression-Free and Overall Survival in Patients Undergoing Autologous Hematopoietic Stem cell …
  1312. Stem cell therapy in animal models of inherited metabolic diseases
  1313. Growth and differentiation of human embryonic Stem cells for cardiac cell replacement therapy
  1314. Drug evaluation: ADA-transduced hematopoietic Stem cell therapy for ADA-SCID.
  1315. In Vitro Model SyStem for Cardiac Stem cell therapy
  1316. Efficacy of posaconazole (POS) vs standard therapy and safety of POS in hematopoietic Stem cell transplant (HSCT) recipients vs other patients with aspergillosis
  1317. Does mesenchymal Stem cell therapy help multiple sclerosis patients? report of a pilot study
  1318. Evaluation of Magnetic Nanoparticles for Stem cell therapy Using a Microfluidic SyStem
  1319. The Role of High Dose therapy and Stem cell Rescue in the Management of T-cell Malignant Lymphomas (TCL): A BSBMT and ABMTRR Study.
  1320. Hematopoietic AC133+ Stem cell therapy for patients with severe peripheral vascular disease
  1321. Increasing importance of Stem cell gene therapy in adenosine deaminase deficiency?
  1322. Dendritic cell therapy for Tolerance Induction to Stem cell Transplantation
  1323. Regenerative medicine and cardiovascular diseases: Stem cell therapy
  1324. Stem cell therapy FOR DEGENERATIVE DISC DISEASE: IN VITRO AND IN VIVO STUDY
  1325. Complete remission upon bortezomib–dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic Stem cell …
  1326. … -retinoic acid+ dexamethasone+ alpha interferon as maintenance therapy following high-dose chemotherapy and autologous Stem cell transplant for multiple …
  1327. Stem cell therapy, smoking and obesity: getting the priorities right for reducing cardiovascular diseases
  1328. The Application of Mesenchymal Stem cell therapy on Multiple SyStem Atrophy
  1329. … High Dose Chemotherapy (HDC) Prior to Autologous Stem cell Transplantation (ASCT) as First Line therapy in Stage III-IV Diffuse Large B-cell Lymphoma (B-DLCL …
  1330. Cancer Stem cell targeted therapy: Removing the sword of Damocles
  1331. Does Stem cell therapy for ischemic cardiomyopathy result in the improvemnt of congestive heart failure: A prospective randomized study
  1332. The effects of music therapy on anxiety, nausea and vomiting in patients receiving total body irradiation for hematopoietic Stem cell transplantation
  1333. Stem cell therapy after irradiation of a malignant asecretory pheochromocytoma–a case report
  1334. Indications for hematopoietic Stem cell therapy for patients with diagnosis of myelodysplastic syndromes
  1335. Stem cell therapy FOR INTERVERTEBRAL DISC DEGENERATION IN-VITRO AND IN-VIVO FEASIBILITY STUDY
  1336. Stem cell therapy in rat hind limb ischemic injury
  1337. … Large B-cell Lymphoma (DLBCL) Does Not Affect Disease-Free (DFS) or Overall Survival (OS) Following High Dose therapy (HDT) and Autologous Stem cell …
  1338. CD34+ Stem cell therapy in Chronic Stroke Patients
  1339. Safety and Efficacy of Enzyme Replacement therapy (ERT) in Combination with Haematopoietic Stem cell Transplantation (HSCT) for Hurler’s Syndrome …
  1340. Molecular imaging of cardiac Stem cell mediated angiogenic gene therapy
  1341. Heart rate variability and cardiac rhythm alterations associated with Stem cell therapy in cardiovascular disease
  1342. … Use of Palifermin and Pegfilgrastim Significantly Reduces Toxicity of High-Dose therapy and Autologous Blood Stem cell Transplantation in Patients with …
  1343. … of Prevention of Severe Oral Mucositis Using Single Dose Velafermin in Patients Receiving Myeloablative therapy and Autologous Hematopoietic Stem cell …
  1344. Restoration of the left ventricular synchronous contraction after acute myocardial infarction by Stem cell therapy
  1345. Rostock Confocal Image Analysis of Patients Treated With Cultured Limbal Epithelial Stem cell therapy
  1346. Bone marrow derived adult Stem cells: characterization and application in cell therapy
  1347. Production, Transplantation and Outcome of Good Manufacturing Practice Compliant Limbal Epithelial Stem cell therapy
  1348. Muscle Derived Stem cell/Alginate/Polycaprolactone/Injection therapy in Rats with Denervated Urethral Sphincter
  1349. High-dose chemotherapy with autologous hematopoietic Stem cell transplantation for non-Hodgkin’s lymphoma in complete response as consolidation therapy …
  1350. Engineering a New Insulin-Like Growth Factor-1 Protein for Embryonic Stem cell therapy
  1351. The effect of cell therapy using a human mesenchymal Stem cell injection on left ventricular systolic function in rat myocardial infarction model
  1352. 90Y-Ibritumomab Tiuxetan (Zevalin®) in Combination with High-Dose therapy (HDT) Followed by Autologous Stem cell Transplant (ASCT) May Improve …
  1353. Human Mesenchymal Stem cell therapy: Platelet Lysate Supports Efficient Preclinical Expansion.
  1354. … of a minimally invasive bone marrow harvest device and method for the rapid extraction of bone marrow for use in bone marrow transplantation and Stem cell therapy
  1355. ENGINEERED MESENCHYMAL Stem cell therapy PROLONGED CARDIAC ALLOGRAFT SURVIVAL.
  1356. Autologous Bone Marrow-Derived Stem cell therapy in Patients with Severe Peripheral Arterial Disorders: A Pilot Study.
  1357. Mesenchymal Stem cell therapy Prevents Ischemia/Reperfusion Injury and Promotes Tissue Regeneration
  1358. Update of melphalan 280 mg/m2 plus amifostine cytoprotection before autologous Stem cell transplantation as part of initial therapy in multiple myeloma patients
  1359. … Correlates with Less Acute Graft-Versus-Host Disease and Better Survival in B-cell Lymphoma Patients Who Received Allogeneic Peripheral Blood Stem cell …
  1360. Bone marrow Stem cell therapy for renal regeneration after acute tubular necrosis: A dream or a reality?
  1361. Autologous Bone Marrow Stem cell Infusion (AMBI) therapy for Chronic Liver Diseases
  1362. Patients with End-Stage Ischemic Heart Failure: a Growing Target Population for Cardiac Stem cell therapy
  1363. … Stem cell therapy for Incurable and Intractable Disease: More than 700 Stem cell Panels are Stored and Umbilical Cord Blood Derived Stem cell Bank will be …
  1364. … effects of hematopoietic Stem cells on cancer (gliosarcoma spheroids) and normal tissues: towards developing hematopoietic Stem cell therapy for astronauts’ cancer
  1365. Molecular Level of Minimal Residual Disease in Bone Marrow Before High-Dose therapy and Autologous Stem cell Transplantation Is a Prognostic …
  1366. Prolonged Clinical and Molecular Remissions Following High-Dose therapy/Autologous Stem cell Transplantation (HDT/ASCT) and Rituximab and …
  1367. Gene therapy and Stem cell therapy for cardiovascular diseases today: a model for translational research Cancer regression in patients after transfer of genetically …
  1368. First trial in a case of Fibrocarcilaginous embolism by dorsolaminectomy and Stem cell therapy in a cocker spaniel dog
  1369. 13N-NH3 PET: The assessment of myocardial perfusion in patients with AMI and Stem cell therapy
  1370. … chemotherapy and autologous hematopoietic Stem cell mobilization, collection and transplantation with simultaneous Imatinib therapy in patients with blast …
  1371. Stem cell therapy with G-CSF Did Not Aggravate Neointimal Growth, but Induced Positive Remodeling in Patients with Myocardial Infarction who Underwent Drug …
  1372. Novel tyrosine kinase inhibitor therapy (NTKI) prior to allogeneic Stem cell transplantation (ASCT) in patients (pts) with chronic myeloid leukemia (CML): No evidence …
  1373. High-Dose therapy and Autologous Stem cell Transplantation for Chemoresistant Diffuse Large B cell Lymphoma: The Seattle Experience.
  1374. Bringing cardiac cell therapy with bone marrow Stem cells to the clinic: where are we now?
  1375. 1018. Stem cell Gene therapy: Toward a Universal Platform Relying on Custom Endonuclease-Boosted Gene Targeting, Cybridization, Transient Regenerative …
  1376. Treosulfan-Based Tandem High-Dose Chemo-Immuno-therapy with Autologous Stem cell Transplantation for Relapsed and Refractory Aggressive B-cell …
  1377. Idiotype (Id) immunotherapy (IT) following high dose therapy and autologous Stem cell transplant (HDT/ASCT) in mantle cell (MC) and indolent lymphoma (IL): cellular …
  1378. Smoothened peptides inhibit prostate and gastric cancer cells by targeting the Hedgehog pathway: a potential cancer Stem cell therapy
  1379. Treatment of AL amyloidosis with high dose therapy and autologous Stem cell transplantation
  1380. Intervertebral disc cell therapy for regeneration: mesenchymal Stem cell cultivation in vitro and intervention in TGF-? 1 implantation in rabbit intervertebral discs
  1381. Fetal Stem–cell and gene therapy
  1382. Allogeneic Hematopoietic Stem cell Transplantation (Allo-SCT) Versus Conventional Postremission therapy (PRT) for AML in First Complete Remission …
  1383. Protein A column therapy for a patient refractory to platelet transfusions undergoing allogeneic hematopoietic Stem cell transplantation
  1384. Treosulfan high dose therapy with autologous Stem cell rescue in high-risk Ewing tumors
  1385. Tandem high-dose therapy with autologous Stem cell support for small-cell lung cancer (SCLC)
  1386. … VTD (VELCADE®, Thalidomide, Dexamethasone) Induction Followed by High-Dose therapy with Autologous Stem cell Transplantation and Maintenance …
  1387. Air Leak Syndrome (ALS) Following Allogeneic Stem cell Transplantation (SCT): A Report of 22 Patients from Kanto Study Group for cell therapy (KSGCT) in Japan.
  1388. High dose therapy with autologous Stem cell transplantation in patients with Hodgkin’s lymphoma: long-term follow-up in patients treated in one center
  1389. Effects of injection therapy using muscle derived Stem cell/chitosan/hydroapatite composite gel in a rat model of urinary incontinence
  1390. Stem cells as Targets for Gene and cell therapy
  1391. … bone marrow mononuclear cells labeled with Tc-99m hexamethylpropylene amine oxime scintigraphy after intracoronary Stem cell therapy in acute myocardial
  1392. Immunomodulatory therapy for SSc: Will high-intensity immunosuppression with Stem cell rescue improve outcome?
  1393. Stem–cell transplant for Hodgkin’s lymphoma: does choice of therapy prior to high-dose treatment matter?
  1394. Bortezomib (BTZ) prior to and as maintenance therapy after autologous Stem cell transplant (ASCT) in multiple myeloma (MM): Long-term follow-up of a phase II study
  1395. Potential of Stem cell based therapy and tissue engineering in the regeneration of the central nervous syStem
  1396. Stem cells a Hope for cell therapy and Regenerative Medicine
  1397. Maintenance therapy with 5-Azacytidine (5-AC) after Allogeneic Stem cell Transplantation (allo-SCT) for Acute Myelogenous Leukemia (AML) and High-Risk …
  1398. Dual-gene transfer and vector targeting for hematopoietic Stem cell gene therapy
  1399. … therapy (ECP) with UVADEX® for the prevention of acute GVHD in patients (pts) undergoing standard myeloablative conditioning and allogeneic hematopoietic Stem …
  1400. Gene therapy and Stem cell activation against stroke
  1401. Directed differentiation of adult neural Stem cells for cell therapy in the nervous syStem
  1402. Stem cell potential for type 1 diabetes therapy
  1403. The Impact of Histologic Grade on the Outcome of High-Dose therapy and Autologous Stem cell Transplantation for Follicular Lymphoma.
  1404. Reply to ‘Autologous Stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome’
  1405. High Dose therapy and Autologous Peripheral Blood Stem cell Transplantation as Salvage therapy for HIV-Associated Lymphoma: Result of the GICAT Study.
  1406. Cefepime as an empiric treatment of febrile neutropenia in patients after high dose therapy and autologous Stem cell transplantation
  1407. Clonal Analyses of Retroviral Vector Integrations in ADA-SCID Patients Treated with Stem cell Gene therapy.
  1408. Prognostic Factors for CMV Reactivation/Infection after Stem cell Transplantation and Value of Oral Valganciclovir for Preemptive therapy.
  1409. Haematopoietic Stem cell Based Gene therapy as a Strategy to Treat Autoimmune Disease
  1410. Functional Comparison of Bone Marrow–Derived Liver Stem cells: Selection Strategy for cell-Based therapy
  1411. Efficacy of Azacytidine (5-AC) Given as Maintenance or Salvage therapy for Patients (pts) with Acute Leukemia Post Allogeneic Stem cell Transplantation (HSCT).
  1412. … Preparative Regimens on the Incidence of therapy Related Myelodysplasia (t-MDS) or AML (t-AML) Following Autologous Stem cell Transplant (ASCT) for …
  1413. High-dose cyclophosphamide as an effective therapy for a patient with refractory multiple myeloma relapsing after autologous Stem cell transplantation
  1414. 1: Cytotoxic T lymphocyte therapy for the treatment and prevention of adenovirus infection after Stem cell transplant
  1415. Preliminary Results of therapy with AM3 in Patients Undergoing Hematopoietic Stem cell Transplantation.
  1416. The role of high-dose therapy and Stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and…
  1417. Stem cell replacement therapy in type 1 diabetes
  1418. 2520: Involved Field Radiation therapy Following Autologous Stem cell Rescue for Hodgkin and Non-Hodgkin Lymphoma-Is it Efficacious?
  1419. … -Adapted therapy of Adult Acute Myeloid Leukemia (AML): Safety and Efficacy of Repetitive HD-ARA-C Courses with Low-Dose Autologous Blood Stem cell …
  1420. The experimental study on bone marrow Stem cell transplantition combinated with bushen fang therapy for DMD
  1421. Phase II trial of GM-CSF as maintenance therapy post–autologous peripheral blood Stem cell transplantation in multiple myeloma
  1422. … after autologous peripheral blood Stem cell transplantation does not add any benefit regarding hematological engraftment and supportive therapy …
  1423. … Incidence in Patients with Hematological Malignancies Receiving Myelotoxic therapy Requiring Hematopoietic Stem cell Support-Palifermin Experience.
  1424. … of Interferon Versus Thalidomide Versus RIC Allotransplant for Maintenance/Consolidation therapy after Autologous Stem cell Transplantation in Patients …
  1425. Stem cell transplantation therapy for diabetes mellitus
  1426. Rituximab maintenance following high dose therapy and autologous Stem cell rescue after RICE cytoreduction improves event free and overall survival
  1427. Posaconazole (POS) salvage therapy allows successful allogeneic hematopoietic Stem cell transplantation (HSCT) in patients with refractory invasive mold infections
  1428. High dose therapy followed by autologous purged Stem cell
  1429. High-Dose therapy/Stem cell Support (HDT), Including Tandem Transplant, for Primary Refractory Multiple Myeloma (MM): Results from the Spanish Myeloma Group …
  1430. Study Progress of Hematopioetic Stem cell Transplantation therapy on Acute Leukemia in Children
  1431. … -CHOP, Based on CT and Gallium 67 Scan (G67S) with or without IFE Salvage therapy Followed by Peripheral Autologous Stem cell Transplant (PBSCT) in …
  1432. … CsA, MTX, MMF and ATG and Triple therapy with CsA, MTX and ATG for Preventing Graft-Versus-Host Disease in Unrelated Donor Hematopoietic Stem cell …
  1433. … Associated with Engraftment of Gene-Corrected Repopulating cells Achieved in ADA-SCID Patients by Stem cell Gene therapy without Myelopreparative Pre …
  1434. Isolation of amniotic Stem cell lines with potential for therapy.
  1435. … WITH LOW DOSE PARATHYROID HORMONE PULSE therapy INCREASES ALLOGENEIC HEMATOPOIETIC Stem cell ENGRAFTMENT IN NON-HUMAN …
  1436. … Stem cells may be uniquely suited for combined gene therapy and cell replacement: evidence from engraftment of neurotrophin-3-expressing Stem cells in hypoxic …
  1437. … neurectodermal tumors (SPNET) treated with risk-adapted craniospinal (CSI) radiation (RT) therapy followed by 4 cycles of high-dose chemotherapy and Stem cell …
  1438. Allogeneic Stem cell Transplantation for therapy-Related Myelodysplastic Syndrome (t-MDS) and Acute Myeloid Leukemia. A Report from the MDS …
  1439. Reply to ‘Promotion of neurogenesis by human Stem cells in high-risk breast cancer survivals after Stem–cell supported high-dose therapy‘by K. Altundag et al.(Ann …
  1440. Gene therapy and Stem cell transplantation in PAD
  1441. Stem cell: From Bone Marrow Transplantation for the Treatment of Hematological Diseases to therapy for Other SyStemic Disorders
  1442. EPIGENETIC INSTABILITY OF HUMAN EMBRYONIC Stem cell LINES: IMPLICATIONS FOR therapy
  1443. Neural Stem cell can mediate immune therapy for brain tumor
  1444. Osteosarcoma target therapy with Stem cell transplant: A case review
  1445. Impact of intensive Stem cell mobilization therapy on outcomes following autologous Stem cell transplantation (ASCT) for non-Hodgkin lymphoma (NHL)
  1446. Immunoablative therapy with Autologous Stem cell Transplantation in the Treatment of Poor Risk Multiple Sclerosis.
  1447. Embryonic Stem cells and cardiac cell therapy
  1448. Which Strategy of Immunoablative therapy with Autologous Stem cell Transplantation (ASCT) Is Preferable in Multiple Sclerosis (MS) Patients?.
  1449. Combination therapy with mesenchymal Stem cell and erythropoietin in patients with ALS
  1450. Experimental substantiation of embryonic Stem cell application in therapy of patients with extrapyramidal hyperkinesis
  1451. therapy of Heart Failure Rats with Mesenchymal Stem cell Transplantation
  1452. Long-term safety and efficacy of Stem cell gene therapy for ADA-SCID.
  1453. Differentiation of Human Embryonic Stem cells; Prospects for Development Biology and cell therapy
  1454. Autologous Stem cell Transplantation Provides Additional Cytoreduction Following Induction therapy in Multiple Myeloma.
  1455. Correction of Murine Hemophilia A by Hematopoietic Stem cell Gene therapy.
  1456. Experimental investigation on therapy of intravenous transplantation of neural Stem cell for spinal cord injury
  1457. Are RIC allogeneic Stem cell transplants ready for prime time in CLL therapy?
  1458. High-dose therapy with autologous Stem cell rescue in patients with breast cancer at high risk for relapse
  1459. Regenerative cellular therapy: How To Enrich The Mesenchymal Stem cell Content In The Periinfarction Zone After Myocardial Infarction
  1460. Bone marrow Stem cells: possible source for cell therapy in Parkinson’s disease
  1461. Second Autologous Stem cell Transplant (ASCT) as Salvage therapy for Relapsed Multiple Myeloma.
  1462. Tacrolimus therapy for Severe Recurrent Crohn’s Disease after Stem cell Transplant: 844
  1463. Improved Survival in Patients with Peripheral T cell Lymphoma, Unspecified Following High-Dose therapy and Stem cell Transplantation: A Retrospective …
  1464. Plasmid transfection of rat bone marrow mesenchymal Stem cells by cationic lipid for gene-modified cell transplantation therapy
  1465. 1672: Early Phase I/II Clinical Trial Results for Human Cord Blood Stem cell Injection therapy for Stress Urinary Incontinence
  1466. Thalidomide salvage therapy following allogeneic Stem cell transplantation for multiple myeloma: A…
  1467. Conditioning therapy with intravenous busulfanum and cyclophosphamide for allogeneic hematopoietic Stem cell transplantation: A report of 19 cases☆
  1468. 433 EVALUATION OF Stem cell POPULATIONS IN THE BLOOD OF PATIENTS UNDERGOING EXTRACORPOREAL MEMBRANE OXYGENATION therapy.
  1469. Estrogen-progestin therapy in women after Stem cell transplant: our experience and literature review.
  1470. Gemtuzumab Ozogamicin as Maintenance therapy after Autologous Stem cell Transplantation (ASCT) in Patients with Acute Myeloid Leukemia (AML).
  1471. Biological modifiers as cytoreductive therapy before Stem cell transplant in previously untreated patientswith m…
  1472. Early Goal Directed therapy for Septic Shock Is Feasible and Safe in Hematopoietic Stem cell Transplant Patients.
  1473. Sca-1+ Progenitors Derived from Stem cells Differentiate into Endothelial cells: Implications for Stem cell-Based therapy in the Injured Artery
  1474. Limbal Stem cell autotansplantation in therapy of recurrent pterygium and ophthalmoherpes
  1475. Characteristics of patients with false positive FDG-PET findings after high dose therapy and autologous Stem cell transplantation (HDT/ASCT)
  1476. Comment on ‘CD34+ selected hematopoietic Stem cell (HSC) not preceded by any immunosuppressive therapy as effective treatment of graft failure’–G Milone et al
  1477. Allogeneic hematopoietic Stem cell transplantation as consolidation therapy for adult T cell Leukemia/Lymphoma patients: A single-center experience in 35 patients.
  1478. … therapy for Thymic Insufficiency after Hematopoietic Stem cell Transplantation: Generation of MTS24 Positive Definitive Endoderm from Murine Embryonic Stem …
  1479. … results of risk adapted pre-emptive therapy of CMV infection with ganciclovir in 169 patients, after allogeneic hematopoietic Stem cell transplantation in Hematology …
  1480. Voriconazole (VOR) is safe and effective as prophylactic antifungal therapy for allogeneic Stem cell transplantation (AT)
  1481. Effects of Prior therapy on the in Vitro Proliferative Potential of Stem cell Factor Plus Filgrastim-mobilized CD34-positive Progenitor cells1
  1482. Hematopoietc Stem cell Targeted Neonatal Gene therapy Cures oc/oc Mice from Osteopetrosis.
  1483. Interferon-α therapy for patients with molecular relapse in leukemia after allogeneic Stem cell transplantation
  1484. NOVEL METHODS IN THE DIAGNOSTICS AND therapy Intracoronary, autologous bone marrow Stem cell transplantation for treatment of postinfarction left …
  1485. Involved Field Radiation therapy Following Autologous Stem cell Rescue for Hodgkin and Non-Hodgkin Lymphoma-Is It Efficacious?.
  1486. Determining the Appropriate PCR Trigger for Pre-Emptive Anti-CMV therapy in Allogeneic Stem cell Transplant Recipients.
  1487. FDG-PET for the prediction of therapy outcome in patients with high risk soft tissue sarcomas receiving high dose chemotherapy with Stem cell rescue
  1488. … initial therapy may be associated with a poorer outcome in young patients subsequently treated with Stem cell transplantation for relapsed chemosensitive large B-cell …
  1489. Clinical Prognostic Factors in Chemosensitive Multiple Myeloma (MM) Patients Intensified with High Dose therapy/Stem cell Support (HDT/SCS): Results of …
  1490. High-dose therapy and autologous Stem cell transplantation for Hodgkin’s lymphoma in relapse or failure after initial chemotherapy: results of the Centre National de …
  1491. … of Patients with Refractory/Relapsed Hodgkin’s Disease (HD) Treated with IGEV Chemotherapy (CT) and High Dose Consolidation therapy (HDT) with Stem cell …
  1492. Gene therapy and neural Stem cell transplantation in rodent models of Huntington’s disease
  1493. Poor Prognosis for Patients after Myelo-and Non-Myeloablative Conditioning therapy Followed by Allogeneic Peripheral Blood Stem cell Transplantation Admitted to …
  1494. … Followed by Early High-Dose therapy and Hematopoietic Stem cell Transplantation Results in Improved Outcome for Patients with Hepatosplenic T-cell …
  1495. High dose chemotherapy with autologous Stem cell rescue as a part of combined modality therapy in stage IIIB inflammatory breast cancer
  1496. … I/II-Study on PCR-Based Pre-Emptive therapy with Valganciclovir or Ganciclovir for Active CMV Infection Following Reduced Intensity Allogeneic Stem cell …
  1497. 248: Novel tyrosine kinase inhibitor therapy (NTKI) prior to allogeneic Stem cell transplantation (ASCT) in patients with chronic myeloid leukemia (CML): No evidence …
  1498. 442. LV Expressing MR Reporter Genes Allows In Vivo Monitoring of Stem cell Gene therapy
  1499. High-Dose therapy (HDT) with Autologous Hematopoietic Stem cell Transplantation (HSCT) in Patients with Poor Prognosis Ewing Family Tumors (EFT).
  1500. Busulfan and melphalan as preparative therapy for Stem cell transplantation in pediatric patients with acute myelogenous leukemia (AML) and myelodysplasia (MDS)
  1501. … chemotherapy and autologous Stem cell transplantation in poor prognosis patients with advanced follicular lymphoma—effective therapy in first complete or partial …
  1502. Administration of Virus-Specific Cytotoxic T-Lymphocytes for the Prophylaxis and therapy of Adenovirus Infection post Allogeneic Stem cell Transplant
  1503. Modified Thalidomide, Cyclophosphamide and Dexamethasone (TCD) to Patients with Multiple Myeloma as Primary therapy Prior to Peripheral Blood Stem cell …
  1504. Hematopoietic Stem cell Transplantation (HSCT) as Curative therapy for Fanconi Anemia (FA) Patients with Acute Leukemia or Advanced Myelodysplasia (MDS).
  1505. Steroid therapy Increase Only Adenovirus Infection but Not Cytomegalovirus Infection in Dose Dependent Manner after Hematopoietic Stem cell Transplantation.
  1506. Stem cell Transplantation (SCT) in Conjunction With Enzyme Replacement therapy (ERT) for a Child With Hurler Syndrome (MPS IH): 42
  1507. Characterization of an Immunodeficient Mucopolysaccharidosis Type I (MPS-I) Mouse Model Suitable for Preclinical Testing of Human Stem cell and Gene therapy.
  1508. … treatment for thrombocytopenia after salvage therapy with arsenic trioxide therapy followed by autologous hematopoietic Stem cell transplantation in acute …
  1509. Comparison of HLA-Identical Sibling Hematopoietic Stem cell Transplant (HCT) Versus Chemotherapy as Postremission therapy in t (8; 21) Acute Myeloid Leukemia …
  1510. Allogeneic Hematopoietic Stem cell Transplantation after Combination therapy with Imatinib and Intensive Chemotherapy for Newly Diagnosed Philadelphia …
  1511. Zoledronic Acid Plus Thalidomide Is Safe and Well Tolerated When Used as Post-Autologous Stem cell Transplant Maintenance therapy in Patients with …
  1512. 1055. High Levels of Human Factor IX Expression in Hemophilia B Mice after Adult Stem cell-Based Gene therapy Combined with Non-Myeloablative Conditioning
  1513. Bortezomib therapy for Multiple Myeloma in Relapse after Reduced Intensity Conditioning Allogeneic Hematopoietic Stem cell Transplantation (RICT).
  1514. Maintenance therapy with Thalidomide/Prednisone Post Autologous Stem–cell Transplant for Patients with Multiple Myeloma Elevates D-Dimer and Possibly …
  1515. Directed differentiation of pancreatic islets from human embryonic Stem cells and cell therapy of diabetes mellitus
  1516. … a Phase II Study of Post-Transplant Maintenance therapy in Patients with Multiple Myeloma Following High-Dose Chemotherapy and Autologous Stem cell …
  1517. … -Rituximab (DC-R) Plus GM-CSF as a Salvage therapy in B-Diffuse Large cell Lymphoma (B-DLCL) after Autologous Stem cell Transplantation (ASCT) Failure.
  1518. Allogeneic Myelo-Ablative Stem cell Transplant (SCT) as Salvage therapy of Reduced-Intensity Conditioned (RIC) SCT: Toxicity and Outcome.
  1519. Molecular mechanisms of immune deficiency in adenosine deaminase (ADA)-deficient SCID patients: implications for Stem cell gene therapy
  1520. … Memory B cell Population with Persistent Hypogammaglobulinemia after Rituximab Administration as an Adjuvant therapy after Autologous Stem cell …
  1521. 347: Intentional induction of mixed hematopoietic chimerism as platform for cellular therapy after HLA-matched allogeneic Stem cell transplantation in childhood …
  1522. Corticosteroid therapy Does Not Increase Relapse Rate after Allogeneic Hematopoietic Stem cell Transplantation for Acute Myelogeneous Leukemia and …
  1523. Tandem high-dose chemotherapy (HDC) with peripheral blood Stem cell rescue (PBSCR) as consolidation therapy for high-risk (primary unresectable pelvic tumors or …
  1524. … -Based Maintenance therapy in Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukaemia (Ph+ ALL) Ineligible for Allogeneic Stem cell …
  1525. … Field Radiation Treatment (IFRT) in Patients With Bulky Non-Hodgkin Lymphoma (NHL) Undergoing High-Dose therapy and Autologous Bone Marrow/Stem cell …
  1526. 131I-Metaiodobenzylguanidine (131I-MIBG) double infusion with autologous Stem cell transplant for neuroblastoma: A New Approaches to Neuroblastoma therapy …
  1527. Allogeneic Stem cell Transplantation (AlloSCT) for the Treatment of therapy-Related Myelodysplastic Syndrome (tMDS) and Acute Myeloid Leukemia (tAML): Results …
  1528. … (Cp) and C. guillermondii (Cg) Blood Stream Infections in Allogeneic Hematopoetic Stem cell (HSC) Recipients Receiving Long Term Caspofungin (C) therapy.
  1529. Gleevec as therapy for CML Relapsed after Allogeneic Stem cell Transplantation: High Rate of BCR-ABL PCR Negativity and Donor Graft Reconstitution.
  1530. Successful Engraftment Using Varied Stem cell Sources, Low Toxicity, and Long-Term Survival Using a Bu/Flu/ATG Reduced Intensity Allogeneic Transplantation in …
  1531. Does Highly Active Anti-Retroviral therapy (HAART) Delay Myeloid Engraftment after Autologous Stem cell Transplant (ASCT) in HIV Associated Lymphoma (HIV+ Ly …
  1532. Low-Dose Methotrexate as Salvage therapy for Refractory Graft-Versus-Host Disease (GVHD) after Reduced-Intensity Conditioning (RIC) for Allogeneic Stem cell …
  1533. 65. Long-Term Effects of Hematopoietic Stem cell Gene therapy in the Murine Model of Wiskott-Aldrich Syndrome: Persistence of Functional Correction of T cells and …
  1534. 263: Non-myeloablative conditioning therapy with fludarabine, cyclophosphamide and ATG allogeneic hematopoietic Stem cell transplantation from HLA-identical …
  1535. … , Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem cell Transplantation Followed by Randomization to therapy with Interleukin-2 Versus …
  1536. Combined Stem cell Mobilization via CXCR4 Antagonist Augments Recruitment of EPCs Following Sonic Hedgehog Gene therapy via Increased Local Expression of …
  1537. … Graft-Versus-Host Disease (GVHD) Following Bortezomib as Salvage therapy after Reduced Intensity Conditioning Allogeneic Stem cell Transplantation (RIC allo …
  1538. DLA-Haploidentical Stem cell Allografts after Anti-CD44 therapy and Nonmyeloablative Conditioning: The Impact of Donor Lymphocyte Infusion (DLI) …
  1539. Sustained effect of first line sequential therapy with intensive consolidation chemotherapy and allogeneic hematopoietic Stem cell transplantation (ASCT) after reduced …
  1540. 356: First line sequential therapy with intensive consolidation chemotherapy and allogeneic hematopoietic Stem cell transplantation (ASCT) after reduced intensity …
  1541. COMBINATION cell AND GENE therapy FOR PERIPHERAL ISCHEMIA USING MYOBLASTS AND Stem cells ENGINEERED WITH CONDITIONALLY …
  1542. Stem cells and cell-based therapy in neurodegenerative disease
  1543. Mobilis in Mobile–Human Embryonic Stem cells and Other Sources for cell therapy
  1544. Stem cells and islet engineering for cell replacement therapy in diabetes
  1545. Investigation into the application of adult human Mueller Stem cells in retinal ganglion cell replacement therapy
  1546. Proliferation of bone marrow mesenchymal Stem cells, skeletal muscle cells and co-culture of both for cell myocardium therapy in Wistar rats
  1547. Mesenchymal Stem cells: Differentiation, hematopoietic support and possible application in cell and gene therapy for osteoarthritis
  1548. Neural Stem cells for cell replacement therapy in Huntington’s disease
  1549. cell and gene therapy via human neural Stem cells (hNSCs) in transgenic SOD1 (G93A) ALS (amyotrophic lateral sclerosis) mice
  1550. cell transplantation for periodontal diseases. A novel periodontal tissue regenerative therapy using bone marrow mesenchymal Stem cells
  1551. Microencapsulation of Mesenchymal Stem cells (MSCs) for cell Based therapy
  1552. Improvement of musculoskeletal function by cell-based therapy using mesenchymal Stem cells with a prolonged life span
  1553. … Stem cells together with differentiated derivatives of human embryonic Stem cells. A novel strategy to enhance the efficacy of autologous cell-transplantation therapy …
  1554. Discovery of a Novel Paracrine Angiogenic Factor from Akt-Transduced Mesenchymal Stem cells for cell/Protein-based therapy in angiogenesis
  1555. Introduction to Stem cell therapy
  1556. Stem–cell therapy for cardiac disease
  1557. Stem cell‐based cell therapy in neurological diseases: a review
  1558. Stem cell therapy in stroke
  1559. Stem cell therapy–Hype or hope? A review
  1560. Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal Stem cells
  1561. Mesenchymal Stem cells: Stem cell therapy perspectives for type 1 diabetes
  1562. Stem cell therapy is proarrhythmic
  1563. The changing face of neural Stem cell therapy in neurologic diseases
  1564. Feasibility of a Stem cell therapy for intervertebral disc degeneration
  1565. A review of gene and Stem cell therapy in cutaneous wound healing
  1566. Stem cell therapy for cardiac repair: benefits and barriers
  1567. Stem cell therapy: MRI guidance and monitoring
  1568. Intravenous mesenchymal Stem cell therapy for traumatic brain injury
  1569. Stem cell therapy restores transparency to defective murine corneas
  1570. Adult Stem cell therapy of female stress urinary incontinence
  1571. Stem cell therapy for heart failure: are arrhythmias a real safety concern?
  1572. Emerging hurdles in Stem cell therapy for peripheral vascular disease
  1573. cellular MRI and its role in Stem cell therapy
  1574. Mesenchymal Stem cell therapy for diabetes through paracrine mechanisms
  1575. Critical issues of clinical human embryonic Stem cell therapy for brain repair
  1576. Current status of Stem cell therapy for liver diseases
  1577. Subacute neural Stem cell therapy for traumatic brain injury
  1578. Mesenchymal Stem cell therapy for equine tendinopathy
  1579. Prospects of Stem cell therapy for replacing dopamine neurons in Parkinson’s disease
  1580. Cartilage tissue engineering: towards a biomaterial-assisted mesenchymal Stem cell therapy
  1581. Stem cell therapy and regenerative medicine
  1582. Olfactory mucosa is a potential source for autologous Stem cell therapy for Parkinson’s disease
  1583. Bone-marrow-derived mesenchymal Stem cell therapy for neurodegenerative diseases
  1584. Stem–cell therapy in retinal disease
  1585. Overview of Stem cell therapy for Crohn’s disease
  1586. Combining growth factor and Stem cell therapy for amyotrophic lateral sclerosis
  1587. Capillary regeneration in scleroderma: Stem cell therapy reverses phenotype?
  1588. Current and future regenerative medicine—principles, concepts, and therapeutic use of Stem cell therapy and tissue engineering in equine medicine
  1589. Cardiac regeneration and Stem cell therapy
  1590. Proinflammatory cytokine effects on mesenchymal Stem cell therapy for the ischemic heart
  1591. Embryonic Stem cell therapy of heart failure in genetic cardiomyopathy
  1592. Mesenchymal Stem cell therapy for nonmusculoskeletal diseases: emerging applications
  1593. Prospects for pluripotent Stem cell‐derived cardiomyocytes in cardiac cell therapy and as disease models
  1594. Autologous mesenchymal Stem cell therapy delays the progression of neurological deficits in patients with multiple syStem atrophy
  1595. Stem cell therapy for cartilage regeneration in osteoarthritis
  1596. Bionetworking: experimental Stem cell therapy and patient recruitment in India
  1597. Stem cell therapy: the great promise in lung disease
  1598. Paracrine mechanisms in adult Stem cell signaling and therapy
  1599. Muscle derived Stem cell therapy for stress urinary incontinence
  1600. Stem cell therapy for cardiac repair
  1601. Mesenchymal Stem cell therapy for protection and repair of injured vital organs
  1602. Stem cell therapy for the kidney?
  1603. Allogenic Stem cell therapy improves right ventricular function by improving lung pathology in rats with pulmonary hypertension
  1604. Potencial role of Stem cell therapy in type 1 diabetes mellitus
  1605. Translational development of mesenchymal Stem cell therapy for cardiovascular diseases
  1606. Stem cell‐based cell therapy for Huntington disease: a review
  1607. Gene and Stem cell therapy in peripheral arterial occlusive disease
  1608. Stem–cell therapy faces more scrutiny in China; but regulations remain unclear for companies that supply treatments
  1609. Stem cell therapy to reduce radiation-induced normal tissue damage
  1610. Stem cell therapy with overexpressed VEGF and PDGF genes improves cardiac function in a rat infarct model
  1611. Immunogenicity and allogenicity: a challenge of Stem cell therapy
  1612. Differential destruction of Stem cells: implications for targeted cancer Stem cell therapy
  1613. Comparison of different culture conditions for human mesenchymal stromal cells for clinical Stem cell therapy
  1614. Cytokines as the major mechanism of mesenchymal Stem cell clinical activity: expanding the spectrum of cell therapy.
  1615. Choosing between Stem cell therapy and drugs in myelofibrosis
  1616. Stem cell therapy for ischemic heart disease: where are we?
  1617. Stem cell therapy for type 1 diabetes mellitus: a review of recent clinical trials
  1618. Tracking Stem cell therapy in the myocardium: applications of positron emission tomography
  1619. Stem cell therapy for end-stage heart failure: indispensable role for the cell?
  1620. Placental mesenchymal and cord blood Stem cell therapy for dilated cardiomyopathy
  1621. Long-term outcome of Stem cell therapy for acute myocardial infarction: right results, wrong reasons
  1622. A new dawn for Stem–cell therapy
  1623. Stem cell therapy in myocardial repair and remodeling
  1624. Stem cell therapy to treat diabetes mellitus
  1625. Stem–cell-based therapy and lessons from the heart
  1626. Stem cell therapy for Alport syndrome: the hope beyond the hype
  1627. Gene and Stem cell therapy in ischemic stroke
  1628. Stem cell therapy: a primer for interventionalists and imagers
  1629. Drawbacks to Stem cell therapy in cardiovascular diseases
  1630. Stem cell therapy for chronic liver disease—choosing the right tools for the job
  1631. Bone marrow-derived mesenchymal Stem cell therapy as a candidate disease-modifying strategy in Parkinson’s disease and multiple syStem atrophy
  1632. Stem cell therapy for heart failure
  1633. Human amnion‐derived mesenchymal Stem cells are a potential source for uterine Stem cell therapy
  1634. Prospects for Stem cell-based therapy
  1635. Mesenchymal Stem cell therapy for degenerative inflammatory disorders
  1636. Isolation of Stem cell populations with trophic and immunoregulatory functions from human intestinal tissues: potential for cell therapy in inflammatory bowel disease
  1637. Mesenchymal Stem cell-based therapy for cartilage repair: a review
  1638. Stem cell therapy for urethral sphincter regeneration.
  1639. Adult Stem cell therapy for acute brain injury in children
  1640. Histocompatibility testing of cultivated human bone marrow stromal cells–A promising step towards pre-clinical screening for allogeneic Stem cell therapy
  1641. Stem cell therapy in multiple sclerosis: promise and controversy
  1642. T cell therapy of Epstein–Barr virus and adenovirus infections after hemopoietic Stem cell transplant
  1643. … into neurons but transform into vascular endothelial cells and secrete neuro-trophic factors to support neuro-genesis—a novel approach in Stem cell therapy
  1644. Inflammatory mediators: parallels between cancer biology and Stem cell therapy
  1645. Strategies for future histocompatible Stem cell therapy
  1646. Establishment of a rat model of myocardial infarction with a high survival rate: A suitable model for evaluation of efficacy of Stem cell therapy
  1647. Cardiovascular regeneration and Stem cell therapy
  1648. Stem cell therapy for cystic fibrosis: current status and future prospects
  1649. What are the prospects of Stem cell therapy for neurology?
  1650. Neuroimaging as a basis for rational Stem cell therapy
  1651. Potential of Stem/progenitor cells in treating stroke: the missing steps in translating cell therapy from laboratory to clinic
  1652. Mesenchymal Stem cell‐based therapy: a new paradigm in regenerative medicine
  1653. T cell therapy in allogeneic Stem cell transplantation
  1654. Immunological considerations for cell therapy using human embryonic Stem cell derivatives
  1655. Stem cell therapy for the broken heart: mini-organ transplantation
  1656. Prostate cancer Stem cell therapy: hype or hope?
  1657. Promise of blood-and bone marrow-derived Stem cell transplantation for functional cardiac repair: putting it in perspective with existing therapy
  1658. … synchronous contraction after acute myocardial infarction by Stem cell therapy: new insights into the therapeutic implication of Stem cell therapy for acute myocardial …
  1659. Stem cell therapy in orthopaedic surgery: Current status and ethical considerations
  1660. Microenvironment at tissue injury, a key focus for efficient Stem cell therapy: A discussion of mesenchymal Stem cells
  1661. cell therapy generates a favourable chemokine gradient for Stem cell recruitment into the infarcted heart in rabbits
  1662. Implications of the cancer Stem–cell hypothesis for breast cancer prevention and therapy
  1663. Stem cell therapy for heart failure: the science and current progress
  1664. A review of current progress in gene and Stem cell therapy for erectile dysfunction
  1665. Adipose Stem cells as a clinically available and effective source of adult Stem cell therapy
  1666. Measurement of oxygenation at the site of Stem cell therapy in a murine model of myocardial infarction
  1667. Autologous Stem–cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study
  1668. cell therapy for the diseased liver: from Stem cell biology to novel models for hepatotropic human pathogens
  1669. Stem cell therapy: a promising and prospective approach in the treatment of patients with severe Buerger’s disease
  1670. Adult Stem cell therapy for autoimmune disease
  1671. Physical exercise as adjuvant therapy for patients undergoing hematopoietic Stem cell transplantation
  1672. cell therapy with autologous bone marrow mononuclear Stem cells is associated with superior cardiac recovery compared with use of nonmodified …
  1673. Targeting the leukemic Stem cell: the Holy Grail of leukemia therapy
  1674. Reduced-intensity allogeneic hematopoietic Stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European …
  1675. Stem cell therapy for critical limb ischaemia—a review
  1676. Immunostimulatory effects of mesenchymal Stem cell‐derived neurons: implications for Stem cell therapy in allogeneic transplantations
  1677. Stem cell therapy for inherited metabolic disorders of the liver
  1678. Placenta-derived Stem cells: new hope for cell therapy?
  1679. Inflammatory bowel disease: moving toward a Stem cell-based therapy
  1680. Drugs, gene transfer, signaling factors: a bench to bedside approach to myocardial Stem cell therapy
  1681. Twisting immune responses for allogeneic Stem cell therapy
  1682. Hematopoietic Stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy
  1683. Human parthenogenetic embryonic Stem cells: one potential resource for cell therapy
  1684. Another new “super muscle Stem cell” leaves unaddressed the real problems of cell therapy for duchenne muscular dystrophy
  1685. Stem cell research and therapy for liver disease
  1686. Stem cell‐based therapy in gastroenterology and hepatology
  1687. Effects of Stem cell therapy with G-CSF on coronary artery after drug-eluting stent implantation in patients with acute myocardial infarction
  1688. cell therapy for ischaemic heart disease: focus on the role of resident cardiac Stem cells
  1689. Stem cell therapy: past, present, and future
  1690. Neural commitment of embryonic Stem cells: molecules, pathways and potential for cell therapy
  1691. Gene therapy and Stem cell transplantation: strategies for hearing restoration
  1692. Genetic basis of inherited macular dystrophies and implications for Stem cell therapy
  1693. A combined artificial chromosome-Stem cell therapy method in a model experiment aimed at the treatment of Krabbe’s disease in the Twitcher mouse
  1694. Stem cell therapy and coordination dynamics therapy to improve spinal cord injury
  1695. Rewiring the heart: Stem cell therapy to restore normal cardiac excitability and conduction
  1696. Immunosuppressive therapy mitigates immunological rejection of human embryonic Stem cell xenografts
  1697. Stem cell therapy for cardiovascular diseases. Experiences in Düsseldorf
  1698. Stem cell therapy for hereditary breast cancer
  1699. Clinical trials update from the American Heart Association 2007: CORONA, RethinQ, MASCOT, AF‐CHF, HART, MASTER, POISE and Stem cell therapy
  1700. Cancer Stem cell: implications in cancer biology and therapy with special reference to lung cancer
  1701. Adoptive precursor cell therapy to enhance immune reconstitution after hematopoietic Stem cell transplantation in mouse and man
  1702. cell therapy for diabetes mellitus: an opportunity for Stem cells?
  1703. Combination of enzyme replacement and hematopoietic Stem cell transplantation as therapy for Hurler syndrome
  1704. Unproven Stem–cell therapy ban
  1705. … of invasive fungal infection in adult hematopoietic Stem cell transplant recipients: analysis of Multicenter Prospective Antifungal therapy (PATH) Alliance registry
  1706. Stem cell therapy trials: a call for standardization
  1707. Stem cell therapy for myocardial regeneration: mechanisms and current clinical applications
  1708. Functional outcome of bone marrow Stem cells (CD45+/CD34−) after cell therapy in acute spinal cord injury: In Exercise training and in sedentary rats
  1709. Continuous renal replacement therapy (CRRT) after Stem cell transplantation. A report from the prospective pediatric CRRT Registry Group
  1710. Rehabilitation of therapy-related cognitive deficits in patients after hematopoietic Stem cell transplantation
  1711. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on Stem cell collection in multiple myeloma
  1712. Compromised Stem cell mobilization following induction therapy with lenalidomide in myeloma
  1713. Is Stem cell-based therapy going on or out for cardiac disease?
  1714. Stem cell and cellular therapy developments
  1715. How to approach Alzheimer’s disease therapy using Stem cell technologies
  1716. High-dose immunosuppressive therapy with autologous hematopoietic Stem cell transplantation as a treatment option in multiple sclerosis
  1717. … working group (IMWG) consensus statement and guidelines regarding the current status of Stem cell collection and high-dose therapy for multiple myeloma …
  1718. Stem cell biology and cell transplantation therapy in the retina
  1719. Cardiac Stem cell therapy: Advances from 2008
  1720. Handbook of cardiac Stem cell therapy
  1721. Stem cell therapy for tendon and ligament injuries in the horse-technique and outcome
  1722. High incidence of leukemia in large animals after Stem cell gene therapy with a HOXB4-expressing retroviral vector
  1723. Improved metabolic correction in patients with lysosomal storage disease treated with hematopoietic Stem cell transplant compared with enzyme replacement therapy
  1724. Stem–cell therapy in China draws foreign patients
  1725. The cancer Stem cell microenvironment and anti-cancer therapy
  1726. The potential of biophotonic techniques in Stem cell tracking and monitoring of tissue regeneration applied to cardiac Stem cell therapy
  1727. High-dose therapy and autologous peripheral blood Stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian …
  1728. Neuroprotective therapy for ischemic stroke with free radical scavenger and gene-Stem cell therapy
  1729. Bone marrow mesenchymal Stem cell therapy on diabetic nephropathy in rats
  1730. The role of cytotoxic therapy with hematopoietic Stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review
  1731. A pilot study with autologous bone marrow-derived Stem cell therapy in patients with severe peripheral arterial disorder
  1732. Mobilization in myeloma revisited: IMWG consensus perspectives on Stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib …
  1733. Functional outcome of bone marrow Stem cells (CD45+/CD34−) after cell therapy in chronic spinal cord injury in wistar rats
  1734. The role of cytotoxic therapy with hematopoietic Stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review
  1735. Translating Stem cell therapy to the clinic: déjà vu all over again
  1736. Stem cell therapy in the treatment of stress urinary incontinence: a significant step in the right direction?
  1737. Stem cell based therapy for skeletal muscle diseases
  1738. Mesenchymal Stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model
  1739. Mesenchymal Stem cell‐based angiopoietin‐1 gene therapy for acute lung injury induced by lipopolysaccharide in mice
  1740. … T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated Stem cell …
  1741. Stem cell therapy in acute myocardial infarction
  1742. Gene therapy approaches for Stem cell protection
  1743. Can radionuclide imaging predict future response to Stem cell therapy?
  1744. Stem cell therapy: The eventual future
  1745. Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic Stem cell transplantation
  1746. Adoptive cellular therapy for cytomegalovirus infection following allogeneic Stem cell transplantation using virus-specific T cells
  1747. Toward a Stem cell gene therapy for breast cancer
  1748. A decision analysis: the dental management of patients prior to hematology cytotoxic therapy or hematopoietic Stem cell transplantation
  1749. cell therapy for Parkinson’s disease: III. Neonatal, fetal and embryonic Stem cell-based applications
  1750. Use of enzyme replacement therapy (Laronidase) before hematopoietic Stem cell transplantation for mucopolysaccharidosis I: experience in 18 patients
  1751. Vascular endothelial growth factor in astroglioma Stem cell biology and response to therapy
  1752. High-dose therapy followed by autologous purged Stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a …
  1753. Prospective multicenter trial comparing repeated immunosuppressive therapy with Stem–cell transplantation from an alternative donor as second-line treatment for …
  1754. Autologous bone marrow Stem cell therapy for the ischemic myocardium during coronary artery bypass grafting
  1755. Expansion of antileukaemia CTL lines and clones for adoptive cell therapy in paediatric patients given allogeneic haematopoietic Stem cell transplantation
  1756. Issues and ethical problems of Stem cell therapy–where is hippocrates?
  1757. Protection of Stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection
  1758. Prenatal Stem cell transplantation and gene therapy
  1759. Emerging Stem cell concepts for imatinib‐resistant chronic myeloid leukaemia: Implications for the biology, management, and therapy of the disease
  1760. … —metaiodobenzylguanidine double infusion with autologous Stem–cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study
  1761. Proof-of-concept trials for lung Stem cell therapy
  1762. High‐dose therapy and autologous Stem cell transplantation for chemoresistant Hodgkin lymphoma: The Seattle experience
  1763. Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, Stem cell transplantation and rituximab: a Cancer and Leukemia …
  1764. Single autologous Stem–cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma …
  1765. … PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic Stem cell …
  1766. … factor (GM-CSF)–secreting cellular immunotherapy in combination with autologous Stem cell transplantation (ASCT) as postremission therapy for acute myeloid …
  1767. Casting doubt on the safety of “off-the-shelf” mesenchymal Stem cells for cell therapy
  1768. The biological and ethical basis of the use of human embryonic Stem cells for in vitro test syStems or cell therapy
  1769. cell and gene therapy using mesenchymal Stem cells (MSCs)
  1770. Validation of a DNAemia cutoff for preemptive therapy of cytomegalovirus infection in adult hematopoietic Stem cell transplant recipients
  1771. Parthenogenetic embryonic Stem cells derived from cryopreserved newborn mouse ovaries: a new approach to autologous Stem cell therapy
  1772. Pfizer acquires a Stem cell therapy
  1773. Bevacizumab therapy before autologous Stem–cell transplantation for POEMS syndrome
  1774. Endothelium‐specific gene and Stem cell‐based therapy for erectile dysfunction
  1775. Perinatal Stem–cell and gene therapy for hemoglobinopathies
  1776. Adipose‐derived Stem cells are a source for cell therapy of the corneal stroma
  1777. Embryonic Stem (ES) cell-derived cardiomyocytes: a good candidate for cell therapy applications
  1778. Regeneration of irradiated salivary glands by Stem cell therapy
  1779. The new challenge of Stem cell: brain tumour therapy
  1780. Stem cell therapy: how should nurses respond?
  1781. … therapy and autologous Stem cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy …
  1782. Involved-field radiotherapy before high-dose therapy and autologous Stem–cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity
  1783. The extent of minimal residual disease reduction after the first 4‐week imatinib therapy determines outcome of allogeneic Stem cell transplantation in adults with …
  1784. Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin’s lymphoma patients receiving autologous hematopoietic Stem cell …
  1785. … Stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy
  1786. Plasma HHV-6 viral load-guided preemptive therapy against HHV-6 encephalopathy after allogeneic Stem cell transplantation: a prospective evaluation
  1787. Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic Stem cell transplantation
  1788. Mesenchymal Stem cell-based gene therapy with prostacyclin synthase enhanced neovascularization in hindlimb ischemia
  1789. High prevalence of early-onset osteopenia/osteoporosis after allogeneic Stem cell transplantation and improvement after bisphosphonate therapy
  1790. Predicting survival in adults with invasive aspergillosis during therapy for hematological malignancies or after hematopoietic Stem cell transplantation: single‐center …
  1791. Loss of enterocyte mass is accompanied by diminished turnover of enterocytes after myeloablative therapy in haematopoietic Stem–cell transplant recipients
  1792. Treating autoimmune diseases: is Stem cell therapy the future?
  1793. Dental regenerative therapy: Stem cell transplantation and bioengineered tooth replacement
  1794. Manufacturing neurons from human embryonic Stem cells: biological and regulatory aspects to develop a safe cellular product for stroke cell therapy
  1795. Stem cell niches as clinical targets: the future of anti-ischemic therapy?
  1796. Multilevel targeting of hematopoietic Stem cell self-renewal, differentiation and apoptosis for leukemia therapy
  1797. Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic Stem cell transplantation: implications for the emergence of drug-resistant …
  1798. Myeloablative therapy with autologous Stem cell rescue for patients with Ewing sarcoma
  1799. Nausea and vomiting with high-dose chemotherapy and Stem cell rescue therapy: a review of antiemetic regimens
  1800. Porcine embryonic Stem cells: a possible source for cell replacement therapy
  1801. Hematopoietic Stem cell gene therapy for adenosine deaminase deficient-SCID
  1802. Stem cells to pancreatic β-cells: new sources for diabetes cell therapy
  1803. … graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic Stem cell transplantation for multiple …
  1804. Mesenchymal Stem cells—Stem cell therapy perspectives for type 1 diabetes
  1805. Combination treatment of human umbilical cord matrix Stem cell-based interferon-beta gene therapy and 5-fluorouracil significantly reduces growth of metastatic …
  1806. Gene-Stem cell therapy for ischemic stroke
  1807. Hematopoietic Stem cell gene therapy in Hurler syndrome, globoid cell leukodystrophy, metachromatic leukodystrophy and X-adrenoleukodystrophy.
  1808. The role of high-dose therapy with autologous Stem cell support in the era of novel agents
  1809. Stem cell-based therapy in central nervous syStem diseases
  1810. Vaccinations in children treated with standard-dose cancer therapy or hematopoietic Stem cell transplantation
  1811. Human cord blood Stem cell applications in cell therapy.
  1812. Antifungal therapy for invasive fungal diseases in allogeneic Stem cell transplant recipients: an update
  1813. High‐dose therapy and autologous Stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B‐cell lymphoma
  1814. Progress in researches on Stem cell therapy for erectile dysfunction
  1815. Establishment of medakafish as a model for Stem cell-based gene therapy: Efficient gene delivery and potential chromosomal integration by baculoviral vectors
  1816. Mathematical modelling of the impact of haematopoietic Stem cell‐delivered gene therapy for HIV
  1817. Embryonic Stem cells and Parkinson’s disease: cell transplantation to cell therapy
  1818. Gene therapy and bone marrow Stem–cell transfer to treat autoimmune disease
  1819. cell therapy for Parkinson’s disease: II. Somatic Stem cell-based applications
  1820. … parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic Stem cell transplant recipients receiving long-term caspofungin therapy
  1821. Differentiation-chronology specific function of DNMT1 and selective anti-leukemia Stem–cell therapy
  1822. Stem cell therapy: an update
  1823. High-dose therapy with hematopoietic Stem cell rescue in patients with poor prognosis Ewing family tumors
  1824. Can patient-specific Stem cell therapy enhance renal repair?
  1825. Stem cell therapy: A “magic bullet” for cardiomyopathies?
  1826. Stem cell therapy for spinal cord injury: A plea for rationality
  1827. therapy for older AML patients: the role of novel agents and allogeneic Stem cell transplant
  1828. The effect of human umbilical cord blood derived mesenchymal Stem cell therapy in rat model of cavernosal nerve injury
  1829. High rate of long-term survival for high-risk lymphoma patients treated with hematopoietic Stem cell transplantation as consolidation or salvage therapy
  1830. Cord blood Stem cell therapy for acquired immune deficiency syndrome
  1831. cell transplant and regenerative Stem cell therapy
  1832. Primed for lethal battle: a step forward to enhance the efficacy and efficiency of Stem cell transplantation therapy
  1833. Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous Stem cell …
  1834. Childhood spinal muscular atrophy and Stem cell research: Is cellular replacement therapy the answer?
  1835. Neural Stem cell-mediated therapy of primary and metastatic solid tumors
  1836. … varicella-zoster virus infection preceding cutaneous manifestations after hematopoietic Stem cell transplantation: utility of PCR for early recognition and therapy
  1837. Does High-Dose therapy and Autologous Hematopoietic Stem cell Transplantation Have a Role in the Primary Treatment of Peripheral T-cell Lymphomas?
  1838. Ethical issues in Stem cell research, therapy, and public policy
  1839. Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic Stem cell transplant recipients
  1840. Comparison of ex vivo expansion culture conditions of mesenchymal Stem cells for human cell therapy
  1841. Radiation therapy Oncology Group translational research program Stem cell symposium: incorporating Stem cell hypotheses into clinical trials
  1842. Stem–cell biology and cancer therapy: the more things change.
  1843. Stem cell therapy in chronic spinal cord injuries
  1844. Stem cell therapy in acute respiratory distress syndrome
  1845. Human cytomegalovirus load measurement and its applications for pre‐emptive therapy in patients undergoing hematopoietic Stem cell transplantation
  1846. Patients with mature T-cell lymphoma show high relapse rates after high dose therapy and autologous Stem cell transplantation
  1847. Reduced-toxicity conditioning therapy with allogeneic Stem cell transplantation for acute leukemia
  1848. Genetic engineering and Stem cells: combinatorial approaches for cardiac cell therapy [cellular/Tissue Engineering]
  1849. Autologous hematopoietic Stem cell transplantation as an intensive consolidation therapy for adult patients in remission from acute myelogenous leukemia
  1850. Partial phenotypic correction and immune tolerance induction to enzyme replacement therapy after hematopoietic Stem cell gene transfer of α‐glucosidase in Pompe …
  1851. … node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous Stem cell …
  1852. Therapeutic window of Stem cell potential for targeting pediatric malignant brain tumors: an opportunity for Stem cell therapy
  1853. Stem cell therapy in Neurodegenerative
  1854. Stem cell therapy FOR BRAIN TUMORS
  1855. Stem cell–Based therapy for Glomerular Diseases: An Evolving Concept
  1856. Cardiac Stem cells: at the heart of cell therapy
  1857. Viral diagnostics and antiviral therapy in hematopoietic Stem cell transplantation
  1858. Is allogeneic Stem cell transplantation for transformed follicular lymphoma anti-lymphoma Stem cell therapy?
  1859. Treatment options for impaired spermatogenesis: germ cell transplantation and Stem–cell based therapy.
  1860. The moral status of human embryos with special regard to Stem cell research and therapy
  1861. Outcome assessment measures for evaluating clinical effectiveness of canine adipose derived Stem cell therapy of osteoarthritis
  1862. Novel cancer Stem cell therapy on the horizon
  1863. Surgical Stem cell therapy for the Treatment of Heart Failure
  1864. Macrophage subpopulations are essential for infarct repair with and without Stem cell therapy
  1865. Hypervitaminosis A in pediatric hematopoietic Stem cell patients requiring renal replacement therapy
  1866. Principles of Stem cell therapy in the horse-the science behind the technology
  1867. Developing cell therapy techniques for respiratory disease: intratracheal delivery of genetically engineered Stem cells in a murine model of airway injury
  1868. Extended mycophenolate mofetil administration beyond day 30 in allogeneic hematopoietic Stem cell transplantation as preemptive therapy for severe graft-versus …
  1869. Sex of muscle Stem cells does not influence potency for cardiac cell therapy
  1870. Properties of mesenchymal Stem cells to consider for cancer cell therapy
  1871. … body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood Stem–cell transplantation followed by randomization to therapy with interleukin-2 …
  1872. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic Stem cell transplantation: a real‐world review
  1873. Future of Stem cell therapy for neuronal regeneration
  1874. Novel and immortalization-based protocols for the generation of neural CNS Stem cell lines for gene therapy approaches
  1875. Translational perspectives—transient epigenetic gene therapy: hazard-free cell reprogramming approach and rising arm of a universal Stem cell gene therapy platform
  1876. Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic Stem cell transplant recipients
  1877. Stem cell therapy for Acute Myocardial Infarction and Heart Failure-Past, Present and Future
  1878. Stem cell therapy: Numerical simulation of In Vivo Nutrient Transport and cells Growth
  1879. Newly diagnosed multiple myeloma in Taiwan: the evolution of therapy, Stem cell transplantation and new treatment agents
  1880. Successful treatment of primary AL amyloidosis by VAD therapy, high-dose melphalan, and autologous peripheral Stem cell transplantation
  1881. Intentional induction of mixed haematopoietic chimerism as platform for cellular therapy after HLA‐matched allogeneic Stem cell transplantation in childhood …
  1882. Post‐translational modifications of orphan nuclear receptor TR2–new insights into drug targets for Stem cell therapy and the effect of retinoic acid
  1883. Autologous Stem cell transplantation is superior to myeloablative allogeneic SCT as a salvage therapy for patients with refractory/relapsed transformed …
  1884. Mesenchymal Stem cells and their use as cell replacement therapy and disease modelling tool
  1885. The role of cardiac ultrasound in Stem cell therapy
  1886. Stem cells for cardiac regeneration by cell therapy and myocardial tissue engineering
  1887. … on PCR-based pre-emptive therapy with valganciclovir or ganciclovir for active CMV infection following alemtuzumab-based reduced intensity allogeneic Stem cell …
  1888. Structural and functional improvement of injured brain after severe acute carbon monoxide poisoning by Stem cell-based therapy in rats.
  1889. Generation of insulin-producing beta cells from Stem cells-perspectives for cell therapy in type 1 diabetes
  1890. Adult Stem cell therapy for acute renal failure: the hope beyond the hype
  1891. The prospect of pluripotent Stem cell-based therapy
  1892. Mesenchymal Stem cell therapy in a Rat Model for GvHD
  1893. Iodine‐131‐metaiodobenzylguanidine therapy with reduced‐intensity allogeneic Stem cell transplantation in recurrent neuroblastoma
  1894. Stem cell therapy
  1895. … , epirubicin and etoposide) is a more effective Stem cell mobilisation regimen than ICE (ifosphamide, carboplatin and etoposide) in the context of salvage therapy for …
  1896. Human cardiac Stem cell therapy for heart failure
  1897. Adult human Stem cell therapy for ischaemic stroke
  1898. Antifungal therapy strategies in hematopoietic Stem–cell transplant recipients: early treatment options for improving outcomes
  1899. Preemptive therapy for cytomegalovirus disease in allogeneic Stem cell transplant recipients
  1900. Haploidentical allogeneic bone marrow Stem cell transplantation combined with peripheral blood Stem cells for therapy of leukemia
  1901. Review of Stem cell-based therapy for the treatment of cardiovascular disease
  1902. A long-term durable remission with high-dose therapy and autologous Stem cell transplant for stage IVB HIV-associated Hodgkins disease
  1903. Adult Mesenchymal Stem cells for cell therapy in Clinical Application.
  1904. Imipenem/cilastatin with or without glycopeptide as initial antibiotic therapy for recipients of autologous Stem cell transplantation: results of a Spanish …
  1905. Comparison of adult versus embryonic Stem cell therapy for cardiovascular disease: insights from molecular imaging studies
  1906. Counterpoint: cord blood Stem cell therapy for acquired immune deficiency syndrome
  1907. Phase III Intergroup Study of Lenalidomide (CC-5013) Versus Placebo Maintenance therapy Following Single Autologous Stem cell Transplant for Multiple …
  1908. Specific Detection of Aberrant and Normal Stem cells in Acute Myeloid Leukemia Patients Opens the Way for Defining Highly Specific Targets for Stem cell therapy.
  1909. Counterpoint: cord blood Stem cell therapy for acquired immune deficiency syndrome
  1910. Cardiac Stem cell therapy and arrhythmogenicity: Prometheus and the arrows of Apollo and Artemis
  1911. Embryonic Stem cells: overcoming the immunological barriers to cell replacement therapy
  1912. Comparison of mesenchymal tissues-derived Stem cells for in vivo chondrogenesis: suitable conditions for cell therapy of cartilage defects in rabbit
  1913. A microfabricated 3-D Stem cell delivery scaffold for retinal regenerative therapy
  1914. Bispecific antibody targeted Stem cell therapy for myocardial repair
  1915. Tissue Engineering for the Respiratory Epithelium: Is There a Future for Stem cell therapy in the Lung?
  1916. Novel Tyrosine Kinase Inhibitor therapy Before Allogeneic Stem cell Transplantation in Patients with Chronic Myeloid Leukemia.
  1917. Role of biomechanical force in Stem cell-based therapy for cartilage repair
  1918. Autologous Stem cell transplantation using MEAM regimen for relapsed AIDS-related lymphoma patients who received highly active anti-retroviral therapy: a report of …
  1919. R-CHOP, Followed by High Dose therapy and Autologous Stem cell Rescue (HDT/ASCR), and R-Hypercvad Have Equivalent Progression-Free Survival and Are …
  1920. Stem cell therapy-An update
  1921. Tweaking the immune syStem: gene therapy-assisted autologous haematopoietic Stem cell transplantation as a treatment for autoimmune disease
  1922. Characterization and genetic manipulation of human umbilical cord vein mesenchymal Stem cells: potential application in cell-based gene therapy
  1923. High-dose therapy and autologous Stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission.
  1924. … Stem cell transplantation after myeloablative therapy in first remission may be beneficial in patients with advanced stage follicular lymphoma after front-line therapy …
  1925. Stem cell transplantation and MBL replacement therapy
  1926. Autologous Stem cell transplantation (autoSCT) as first-line therapy in peripheral T cell lymphomas (PTCL): results of a prospective multicenter study
  1927. Adult and Embryonic Stem cell therapy
  1928. New strategy of treatment for POEMS syndrome–autologous peripheral blood Stem cell transplantation and thalidomide therapy
  1929. cell therapy using induced pluripotent Stem (iPS) cells meets next-next generation DNA sequencing technology
  1930. Impact of lenalidomide therapy on Stem cell mobilization in myeloma
  1931. Wnt5a-treated midbrain neural Stem cells improve dopamine cell replacement therapy in parkinsonian mice
  1932. Plasma cell leukemia maintaining complete remission by syngeneic Stem cell transplantation combined with low-dose thalidomide maintenance therapy
  1933. … Ibritumumab Tiuxetan (Zevalin®)-BEAM/C with Autologous Stem cell Support as Frontline therapy for Advanced Mantle cell Lymphoma.–Preliminary Results …
  1934. Stem and progenitor cell-mediated tumor selective gene therapy
  1935. Stem cell therapy in cardiovascular diseases
  1936. Parkinson’s disease: Role of molecular imaging in monitoring the effectiveness of Stem cell therapy
  1937. Effects of Embryonic Neural Stem cell therapy on Oxidative and Nitrosative Stress Biomarkers in Acute and Chronic Spinal Cord Injured Rats
  1938. Ethical Issues in Stem cell therapy
  1939. Induced pluripotent Stem cells offer new approach to therapy in thalassemia and sickle cell anemia and option in prenatal diagnosis in genetic diseases
  1940. Treatment of refractory severe autoimmune disease by combined therapy with Chinese drug and autohemopoietic Stem cell transplantation
  1941. Second Autologous Stem cell Transplant (ASCT) as Salvage therapy in Patients with Relapsed Multiple Myeloma.
  1942. Stem cell therapy× ETHICS AND RELIGION
  1943. Islet cell therapy and pancreatic Stem cells
  1944. … molecular response in the absence of any antileukaemic therapy after dasatinib treatment and autologous peripheral blood Stem cell transplantation in a …
  1945. Minimally invasive Stem cell therapy
  1946. Stem cell therapy-emerging new field of medicine.
  1947. Hematopoietic Stem cell gene therapy trial with lentiviral vector in X-linked adrenoleukodystrophy
  1948. … does not adversely affect the Stem cell mobilization and engraftment after high-dose therapy and autologous transplantation in patients with diffuse large B-cell …
  1949. Fetal Stem cell therapy
  1950. In vivo MRI of mouse heart at 11.7 t: monitoring of Stem–cell therapy for myocardial infarction and evaluation of cardiac hypertrophy
  1951. INTERLEUKIN-10 ENGINEERED MESENCHYMAL Stem cell therapy TO PREVENT ISCHEMIA-REPERFUSION INJURY IN LUNG TRANSPLANTS: 167
  1952. Stem cell therapy: Hype or Hope?
  1953. Effects of Mesenchymal Stem cell therapy in BPD
  1954. Exposing gaps in our knowledge of Stem cell therapy
  1955. Brazilian experience using high-dose sequential therapy (HDS) followed by autologous hematopoietic Stem cell transplantation (ASCT) for malignant lymphomas
  1956. Stem cell Transplant (SCT) and Pralatrexate therapy: Outcome of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma Who Received SCT …
  1957. … Monoclonal Gammopathy: pulmonary hemorrhage during Stem cell mobilization and complete hematological response with bortezomib and dexamethasone therapy
  1958. Fibrin microthreads promote Stem cell growth for localized delivery in regenerative therapy
  1959. Stem cell Gene therapy for ADA-Deficiency without Myelopreparative Conditioning
  1960. Progress in Stem cell therapy for Alzheimer’s disease
  1961. cell therapy in Hematopoietic Stem cell Transplantation
  1962. Stem cell therapy for Alzheimer’s
  1963. Ethical aspects of Stem cell therapy and gene therapy
  1964. A possible approach for Stem cell gene therapy of Fanconi anemia
  1965. Outcomes with High Dose therapy and Peripheral Blood Stem cell Transplantation for Light Chain (AL) Amyloidosis with Cardiac Involvement.
  1966. Cardiovascular Regeneration and Stem cell therapy
  1967. Stem–cell therapy is the last option for cardiac disease?
  1968. Second Autologous Stem cell Transplantation Is Effective Salvage therapy for Relapsed Multiple Myeloma.
  1969. Stem cell therapy for corneal defects
  1970. Potential applications of combined Stem cell and gene therapy for the treatment of infarcted heart
  1971. Handbook Of Cardiac Stem cell therapy
  1972. Cardiac regenerative therapy integrated via human autologous cardiac Stem cell and biodegradable bFGF-incorporating gelatin hydrogel
  1973. 237. Stem cell therapy: Neuroplasticity as a novel cellular mechanism for regeneration
  1974. Future Implementation of Adult Stem cell therapy in the Current Standards of Care for Myocardial Infarction
  1975. Experience of Hanyang ALS Clinic for Autologous BM Stem cell therapy in the Patients with ALS
  1976. Stem cell-targeted therapy–a new strategy for cancer treatment
  1977. Red Fluorescent Protein as a Marker for Stem cell therapy
  1978. … , pegylated-lyposomal-doxorubicin and dexamethasone (PAD) as induction therapy prior to reduced intensity autologous Stem cell transplant (ASCT) followed by …
  1979. Microencapsulated Stem cells for tissue repairing: implications in cell-based myocardial therapy
  1980. Involved field radiation therapy and donor lymphocyte infusion for relapsed or refractory non-Hodgkin lymphoma after allogeneic hematopoietic Stem cell …
  1981. Liver Stem cell therapy: current and near future
  1982. Maintenance therapy with Low-Dose Azacitidine (AZA) after Allogeneic Hematopoietic Stem cell Transplantation (HSCT) for Relapsed or Refractory AML or …
  1983. Selection of Optimal M esenchymal Stem cells for Stem cell therapy in Amyotrophic Lateral Sclerosis Patients
  1984. Outcome of high-dose cytarabine-based induction therapy followed by hematopoietic Stem cell transplantation in acute myeloid leukemia: influence of karyotype
  1985. Autologous and Cancer Stem cell Gene therapy
  1986. MO‐FF‐A2‐01: Neural Stem cell Sparing Radiation therapy—A Feasibility Study
  1987. Stem cell mobilization following initial therapy with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma
  1988. Experimental Stem cell therapy in acquired neurological illnesses: Current status
  1989. Gene and Stem cell therapy in pulmonary arterial hypertension
  1990. Research progress of traditional Chinese medicine for Stem cell therapy of ischemic heart disease
  1991. The evaluation of acute renal failure models for the study of Stem cell therapy
  1992. Clinical Trials in Cardiac Stem cell therapy: An Update
  1993. Low level laser therapy and phototherapy assisted hydrogel dressing in burn wound healing: light guided epithelial Stem cell biomodulation
  1994. Stem cell therapy following acute myocardial infarction: Comparative studies with adipose tissue-derived Stem cells and bone marrow-derived Stem cells
  1995. Cardiac Stem cell therapy, from bench to bedside
  1996. Stem cell therapy to Promotor Functional Recovery Following Injury to the Nervous SyStem
  1997. Mesenchymal Stem cell therapy Prevents Ischemia/Reperfusion Injury
  1998. Impact of Allogeneic Stem cell Transplantation as Salvage therapy After T315I Mutation Detection in Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic …
  1999. Chondroitin sulfate, a major niche substance of neural Stem cells, and cell transplantation therapy of neurodegeneration combined with niche modification
  2000. Characterization and optimization of in vitro culture conditions of adult Stem cells for clinical cell therapy
  2001. Noninvasive methods for monitoring cardiac Stem cell therapy
  2002. Effectiveness of Mesenchymal Stem cell therapy in Patients With Amyotrophic Lateral Sclerosis
  2003. Stem cell therapy for age-related retinal disease
  2004. Analysis of Umbilical Cord Blood Stem cell therapy for Regenerative Medicine Applications
  2005. Cardiac resynchronization and Stem cell therapy: do associative benefits exist?
  2006. Difficulty of peripheral blood Stem cell collection after multiple consolidation therapy in acute myeloid leukemia
  2007. Cytoprotective Actions of Mesenchymal Stem cell therapy After Acute Myocardial Infarction
  2008. Muscle‐derived Stem cell therapy for Stress Urinary Incontinence
  2009. Autologous in vitro expanded mesenchymal Stem cell therapy for human old myocardial infarction
  2010. 2 Overview of Adult Stem cell therapy in Cardiac Disease
  2011. Autologous Stem cell therapy with surgical myocardial revascularization/Otolog kok hucre tedavisi ve cerrahi miyokardiyal revaskularizasyon
  2012. Panoramic View of The Fifth International Symposium on Stem cell therapy and Applied Cardiovascular Biotechnology, April 2008, Madrid (Spain)
  2013. Engineering Cardiac Tissue Using Stem cell therapy to Mend the Broken Heart
  2014. Adult Stem cell therapy for acute and subacute spinal cord injury: Early clinical results and combined therapy strategy
  2015. ADIPOSE-TISSUE DERIVED MESENCHYMAL Stem cell (ASC) AS ALTERNATIVE SOURCE FOR AUTOLOGOUS cell therapy
  2016. Allay the ailing hearts-promising Stem cell therapy through apheresis: An experience of a tertiary care hospital in South India, ie SVIMS, Tirupati, Andhra Pradesh.
  2017. Long term follow-up after intramyocardial Stem cell therapy with AC133+ bone marrow cells
  2018. cell therapy for Diabetes Mellitus: An Opportunity for Stem cells?
  2019. Baylor’s contribution to thoracic surgery and cardiac Stem cell therapy for heart failure
  2020. SyStemic and Gene Modified Mesenchymal Stem cell therapy for Metastatic Prostate Cancer
  2021. G-CSF Based Peripheral Blood Stem cell therapy in Myocardial Infarction: Results of MAGIC cell Clinical Trial
  2022. UMBILICAL CORD BLOOD DERIVED MESENCHYMAL Stem cell therapy IN NOVEL CORONA VIRUS INFECTION–A REVIEW
  2023. Aspects of Embryonic Stem cell Derived Somatic cell therapy of Degenerative Diseases
  2024. (90) y-Ibritumumab Tiuxetan (Zevalin (R))-BEAM/C with Autologous Stem cell Support as Frontline therapy for Advanced Mantle cell Lymphoma.-Preliminary Results …
  2025. Cardiac regeneration by intramyocardial Stem cell therapy: clinical development
  2026. … and VTD (Bortezomib, Thalidomide, Dexamethasone) Induction Followed by High-Dose therapy with Autologous Stem cell Transplantation and Maintenance …
  2027. Mesenchymal Stem cell therapy for traumatic brain injury: Implications for intracranial inflammation
  2028. Value of MRI and iron oxide particle labeling in Stem cell therapy of brain ischemic rats
  2029. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: influence of prior autologous Stem–cell transplantation on outcome
  2030. Results from functional and cellular studies using an ovine model to assess response to mesenchymal Stem cell therapy after induction of myocardial infarction
  2031. Human Embryonic Stem cell‐Derived Cardiomyocytes for cell therapy and Drug Discovery
  2032. Stem cell therapy for myocardial infarction: Overcoming the hypoxic impediment to enhance cell-survival and engraftment
  2033. Two Patients with Sporadic Late-Onset Nemaline Myopathy Respond to Stem cell therapy
  2034. Single Versus Tandem High Dose therapy (HDT) Supported with Autologous Blood Stem cell (ABSC) Transplantation Using Unselected or CD34-Enriched ABSC …
  2035. Adoptive Immune cell therapy for the Control of Fungal Infections in Hematopoietic Stem cell Transplant Patients
  2036. … Expression on Human CD34+ cells During Murine Leukemia Virus-Derived Retroviral Transduction with Recombinant Fibronectin for Stem cell Gene therapy
  2037. Hedgehog Signaling Pathway Is a New Target of Cancer Stem cell therapy for Breast Cancer Patients.
  2038. Placental mesenchymal and cord blood Stem cell therapy for dilated cardiomyopathy
  2039. Autologous bone marrow-derived Stem cell therapy in patients with Buerger’s disease
  2040. Intracoronary autologous bone marrow Stem cell therapy in diastolic heart failure
  2041. Serendipity—Methotrexate and 6-mercaptopurine for Continuation therapy for Patients With Acute Lymphoblastic Leukemia: The Leukemic Stem cell and Beyond?
  2042. … ®), Doxil®, and dexamethasone (VDD) is superior to thalidomide and dexamethasone (TD) as initial therapy prior to autologous Stem cell transplantation (ASCT) for …
  2043. RESCUE OF LUMICAN NULL CORNEAL PHENOTYPE USING Stem cell therapy
  2044. Autologous Bone Marrow-Derived Stem cell therapy: A Promising and Prospective Approach in the Treatment of Patients with Severe Buerger’s Disease.
  2045. 100. Subacute Neural Stem cell therapy for Traumatic Brain Injury
  2046. Lenalidomide as Salvage therapy after Allogeneic Stem′ cell Transplantation in Multiple Myeloma
  2047. Sci—Thurs AM: YIS—11: A Hybrid SPECT and Contrast Enhanced CT Platform: Application in Stem cell therapy
  2048. Rituximab based therapy followed by autologous Stem cell transplantation leads to superior outcome and high rates of PCR negativity in patients with indolent B-cell …
  2049. The role of allogeneic Stem cell transplantation in the therapy of adult acute lymphoblastic leukemia (ALL)
  2050. Laboratory of Neurogenesis and cell therapy, Wallenberg Neuroscience Center, and Lund Stem cell Center, University Hospital, SE-221 84 Lund, Sweden. 2 …
  2051. Defibrotide therapy for patients with sinusoidal obstruction syndrome after hematopoietic Stem cell transplantation
  2052. … by granulocyte colony-stimulating factor on myocardial perfusion and viability: Improvement of myocardial perfusion as a plausible mechanism of Stem cell therapy
  2053. Advance of researches on thyroid tissues autotransplantation and embryonic Stem cell transplantation in therapy of hypothyroidism
  2054. Beta cells can be generated from endogenous progenitors in injured adult mouse pancreas. An open gate towards endogenous Stem cell therapy in diabetes.
  2055. Multipotent Progenitor cells: A New Era In Stem cell-Mediated Gene therapy?
  2056. Mesenchymal Stem cell therapy increases proinflammatory cytokine production via NFkB activation independent of the PI3 kinase pathway
  2057. Early evaluation of genetically engineered mesenchymal stromal Stem cell therapy for prevention of left ventricular dysfunction in pigs
  2058. Stem cell Transplantation: Biology, Processes, therapy
  2059. … Mononuclear cell Transfer Is Associated with Superior Cardiac Recovery and Neovascularization as Compared to Nonmodified Mesenchymal Stem cell therapy in …
  2060. 2.5 Mesenchymal Stem cell therapy has significant clinical effect in proteoglycan induced arthritis
  2061. Effects of Bone Marrow-Derived Stem cell therapy on Airway and Lung Parenchyma Remodeling in a Murine Model of Chronic Allergic Asthma.
  2062. Allogeneic Stem cell transplantation (SCT) in advanced chronic myeloid leukemia (CML) patients after tyrosine kinase inhibitor (TKI) therapy
  2063. 78. Genetically Modified Mesenchymal Stem cell therapy for Prostate Cancer Bone Metastasis
  2064. Locally induced neural Stem cells/pluripotent Stem cells for in vivo cell replacement therapy
  2065. Treatment failure due to intracerebral Stem cell-like behavior of glioblastoma (GBM) cells: A reason for targeted maintenance therapy with imatinib (I) and hydroxyurea …
  2066. Corneal epithelial Stem cell deficiency and its therapy with transplantation of in vitro cultivated limbal Stem cells
  2067. Allogeneic Hematopoietic Stem cell Transplantation (HSCT) as a Curative therapy in Primary and Secondary Myelofibrosis (MF): A 14-Year Period …
  2068. … II Study of Sequential Velcade/Thalidomide/Dexamethasone (VTD) as Maintenance therapy Post Single Autologous Peripheral Stem cell (PSCT) in Patients …
  2069. Salvage therapy with Allogeneic Stem cell Transplantation Results in Better Outcome for Patients with Relapsed/Refractory Follicular Lymphoma Compared …
  2070. Endonuclease-Boosted Gene Targeting and Cybridization for Long-Term Stem cell Gene therapy
  2071. Stem cell based therapy for the treatment of prion diseases
  2072. Stem cell-based therapy in Parkinson disease
  2073. Stem–cell collection before high-dose therapy for multiple myeloma: time has come to raise the standards!
  2074. … Phase II Study Using Dexamethasone Induction therapy and High-Dose Melphalan Chemotherapy Followed by Autologous Stem cell Transplantation in 30 …
  2075. Novel Stem/Progenitor Populations: Implications for cell therapy
  2076. … Reduces the Cytotoxic Effects of in vitro Expanded NK cells: Implications for Adoptive NK cell therapy in the Setting of Allogeneic Hematopoietic Stem cell (HCT) …
  2077. Application potential of human fetal Stem/progenitor cells in cell therapy
  2078. Feasibility and Monitorization of Stem–cell Replacement therapy
  2079. Sequential Chemotherapy Followed by High Dose therapy and Autologous Stem cell Rescue for Mantle cell Lymphoma: Impact of MIB-1 on Outcome
  2080. Is the era of the therapy by tailor-made Stem cell coming?
  2081. Stem cell based therapy to restore nearly normal hearing
  2082. Mesenchymal Stem cell Based therapy in Liver Disease
  2083. Stem cell research and therapy: A preliminary theological-ethical evaluation
  2084. Bortezomib therapy followed by autologous Stem cell transplantation in POEMS syndrome
  2085. Stem cell research and therapy: An overview of its feasibility with accompanying ethical implications
  2086. Yasuo Takeuchi, Makoto Otsu, Akihiro Kume, 2 Masafumi Onodera, 3 Tadatoshi Kuratsuji, 4 Hiromitsu Nakauchi. 1Lab of Stem cell therapy, Center for Experimental …
  2087. Prospective Study of Oral Valganciclovir for Pre-Emptive therapy of Cytomegalovirus After Allogeneic Stem cell Transplantation.
  2088. High-Dose therapy with Peripheral Blood Stem cell Transplantation for Patients with Multiple Myeloma: Prognostic Impact of Chromosomal Aberrations and …
  2089. Cancer Stem cell theory and cancer therapy
  2090. Autologous haematopoietic Stem cell transplantation followed by thalidomide therapy in poems syndrome
  2091. Outcomes of Allogeneic Stem cell Transplant in Patients with Myeloid Leukemias Over 65 Years of Age. Rationale for Aggressive therapy with Curative Intent.
  2092. Hodgkin-lymphoma with relapsed or progressive disease after autologous Stem cell transplantation: efficacy of salvage radiation therapy
  2093. Adipose derived Stem cells for regenerative cell therapy in peripheral vascular disease
  2094. Rituximab combined with autologous hematopoietic Stem cell transplantation for therapy of CD_ (20), positive B-cell lymphoma
  2095. DEVELOPING THE TOOLS FOR A Stem cell-BASED therapy FOR DEAFNESS: ISOLATION AND ANALYSIS OF HUMAN AUDITORY Stem cells
  2096. 236: Busulfan and Single-Dose Melphalan as Preparative therapy for Infants and Young Children Undergoing Stem cell Transplantation for Leukemia: A Single …
  2097. Caspofungin as secondary prophylaxis or therapy in patients undergoing allogeneic Stem cell transplantation with a prior or ongoing history of syStemic or …
  2098. Bortezomib-based induction therapy induces better responses and outcomes of autologous Stem cell transplantation in newly diagnosed patients with multiple …
  2099. Engineering embryonic Stem cells for myelin cell therapy
  2100. Newly diagnosed multiple myeloma in Taiwan: the evolution of therapy, Stem cell transplantation and new treatment agents
  2101. High Dose Chemotherapy and Autologous Stem cell Transplantation in the Primary therapy of Advanced Follicular Lymphoma in Adults: A SyStematic …
  2102. Role of autologous Stem cell transplant after induction therapy with bortezomib-lenolidomide or bortezomib-thalidomide in newly diagnosed multiple myeloma patients
  2103. Characterisation of neural Stem cells for oestrogen in vitro: potential for improving Stem cell based therapy for stroke
  2104. Stem cell based therapy of malignant brain tumors
  2105. … Interferon-Alpha Maintenance therapy for Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Ineligible for Allogeneic Stem cell …
  2106. Emerging therapy for improving wound repair of severe radiation burns using local bone marrow-derived Stem cell…
  2107. Stem cell therapy for Vascular Disease
  2108. Regenerative therapy and mesenchymal Stem cell for veterinary medicine.
  2109. … Stem cell Transplantation in the therapy of Acute Myeloid Leukemia in Adults Evidence-Based Review 137 The Role of Cytotoxic therapy with Hematopoietic Stem …
  2110. … , Melphalan (RBEAM) and Autologous Stem cell Transplantation (ASCT) for Poor Prognosis Diffuse Large B-cell Lymphoma (DLBCL). ClinicalTrials. Gov …
  2111. Allogeneic Stem cell Transplantation (Allo-SCT) For Relapsed, Refractory Myeloid Leukemia and Mds Using Clofarabine (Clo)±Fludarabine (Flu) with IV Busulfan (Bu …
  2112. Evaluation of Selected Human Embryonic Stem cell Lines for Differentiation to Retinal cells and for cell-Based therapy
  2113. Muscular dystrophy cell therapy: an in utero approach using human fetal mesenchymal Stem cells
  2114. Role of high-dose therapy and autologous Stem cell transplantation in treatment of chemotherapy-efractory Hodgkin lymphoma
  2115. Development of new human Stem cell-derived cellular vehicles for glioma gene therapy
  2116. Generation of cells for cell Replacement therapy: Specification of Neural Precursors in Vivo and in Neural Stem cell Cultures
  2117. Stem cell-based therapy of ocular surface diseases: novel approaches to expansion of adult epithelial Stem cells in culture
  2118. Optimization of suicide gene therapy in Stem cell transplantation with special reference to the selection marker OuaSelect
  2119. Feasibility and Efficacy of Autologous Stem cell Transplantation as First-Line therapy for Peripheral T-cell Lymphoma: a Single Center Experience
  2120. High dose immunosuppressive therapy with autologous hematopoietic Stem cell transplantation in secondary progressive multiple sclerosis: Case report
  2121. Adult Stem cell-based gene therapy for alpha 1-antitrypsin deficiency
  2122. Long-Term Follow-up of HCV Infected Stem cell Transplant Patients and Effects of Antiviral therapy.
  2123. The Effect of SyStemic Steroid therapy on Dry Eye in Hematopoietic Stem cell Transplantated Patients
  2124. … of DNA Methylation Changes in a Phase I Clinical Trial of Low-dose 5-azacitidine (AZA) given as Maintenance therapy after Allogeneic Hematopoietic Stem cell …
  2125. Protection of Stem cell-Derived Lymphocytes in a Primate AIDS Gene therapy Model
  2126. A comparative study of the curative effects of cytomegalovirus preemptive therapy in various kinds of hematopoietic Stem–cell transplantation
  2127. … outcome in transformed follicular lymphoma compared to de novo aggressive B-cell lymphoma treated with high-dose therapy and autologous Stem–cell …
  2128. Hematopoietic Stem cell based gene therapy for the treatment of metachromatic leukodystrophy: towards clinical testing
  2129. Preemptive therapy of HHV-6 Encephalitis with Foscarnet Sodium for High Risk Patients After Hematopoietic Stem cell Transplantation.
  2130. Gemtuzumab-ozogamicin as maintenance therapy after autologous Stem cell transplantation in elderly patients with acute myeloid leukaemia
  2131. Successful autologous Stem cell transplantation in a woman with Severe SyStemic Sclerosis, refractory to immunosuppressive therapy
  2132. CML: Is Allogeneic Stem cell Transplantation the Second-Line therapy of Choice following Resistance to Imatinib?
  2133. Bortezomib-Based therapy, without Stem cell Transplantation, for Newly Diagnosed Multiple Myeloma Patients with t (4; 14).
  2134. Gemtuzumab Ozogamicin as Induction therapy Followed by Post-Remission Hematopoietic Stem cell Transplantation in Elderly Patients with Acute Myeloid …
  2135. Prognostic Value of Bone Marrow Angiogenesis in Patients with Multiple Myeloma Undergoing High-Dose therapy and Autologous Stem cell Transplantation …
  2136. The rate of cytomegalovirus infection and disease in correlation with the type of haematopoietic Stem cell transplantation in the era of pre-emptive antiviral therapy
  2137. … of Prior Radiation therapy Predicts Poor Progression Free Survival and Overall Survival in African Americans with Multiple Myeloma after Autologous Stem cell …
  2138. Biological quantification of murine osteoarticular joints following treatment using Stem cell-based gene therapy
  2139. High-Dose therapy with Peripheral Blood Stem cell Transplantation for Patients with Relapsed or Refractory Hodgkin’s Disease: A Single-Institution 20-Year …
  2140. Treatment of diabetes by cell therapy: new insights on Stem cells and precursors
  2141. “Hiper CVAD Followed by Rituximab Purging Previous to Autologous Stem–cell Transplantation as therapy of Mantle cell Lymphoma. Results of Manto 2000 …
  2142. Epithelial to mesenchymal transition in breast cancer is associated with resistance to therapy and a cancer Stem cell-like phenotype
  2143. Autologous Stem cell Transplant in Recurrent Diffuse Large B-cell Lymphoma: Prior Rituximab therapy Has No Impact On Early Lymphocyte Recovery and …
  2144. Adoptive therapy with T-cell Precursors for Immune Reconstitution After Allogeneic Hematopoietic Stem cell Transplantation.
  2145. Case Closed (If There Was Still Any Doubt): High-Dose Chemotherapy & Autologous Stem–cell Transplant As Adjuvant therapy for Breast Cancer
  2146. 267. Targeted therapy of Metastatic Melanoma Using Neural Stem cell-Based Drug Delivery
  2147. Mechanism of Action of Prostate Stem cell Antigen Targeted Antibody therapy and Its Relevance to Clinical Application in Prostate Cancer
  2148. 90y-Ibritumumab Tiuxetan (Zevalin®-BEAM/C with Autologous Stem cell Support as therapy for Advanced Mantle cell Lymphoma.-Preliminary Results From …
  2149. … of Cytomegalovirus Infection and Disease in Correlation with the Type of Hematopoietic Stem cell Transplantation in the Era of Preemptive Antiviral therapy
  2150. Hyperbaric oxygen therapy for post-Stem cell transplant haemorrhagic cystitis in children and adolescents
  2151. Stem cell Mobilization In Patients With Newly Diagnosed Multiple Myeloma Following therapy With Lenalidomide and Dexamethasone
  2152. Comparative study of allogeneic peripheral blood Stem cell transplantation and immunosuppressive therapy for severe aplastic anemia
  2153. … Seropositivity Does Not Affect the Outcome of Allogeneic Hematopoietic Stem cell Transplantation with Intensive Monitoring and Modern Anti-Viral therapy
  2154. Adding Fludarabine to Cyclophophamide-dexamethason induction therapy impair Stem cell harvest in MM: Report from an interim analysis of the NMSG 13/03 …
  2155. The effect of rituximab in first line therapy to results of autologus haematopoietic Stem cell transplantation in relapsed non-Hodgkin’s lymphoma patients
  2156. Allogeneic haematopoietic Stem cell transplantation as a curative therapy in primary and secondary myelofibrosis
  2157. Allogeneic Stem cell transplantation after sequential therapy using high-dose melphalan and myeloablative conditioning in patients with refractory acute myeloid …
  2158. cell death of colorectal cancer Stem-like cell was induced by photodynamic therapy with protoporphyrin IX
  2159. In the article entitled ”The Role of Cytotoxic therapy with Hematopoietic Stem cell Transplantation in the therapy of Myelodysplastic Syndromes: An Evidence-Based …
  2160. Allogeneic haematopoietic Stem cell transplantation as front line therapy for patients with” de novo” or secondary myelodysplastic syndrome: a single-centre …
  2161. Frequency of Allogeneic Stem cell Transplant (SCT) in Patients Presenting with Newly-Diagnosed AML or AML at Time of First Salvage therapy.
  2162. The Combination of Cyclophosphamide and Thalidomide During Induction therapy for Multiple Myeloma Results in a High Rate of Stem cell Mobilization Failure.
  2163. Future advances in glaucoma therapy: today’s research–gene therapy, Stem cell transplants, neuroprotective drugs and’real-time’pressure monitoring–will help …
  2164. Gauging the response of circulating epithelial tumor cells (CETC) and tumor Stem cell subpopulations to therapy of early-stage cancer in the individual patient
  2165. Immunosuppressive therapy and Future Response to Androgens or Survival After Hematopoietic Stem cell Transplantation in Fanconi Anemia.
  2166. Peripheral Blood Stem cell (PBSC) Harvest Is More Expensive Following Bortezomib-Based therapy in Multiple Myeloma (MM), Related to Increase Number …
  2167. Up-front allogeneic Stem cell transplantation as part of induction or salvage therapy in primary high-risk and relapsed acute myeloid leukaemia
  2168. Resolution of pure red cell aplasia after reduced-intensity allogenic Stem cell transplantation with major ABO mismatch during therapy with lenalidomide
  2169. Achievement of CR and nCR Before and After First High-Dose therapy Followed by Autologous Stem cell Transplantation Is a Major Marker for Long-Term …
  2170. Combination Of Ifn-α/GM-CSF as Maintenance therapy for Multiple Myeloma Patients After Autologous Stem cell Transplantation (ASCT): Results of a Prospective …
  2171. 902. Mucopolysaccharidosis Type I Ex Vivo Gene therapy Based on MLV-Mesenchymal Stem cell Transduction: Is There a Way To Be Attenuated When Older?
  2172. Double Reduced-Intensity Allogeneic Hematopoietic Stem cell Transplantation: French Society of Bone Marrow Graft Transplantation and cellular therapy …
  2173. Hypogammaglobulinemia Following Rituximab and High-Dose therapy and Autologous Stem–cell Transplant: Incidence and Predictors of Prolonged …
  2174. Early allogeneic Stem cell transplantation for peripheral T-cell lymphoma results in a lower relapse rate and a higher non-relapse mortality than high-dose therapy …
  2175. No benefit of autologous Stem cell transplantation as consolidation for high and high-intermediate risk diffuse large B-cell lymphoma in 1. CR after R-CHOP therapy–a …
  2176. PAD Induction therapy Followed by Autologous Peripheral Blood Stem cell Transplant (APBSCT) as Upfront Treatment for Myeloma (MM) in Chinese Patients.
  2177. … (Ph+) Leukemia cells in the Primitive (CD34posCD38neg) Stem cell Fraction in Chronic Myeloid Leukemia (CML) Patients during Tyrosine Kinase Inhibitor therapy.
  2178. … of an immunodeficient mouse model of mucopolysaccharidosis type I suitable for preclinical testing of human Stem cell and gene therapy“[Brain. Res. Bull 74 (2007) …
  2179. Translation and validation of the Functional Assessment of Cancer therapy-Bone Marrow Transplant (FACT-BMT) Version 4 quality of life instrument into Arabic …
  2180. Neural Stem cell-mediated enhanced gene therapy of malignant gliomas using a novel plant thymidine kinase
  2181. … of Second-Line therapy in Multiple Myeloma Patients Relapsing After Uniform Front-Line Treatment with High-Dose Melphalan and Autologous Stem cell …
  2182. … targeted therapy into conditioning regimen for patients undergoing autologous Stem cell transplant (ASCT) for aggressive CD20 positive B-cell lymphoma has altered …
  2183. Thiotepa-cyclophosphamide high-dose immunosuppressive therapy with autologous haematopoietic Stem cell transplantation in aggressive forms of multiple sclerosis …
  2184. Post Tandem Autologous Stem cell Transplant Maintenance therapy with Bortezomib Improves Remission Duration and Quality of Response in Multiple …
  2185. BCCA Protocol Summary for Myeloablative Conditioning therapy Prior to Autologous and Allogeneic Hematopoietic Stem cell Transplantation for Myeloid …
  2186. Effect of prior therapy with Nilotinib or Dasatinib on the outcome after allogeneic Stem cell transplantation for patients with chronic myeloid leukaemia
  2187. Evaluating the Safety and Efficacy of Anti-HIV Transgenic cells in a Humanized Mouse Model (NOD/SCIDγc−/−) for HIV Stem cell Gene therapy.
  2188. Abstract# 1071: Tumor Stem cell targeted therapy with mTOR inhibitor RAD001 and hedgehog signalling inhibitor Cyclopamine reverts chemoresistance towards 5 …
  2189. … proliferative index in mantle cell lymphoma (MCL) treated with sequential chemotherapy followed by high-dose therapy and autologous Stem cell rescue (HDT/ASCR)
  2190. Thalidomide-Dexamethasone as Induction therapy Prior to Autologous Stem–cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma and …
  2191. Steroid Refractoriness, but Not Rapidity of Response, to Induction therapy Predicts for Outcome Post-Autologous Stem cell Transplant (ASCT) in Patients …
  2192. Ganciclovir and Leflunomide Combination therapy for a Patient with Cytomegalovirus Pneumonia after Unrelated Allogenic Stem cell Transplantation
  2193. … factors in relapsed acute myeloid leukaemia patients receiving an allogeneic haematopoetic Stem cell transplantation as salvage therapy: a retrospective analysis on …
  2194. TI 4 Potential of muscle Stem cells and cell therapy for Duchenne muscular dystrophy
  2195. … (MFAC) regimen as induction therapy in relapsed or refractory CD33+ acute myeloid leukaemia prior to allogeneic haematopoetic Stem cell transplantation: a single …
  2196. … Haematopoietic Stem cell Transplantation for Myeloid Malignancies Can Be Effectively Salvaged with Intensive Chemotherapy Followed by cellular therapy …
  2197. Sequential therapy With Nonablative Allogeneic Stem cell Transplantation, Post Transplant Imatinib and Donor Lymphocyte Infusion for Chronic Myeloid Leukemia
  2198. … Is No Longer An Adverse Prognostic Factor for Patients with Relapsed HL Undergoing High Dose therapy and Autologous Stem cell Transplant: Results of a …
  2199. … with Multiple Myeloma Who Have Undergone High-Dose Melphalan therapy Followed by Autologous Peripheral Blood Stem cell Transplantation and Failed …
  2200. 1007. Factor VIII Transgene Tolerance Is Induced by Nonmyeloablative Hematopoietic Stem cell Gene therapy for Hemophilia A
  2201. … Trial of Pre-Emptive therapy with Oral Valganciclovir Compared with IV Ganciclovir for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem cell …
  2202. 340: Response to Steroids as Primary therapy for Acute Graft-Versus-Host Disease (GVHD) in 280 Hematopoietic Stem cell Transplant (HSCT) Recipients …
  2203. Antitumor Effects of Canine Adipose Tissue-Derived Mesenchymal Stem cell Based IFN- Gene therapy and Cisplatin in a Mouse Melanoma Model
  2204. … (VD) or Bortezomib, Adriamycine and Dexamethasone (PAD) Followed by High Dose therapy and Peripheral Blood Stem cell Transplantation in First-Line Treatment …
  2205. 13: The Outcome of Allogeneic Stem cell Transplantation (alloSCT) for the Treatment of therapy-Related Myelodysplastic Syndrome (tMDS) and Acute Myeloid …
  2206. … A, on behalf of the Tunisian Multiple Myeloma Study Group. Single autologous Stem–cell transplantation followed by maintenance therapy with thalidomide is superior …
  2207. Mesenchymal Stem cells: Applications in cell and gene therapy
  2208. … without Preceding Remission Induction therapy Induces Durable Remission in Patients with Relapsed Acute Leukemia After the First Allogeneic Stem cell …
  2209. … with hematological malignancy and hematopoietic Stem cell transplant (HSCT) recipients in the absence of active immunization and approved therapy: The role of …
  2210. Clofarabine [+ or-] fludarabine with IV busulfan as reduced-toxicity conditioning therapy for allogeneic Stem cell transplantation (Allo-SCT) in advanced myeloid …
  2211. Islet neogenesis potential of human adult Stem cells and its applications in cell replacement therapy for diabetes
  2212. High-dose therapy/autologous Stem cell transplantation increases complete remission rate in multiple myeloma irrespective of the induction regimen used: TD …
  2213. The Effect of Mesenchymal Stem cells as a cell therapy in Renal Ischemia
  2214. Stem cells and cell replacement therapy for Parkinson’s disease
  2215. Developing cell therapy techniques for respiratory disease: Intratracheal delivery of genetically engineered Stem cells in a murine model of airway injury
  2216. Bioluminescence Imaging of X-Ray Visible Microencapsulated Mesenchymal Stem cells for cell Based therapy of Peripheral Arterial Disease
  2217. … Transduction of the Human Purine Nucleoside Phosphorylase (PNP) Gene in Murine Hematopoietic Stem cells: An In Vivo Model of Gene therapy for PNP-T-cell …
  2218. … AND GENETIC MANIPULATION OF HUMAN UMBILICAL CORD VEIN MESENCHYMAL Stem cells: POTENTIAL APPLICATION IN cell-BASED GENE therapy
  2219. Development of real-time MR cell tracking for human neural Stem/progenitor cell-mediated brain tumor therapy
  2220. Lymphatic Reprogramming of Adult Endothelial Stem cells for a cell-Based therapy for Lymphedema in Breast Cancer Patients
  2221. WITHDRAWN: Treatment of combining antiangiogenic therapy and cytotoxic chemotherapy reduce the cancer Stem-like cell fraction in hepatocarcinoma xenografts
  2222. Evaluation of human fetal neural Stem/progenitor cells as a source for cell replacement therapy for neurological disorders: Properties and tumorigenicity after long …
  2223. 323: Immunosuppressive therapy Mitigates Murine T-cell Mediated Rejection of Human Embryonic Stem cells Following Transplantation
  2224. Hematopoietic Stem and progenitor cells and potentials for application in fetal cell replacement therapy
  2225. Stem cells and Genetic therapy for Hair cell–Related Hearing Loss
  2226. Molecular Characterization, Safety and Feasibility of Induced Pluripotent Stem (iPS) cell Derived Cardiomyocytes for Heart Regenerative therapy
  2227. The effect of angiotensin (1-7) on bone marrow Stem cells: adjunctive pharmacological therapy for cell transplantation in heart failure
  2228. Risk factors in the development of Stem cell therapy
  2229. Embryonic and adult Stem cell therapy
  2230. Mesenchymal Stem cell therapy: Two steps forward, one step back
  2231. Angiomyeloproliferative lesions following autologous Stem cell therapy
  2232. Stem cell therapy as an emerging paradigm for stroke (STEPS) II
  2233. Stem cell therapy for type 1 diabetes mellitus
  2234. Mesenchymal Stem cell therapy for knee osteoarthritis. Preliminary report of four patients
  2235. Limbal Stem–cell therapy and long-term corneal regeneration
  2236. Stem cell and progenitor cell therapy in peripheral artery disease
  2237. Translation of Stem cell therapy for neurological diseases
  2238. Stem cell therapy for heart diseases
  2239. Autologous Stem cell therapy for peripheral arterial disease: meta-analysis and syStematic review of the literature
  2240. Stem cell therapy for neonatal brain injury: perspectives and challenges
  2241. Mesenchymal Stem cell therapy for nonhealing cutaneous wounds
  2242. Stem cell therapy: A challenge to periodontist
  2243. Stem cell therapy for vascular regeneration: adult, embryonic, and induced pluripotent Stem cells
  2244. Mesenchymal Stem cell therapy for cardiac repair
  2245. Combination Stem cell therapy for heart failure
  2246. Feasibility of combination allogeneic Stem cell therapy for spinal cord injury: a case report
  2247. Stem cell therapy: a new treatment for burns?
  2248. Challenges of Stem cell therapy for spinal cord injury: human embryonic Stem cells, endogenous neural Stem cells, or induced pluripotent Stem cells?
  2249. Stem cell therapy in acute myocardial infarction: a review of clinical trials
  2250. Experimental Stem cell therapy: Biohierarchies and bionetworking in Japan and India
  2251. Intestinal myofibroblasts: targets for Stem cell therapy
  2252. Stem cell therapy in PAD
  2253. Stem cell therapy for Alzheimer’s disease
  2254. Prospects of Stem cell therapy in osteoarthritis
  2255. Human Stem cell therapy in ischaemic stroke: a review
  2256. cellular antioxidant levels influence muscle Stem cell therapy
  2257. Update on Stem cell therapy for cerebral palsy
  2258. Combination Stem cell therapy for the treatment of severe limb ischemia: safety and efficacy analysis
  2259. Congenic mesenchymal Stem cell therapy reverses hyperglycemia in experimental type 1 diabetes
  2260. Recent advances in liver Stem cell therapy
  2261. Stem cell therapy: pieces of the puzzle
  2262. Stem cell separation: a bottleneck in Stem cell therapy
  2263. What Have I Got to Lose?: An Analysis of Stem cell therapy Patients’ Blogs
  2264. Mesenchymal Stem cell therapy modulates the inflammatory response in experimental traumatic brain injury
  2265. Allogeneic periodontal ligament Stem cell therapy for periodontitis in swine
  2266. The Stem cell niche should be a key issue for cell therapy in regenerative medicine
  2267. Results of intracoronary Stem cell therapy after acute myocardial infarction
  2268. Chemokines in mesenchymal Stem cell therapy for bone repair: a novel concept of recruiting mesenchymal Stem cells and the possible cell sources
  2269. Mesenchymal Stem cell therapy for the treatment of chronic obstructive pulmonary disease
  2270. Combined gene and Stem cell therapy for cutaneous wound healing
  2271. Non-invasive Stem cell therapy in a rat model for retinal degeneration and vascular pathology
  2272. Successful clinical implementation of corneal epithelial Stem cell therapy for treatment of unilateral limbal Stem cell deficiency
  2273. Concise review: limbal epithelial Stem cell therapy: controversies and challenges
  2274. Stem cell therapy in heart diseases: a review of selected new perspectives, practical considerations and clinical applications
  2275. Stem cell therapy for idiopathic pulmonary fibrosis: a protocol proposal
  2276. Stem cell therapy for retinal diseases: update
  2277. Imaging: guiding the clinical translation of cardiac Stem cell therapy
  2278. Stem cell therapy in pulmonary fibrosis
  2279. Stem cell therapy for cardiac disease
  2280. The regenerative medicine laboratory: facilitating Stem cell therapy for equine disease
  2281. Stem cell therapy improves the outcome of liver resection in cirrhotics
  2282. Human cord blood Stem cell therapy for treatment of stress urinary incontinence
  2283. Mesenchymal Stem cell therapy for chronic renal failure
  2284. Mesenchymal Stem cell therapy for treatment of cardiovascular disease: helping people sooner or later
  2285. Human relevance of pre-clinical studies in Stem cell therapy: syStematic review and meta-analysis of large animal models of ischaemic heart disease
  2286. Advancement of mesenchymal Stem cell therapy in solid organ transplantation (MISOT)
  2287. Selection of optimal passage of bone marrow-derived mesenchymal Stem cells for Stem cell therapy in patients with amyotrophic lateral sclerosis
  2288. Human placenta-derived mesenchymal Stem cells and islet-like cell clusters generated from these cells as a novel source for Stem cell therapy in diabetes
  2289. Dental Stem cell therapy with calcium hydroxide in dental pulp capping
  2290. Stem cell therapy in cardiovascular disorders
  2291. Advances in Stem cell therapy for the lower urinary tract
  2292. Case control series of intrathecal autologous bone marrow mesenchymal Stem cell therapy for chronic spinal cord injury
  2293. Mesenchymal Stem cell therapy for cutaneous radiation syndrome
  2294. Promises of Stem cell therapy for retinal degenerative diseases
  2295. Stem cell therapy for spinal cord injury
  2296. Animal models of cardiac disease and Stem cell therapy
  2297. Mesenchymal Stem cell therapy regenerates the native bone-tendon junction after surgical repair in a degenerative rat model
  2298. G-CSF for Stem cell therapy in acute myocardial infarction: friend or foe?
  2299. Dual Stem cell therapy after myocardial infarction acts specifically by enhanced homing via the SDF-1/CXCR4 axis
  2300. Effects of adipose tissue-derived Stem cell therapy after myocardial infarction: impact of the route of administration
  2301. Terminal differentiation is not a major determinant for the success of Stem cell therapy-cross-talk between muscle-derived Stem cells and host cells
  2302. Can HIV be cured with Stem cell therapy?
  2303. Mesenchymal Stem cell therapy in necrotizing enterocolitis: a rat study
  2304. Intracoronary autologous CD34+ Stem cell therapy for intractable angina
  2305. Extinction models for cancer Stem cell therapy
  2306. Potential and pitfalls of Stem cell therapy in old age
  2307. Stem cell therapy for glaucoma: possibilities and practicalities
  2308. Stem cell therapy for digestive tract diseases: current state and future perspectives
  2309. Stem cell therapy for the kidney: a cautionary tale
  2310. 10 years of intracoronary and intramyocardial bone marrow Stem cell therapy of the heart: from the methodological origin to clinical practice
  2311. Regenerative medicine in the field of pain medicine: Prolotherapy, platelet-rich plasma therapy, and Stem cell therapy—Theory and evidence
  2312. Mesenchymal Stem cell therapy and delivery syStems in nonhealing wounds
  2313. Safety and efficacy of bone marrow-derived autologous CD133+ Stem cell therapy
  2314. cell delivery and tracking in post-myocardial infarction cardiac Stem cell therapy: an introduction for clinical researchers
  2315. In vivo imaging of embryonic Stem cell therapy
  2316. Cervical multilevel intraspinal Stem cell therapy: assessment of surgical risks in Gottingen minipigs
  2317. Gene and Stem cell therapy: alone or in combination?
  2318. Stem cell therapy for myocardial infarction: are we missing time?
  2319. Imaging cardiac Stem cell therapy: translations to human clinical studies
  2320. Stem–cell therapy in an experimental model of pulmonary hypertension and right heart failure: role of paracrine and neurohormonal milieu in the remodeling process
  2321. Stem cell therapy: a future treatment of stress urinary incontinence
  2322. Oxygen and oxygenation in Stem–cell therapy for myocardial infarction
  2323. Dermal substitute-assisted healing: enhancing Stem cell therapy with novel biomaterial design
  2324. Stem cell therapy for incontinence: where are we now? What is the realistic potential?
  2325. Stem cell therapy in stroke: designing clinical trials
  2326. Combination Stem cell therapy for the treatment of medically refractory coronary ischemia: a Phase I study
  2327. FOXP3 gene expression in multiple sclerosis patients pre-and post mesenchymal Stem cell therapy
  2328. Recruiter-patients as ambiguous symbols of health: bionetworking and Stem cell therapy in India
  2329. Stem cell therapy for dermal wound healing
  2330. Stem cell therapy for ischemic heart disease
  2331. Stem cell therapy in acute myocardial infarction: a pot of gold or Pandora’s box
  2332. Autologous Stem cell therapy maintains vertebral blood flow and contrast diffusion through the endplate in experimental intervertebral disc degeneration
  2333. Allogeneic haematopoietic Stem cell transplantation: individualized Stem cell and immune therapy of cancer
  2334. Current perspectives on imaging cardiac Stem cell therapy
  2335. A new paradigm for Stem cell therapy: substance-P as a Stem cell-stimulating agent
  2336. Advances in cardiovascular molecular imaging for tracking Stem cell therapy
  2337. Cardiac Stem cell therapy: progress from the bench to bedside
  2338. Stem cell therapy for chronic heart failure. Lessons from a 15-year experience
  2339. Human umbilical cord blood as an emerging Stem cell therapy for diabetes mellitus
  2340. Progenitors for the corneal endothelium and trabecular meshwork: a potential source for personalized Stem cell therapy in corneal endothelial diseases and …
  2341. Effects of Stem cell therapy on Left Ventricular Remodeling After Acute Myocardial Infarction: A Meta‐Analysis
  2342. Neural crest regionalisation for enteric nervous syStem formation: implications for Hirschsprung’s disease and Stem cell therapy
  2343. Surgical approaches to gene and Stem cell therapy for retinal disease
  2344. Current status of Stem cell therapy in heart failure
  2345. Synergistic effect of adipose-derived Stem cell therapy and bone marrow progenitor recruitment in ischemic heart
  2346. Stem cell therapy for neuromuscular diseases
  2347. Stem cell therapy for the heart: a perspective
  2348. Effect of oxygenation on Stem–cell therapy for myocardial infarction
  2349. Evidence-based medicine and Stem cell therapy: how do we know such technologies are safe and efficacious?
  2350. Host tissue response in Stem cell therapy
  2351. Stem cell therapy for stress urinary incontinence
  2352. Mesenchymal Stem cell therapy of intestinal disease: are their effects syStemic or localized?
  2353. Stem cell therapy for chronic lung diseases: hope and reality
  2354. Stem cell therapy for the treatment of myocardial infarction
  2355. Regenerative stromal cell therapy in allogeneic hematopoietic Stem cell transplantation: current impact and future directions
  2356. GRNOPC1: the world’s first embryonic Stem cell-derived therapy
  2357. Stem–cell therapy for peripheral arterial occlusive disease
  2358. Bone marrow Stem cell therapy for recessive dystrophic epidermolysis bullosa
  2359. The bioethics of Stem cell research and therapy
  2360. Neural tube defects: review of experimental evidence on Stem cell therapy and newer treatment options
  2361. Stem cell therapy in cardiology
  2362. Evaluation of 28 human embryonic Stem cell lines for use as unrelated donors in Stem cell therapy: implications of HLA and ABO genotypes
  2363. Clinical applications of Stem cell therapy for regenerating the heart
  2364. Human pluripotent Stem cell therapy for Huntington’s disease: technical, immunological, and safety challenges
  2365. Mesenchymal Stem cell exosome: a novel Stem cell-based therapy for cardiovascular disease
  2366. From bone to brain: human skeletal Stem cell therapy for stroke
  2367. Current and future status of Stem cell therapy in heart failure
  2368. In vivo imaging for Stem cell therapy: new developments and future challenges
  2369. Potential clinical applications of adult human mesenchymal Stem cell (Prochymal®) therapy
  2370. Allogeneic human mesenchymal Stem cell therapy (Prochymal®) as a rescue agent for severe treatment resistant GVHD in pediatric patients
  2371. Stem cell therapy for Parkinson’s disease: a road map for a successful future
  2372. Stem cell therapy and research status in Iran: at A glance
  2373. In sickness and in health: corneal epithelial Stem cell biology, pathology and therapy
  2374. Stem cell therapy in patients with thromboangiitis obliterans: assessment of the long-term clinical outcome and analysis of the prognostic factors
  2375. Mesenchymal Stem cell therapy in the Treatment of Acute and Chronic Graft Versus Host Disease
  2376. Stem cell therapy for the bladder: where do we stand?
  2377. ABCG2: a potential marker of Stem cells and novel target in Stem cell and cancer therapy
  2378. … of left ventricular ejection fraction the proper end point for cell therapy trials? An analysis of the effect of bone marrow mononuclear Stem cell administration on left …
  2379. Bionetworking: between guidelines and practice in Stem cell therapy enterprise in India
  2380. Emerging therapy for improving wound repair of severe radiation burns using local bone marrow‐derived Stem cell administrations
  2381. Stem cell therapy extends incubation and survival time in prion-infected mice in a time window–dependant manner
  2382. Stem cell based cancer gene therapy
  2383. Stem cell therapy for chronic myocardial infarction
  2384. Stem–cell gene therapy for the Wiskott–Aldrich syndrome
  2385. Cultured and freshly isolated adipose tissue-derived cells: fat years for cardiac Stem cell therapy
  2386. Adult Stem cell therapy for periodontal disease
  2387. Hematopoietic Stem cell transplantation and implications for cell therapy reimbursement
  2388. … of Mesenchymal and hematopoietic Stem cells derived from Peripheral blood of Acute Lymphocytic Leukemia patients for regenerative Stem cell therapy
  2389. Cardiac Stem cell therapy
  2390. PET molecular imaging in Stem cell therapy for neurological diseases
  2391. Stem cell therapy for diabetes mellitus
  2392. cell therapy for spinal cord injury by neural Stem/progenitor cells derived from iPS/ES cells
  2393. A controlled randomized study examining the effects of exercise therapy on patients undergoing haematopoietic Stem cell transplantation
  2394. Early increase in myocardial perfusion after Stem cell therapy in patients undergoing incomplete coronary artery bypass surgery
  2395. Practical barriers to delivering autologous bone marrow Stem cell therapy as an adjunct to liver resection
  2396. Stem cell therapy for the treatment of acute myocardial infarction
  2397. The role of cardiac electrophysiology in myocardial regenerative Stem cell therapy
  2398. Mesenchymal Stem cells for cardiac cell therapy
  2399. Hematopoietic Stem cell transplantation and hematopoietic Stem cell gene therapy in X‐linked adrenoleukodystrophy
  2400. Neural Stem cell-based gene therapy for brain tumors
  2401. Identification of hematopoietic Stem cell–specific miRNAs enables gene therapy of globoid cell leukodystrophy
  2402. The cardiomyocyte lineage is critical for optimization of Stem cell therapy in a mouse model of myocardial infarction
  2403. New concepts in cardiac Stem cell therapy
  2404. Treatment of peripheral arterial disease using Stem and progenitor cell therapy
  2405. Advances in mesenchymal Stem cell-mediated gene therapy for cancer
  2406. Stem cell therapy for cardiac disease: what can be learned from oncology
  2407. Effect of Stem cell therapy on amiodarone induced fibrosing interstitial lung disease in albino rat
  2408. Current developments in the use of Stem cell for therapeutic neovascularisation: is the future therapy” cell-free”?
  2409. cell therapy of congenital corneal diseases with umbilical mesenchymal Stem cells: lumican null mice
  2410. ATP‐Sensitive K+ Channel‐Deficient Dilated Cardiomyopathy Proteome Remodeled by Embryonic Stem cell therapy
  2411. Stem cell therapy for diabetes
  2412. … combined granulocyte colony stimulating factor and erythropoetin based-Stem cell therapy using intracoronary infusion of peripheral blood Stem cells in patients …
  2413. Allogeneic Stem–cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin’s lymphoma relapsing after an autologous Stem–cell …
  2414. An increase in cancer Stem cell population after primary syStemic therapy is a poor prognostic factor in breast cancer
  2415. A case study of experimental Stem cell therapy and the risks of over-regulation
  2416. Stem cell therapy for articular cartilage defects
  2417. Targeting Stem cell niches and trafficking for cardiovascular therapy
  2418. Toward an ideal animal model to trace donor cell fates after Stem cell therapy: production of stably labeled multipotent mesenchymal Stem cells from bone marrow of …
  2419. Mesenchymal Stem cell therapy of Crohn’s disease: are the far-away hills getting closer?
  2420. Stem cell-based anti-HIV gene therapy
  2421. Stem cells and cell therapy approaches in lung biology and diseases
  2422. Interview: Affordability at the cutting edge: Stem cell therapy for ocular surface reconstruction
  2423. … to requests of families for unproven interventions in neurodevelopmental disorders: Hyperbaric oxygen “treatment” and Stem cell “therapy” in Cerebral Palsy
  2424. The role of cytotoxic therapy with hematopoietic Stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based …
  2425. Stem cells from human exfoliated deciduous teeth (SHED) enhance wound healing and the possibility of novel cell therapy
  2426. Nodal/Activin signaling: a novel target for pancreatic cancer Stem cell therapy
  2427. Stem cell therapy for peripheral arterial disease: a review of clinical trials
  2428. Human gingiva-derived mesenchymal Stem cells are superior to bone marrow-derived mesenchymal Stem cells for cell therapy in regenerative medicine
  2429. Which is the most suitable and effective route of administration for mesenchymal Stem cell-based immunomodulation therapy in experimental kidney transplantation …
  2430. Clinical impact of suicide gene therapy in allogeneic hematopoietic Stem cell transplantation
  2431. Maintenance therapy with low‐dose azacitidine after allogeneic hematopoietic Stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic …
  2432. … compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous Stem–cell transplantation in newly …
  2433. Eyes open to Stem cells: safety trial may pave the way for cell therapy to treat retinal disease in patients
  2434. Enzyme replacement therapy and/or hematopoietic Stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European …
  2435. Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity
  2436. Combination of Stem cell mobilized by granulocyte-colony stimulating factor and human umbilical cord matrix Stem cell: therapy of traumatic brain injury in rats
  2437. Neural Stem cell therapy
  2438. A novel molecule integrating therapeutic and diagnostic activities reveals multiple aspects of Stem cell‐based therapy
  2439. Getting to the heart of myocardial Stem cells and cell therapy
  2440. Hematopoietic Stem cell gene therapy for adenosine deaminase–deficient severe combined immunodeficiency leads to long-term immunological recovery and …
  2441. Stroke patients take part in “milestone” UK trial of Stem cell therapy
  2442. A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after Stem cell transplantation
  2443. Hypoxia-inducible factor 1-alpha release after intracoronary versus intramyocardial Stem cell therapy in myocardial infarction
  2444. High-dose chemotherapy with autologous Stem–cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials
  2445. Pluripotent Stem cell-derived natural killer cells for cancer therapy
  2446. Maladaptive hypertrophy after acute myocardial infarction positive effect of bone marrow-derived Stem cell therapy on regional remodeling measured by cardiac MRI
  2447. Concerns and hopes for Stem cell therapy in cardiology: focus on endothelial progenitor cells
  2448. Glioma gene therapy using induced pluripotent Stem cell derived neural Stem cells
  2449. Republished review: cardiac Stem cell therapy: progress from the bench to bedside
  2450. Mesenchymal Stem cell infusion therapy in a carbon tetrachloride‐induced liver fibrosis model affects matrix metalloproteinase expression
  2451. Stem cell labeling for noninvasive delivery and tracking in cardiovascular regenerative therapy
  2452. Neural Stem cell-based therapy for ischemic stroke
  2453. How to measure the effects of the intracoronary Stem cell therapy?
  2454. Stem cells and cell therapy
  2455. Human embryonic Stem cell-derived mesenchymal Stem cells as cellular delivery vehicles for prodrug gene therapy of glioblastoma
  2456. High-dose therapy and autologous Stem–cell transplantation in Waldenström macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and …
  2457. … trial of telephone-administered cognitive-behavioral therapy to reduce post-traumatic stress disorder and distress symptoms after hematopoietic Stem–cell …
  2458. Advances in Stem cell therapy: application to veterinary medicine.
  2459. Shedding new light on the mechanism underlying Stem cell therapy for the heart
  2460. Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic Stem cell transplantation for BCR–ABL-positive acute lymphoblastic …
  2461. Intracoronary administration of cardiac Stem cells in mice: a new, improved technique for cell therapy in murine models
  2462. Amniotic fluid Stem cell migration after intraperitoneal injection in pup rats: implication for therapy
  2463. Large animal models of hematopoietic Stem cell gene therapy
  2464. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic Stem cell transplant patients: an European Organisation for Research and …
  2465. … connexin channel-dependent intercellular communication in human adult hematopoietic progenitor/Stem cells: probing mechanisms of autologous Stem cell therapy
  2466. Neural Stem cell gene therapy ameliorates pathology and function in a mouse model of globoid cell leukodystrophy
  2467. B-cell function in severe combined immunodeficiency after Stem cell or gene therapy: a review
  2468. Mesenchymal Stem cell-based prostacyclin synthase gene therapy for pulmonary hypertension rats
  2469. Stem cell therapy for cardiovascular regeneration: the beginning or the end of all hearts’ hopes
  2470. Hematopoietic Stem cell expansion and gene therapy
  2471. Stem cell therapy for islet regeneration
  2472. Nanoscaffold based Stem cell regeneration therapy: recent advancement and future potential
  2473. The role of cytotoxic therapy with hematopoietic Stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review
  2474. … remains the most important determinant of CMV reactivation after allogeneic hematopoietic Stem cell transplantation in the era of surveillance and preemptive therapy
  2475. Clinical application of adult Stem cell therapy in neurological disorders
  2476. Development of novel efficient SIN vectors with improved safety features for Wiskott–Aldrich syndrome Stem cell based gene therapy
  2477. Predifferentiated adult Stem cells and matrices for cardiac cell therapy
  2478. Mesenchymal Stem cell-mediated cancer therapy: A dual-targeted strategy of personalized medicine
  2479. Stem cell gene therapy for fanconi anemia: report from the 1st international Fanconi anemia gene therapy working group meeting
  2480. Stem cell-based therapy and regenerative approaches to diseases of the respiratory syStem.
  2481. Stem cell transplantation for hematological malignancies: prospects for personalized medicine and co-therapy with mesenchymal Stem cells
  2482. Use of encapsulated Stem cells to overcome the bottleneck of cell availability for cell therapy approaches
  2483. Genetic basis for skeletal disease. Stem cell therapy for genetic bone disorders
  2484. The continued promise of Stem cell therapy in regenerative medicine.
  2485. Real-time 3D ultrasound guided interventional syStem for cardiac Stem cell therapy with motion compensation
  2486. Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic Stem cell recipients
  2487. Taking Stem cells beyond discovery: a milestone in the reporting of regulatory requirements for cell therapy
  2488. Personalizing Stem cell research and therapy: the arduous road ahead or missed opportunity?
  2489. Research for cell therapy by induced pluripotent Stem cell
  2490. Genotoxicity of retroviral hematopoietic Stem cell gene therapy
  2491. Vasculogenic Stem cell mobilization and wound recruitment in diabetic patients: increased cell number and intracellular regulatory protein content associated with …
  2492. Image-guided, tumor stroma-targeted 131I therapy of hepatocellular cancer after syStemic mesenchymal Stem cell-mediated NIS gene delivery
  2493. … but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous Stem–cell …
  2494. Stem cell based therapy in the inner ear: appropriate donor cell types and routes for transplantation
  2495. Alterations of epithelial Stem cell marker patterns in human diabetic corneas and effects of c-met gene therapy
  2496. Possible mechanisms of retinal function recovery with the use of cell therapy with bone marrow-derived Stem cells
  2497. Therapeutic angiogenesis using gene transfer and Stem cell therapy in peripheral artery disease
  2498. … III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic Stem cell transplantation (AHSCT) for …
  2499. Limbal Stem cell deficiency after topical mitomycin C therapy for primary acquired melanosis with atypia
  2500. … of prolyl hydroxylase and factor-inhibiting hypoxia-inducible factor with nonviral minicircle gene therapy enhances Stem cell mobilization and angiogenesis after …
  2501. Vessel-associated Stem cells from skeletal muscle: From biology to future uses in cell therapy
  2502. Cyclosporine A-loaded and Stem cell-seeded electrospun nanofibers for cell-based therapy and local immunosuppression
  2503. Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy
  2504. Cytoprotection and preconditioning for Stem cell therapy
  2505. Welcome to Stem cell Research & therapy
  2506. Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood Stem cell transplantation
  2507. Induced pluripotent Stem cell technology and Stem cell therapy for diabetes
  2508. Outcome of hematopoietic Stem cell transplant as salvage therapy for Hodgkin’s lymphoma in adolescents and young adults at a single institution
  2509. Progress in hematopoietic Stem cell transplantation as allogeneic cellular gene therapy in thalassemia
  2510. Mesenchymal Stem cells derived from canine umbilical cord vein—a novel source for cell therapy studies
  2511. Surgical intramyocardial Stem cell therapy for chronic ischemic heart failure
  2512. Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen
  2513. Cancer Stem cell radioresistance and enrichment: where frontline radiation therapy may fail in lung and esophageal cancers
  2514. Study and analysis of Stem cell therapy and its ethical consideration
  2515. Stem cell therapy for intractable skin diseases
  2516. Hierarchical scaffold design for mesenchymal Stem cell-based gene therapy of hemophilia B
  2517. Generation of dendritic cells and macrophages from human induced pluripotent Stem cells aiming at cell therapy
  2518. Establishment of a Brazilian line of human embryonic Stem cells in defined medium: implications for cell therapy in an ethnically diverse population
  2519. Evolving role of high dose Stem cell therapy in multiple myeloma
  2520. General overview of the seventh international symposium on Stem cell therapy and cardiovascular innovations
  2521. Stem cell therapy feasible, safe and beneficial for fistulizing Crohn’s disease
  2522. Lp3: endogenous Stem cell therapy improves diabetic wound healing
  2523. Stem cell therapy for neurodegenerative disorders
  2524. Gemtuzumab ozogamicin therapy for isolated extramedullary AML relapse after allogeneic hematopoietic Stem–cell transplantation
  2525. Mesenchymal Stem cell therapy for Apoptosis After Spinal Cord Injury
  2526. Stem–cell therapy for retinal diseases
  2527. Neural Stem cell therapy for temporal lobe epilepsy
  2528. Stem cell therapy in chronic ischemic heart dysfunction with and without viability
  2529. Molecular imaging of the pro-angiogenic paracrine effects of Stem cell therapy
  2530. Stem cell-based therapy for erectile dysfunction
  2531. Hematopoietic Stem cell mobilization strategies for gene therapy of beta thalassemia and sickle cell disease
  2532. Role of molecular imaging in Stem cell therapy for myocardial restoration
  2533. Allogeneic Stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG …
  2534. Outcomes of hematopoietic Stem cell transplant patients who received continuous renal replacement therapy in a pediatric oncology intensive care unit
  2535. Stem cell therapy in the inner ear: recent achievements and prospects
  2536. Stem cells and cell therapy: on the eve of scientific discovery
  2537. Sparing of the neural Stem cell compartment during whole-brain radiation therapy: a dosimetric study using helical tomotherapy
  2538. … CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic Stem cell …
  2539. High-dose therapy followed by autologous Stem–cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma
  2540. Tumor Stem cell research-basis and challenge for diagnosis and therapy
  2541. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous Stem cell transplant (ASCT) for multiple myeloma (MM) …
  2542. Association of polymorphisms of zinc metalloproteinases with clinical response to Stem cell therapy
  2543. Modulation of the major histocompatibility complex by neural Stem cell-derived neurotrophic factors used for regenerative therapy in a rat model of stroke
  2544. … derived from chlorophyll-a: the ABCG2 transporter affects the phototoxic response of side population Stem cell-like cancer cells to photodynamic therapy
  2545. Bone marrow Stem cell therapy for stroke
  2546. Some notes on Stem cell therapy in cardiovascular diseases
  2547. Definition of an enhanced immune cell therapy in mice that can target Stem-like lymphoma cells
  2548. First-line matched related donor hematopoietic Stem cell transplantation compared to immunosuppressive therapy in acquired severe aplastic anemia
  2549. Stem cell therapy & Other Recent Advances in Muscular Dystrophy
  2550. Preclinical studies on mesenchymal Stem cell-based therapy for growth plate cartilage injury repair
  2551. Stem cell therapy for stroke
  2552. FDA approves first Stem–cell therapy
  2553. Recent progress and challenges for the use of Stem cell derivatives in neuron replacement therapy for Parkinson’s disease
  2554. High-dose therapy and Stem cell transplantation
  2555. … initial and recurrent episodes of active CMV infection in the allogeneic Stem cell transplantation setting: implications for designing preemptive antiviral therapy …
  2556. Stem cell therapy: A role for CXCR4 in homing bone marrow side population cells to areas of myocardial damage
  2557. Allogeneic hematopoietic Stem cell transplantation is superior to immunosuppressive therapy in Indian children with aplastic anemia—a single-center analysis of 100 …
  2558. Phage display technology for Stem cell delivery and syStemic therapy
  2559. Mesenchymal Stem cell transplantation: a potential therapy for oral lichen planus
  2560. Thalidomide, dexamethasone and lovastatin with autologous Stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and …
  2561. A randomized phase III trial of thalidomide and prednisone as maintenance therapy following autologous Stem cell transplantation (ASCT) in patients with …
  2562. Dual transfer of GFP gene and MGd into Stem-progenitor cells: toward in vivo MRI of Stem cell-mediated gene therapy of atherosclerosis
  2563. Combined enzyme replacement therapy and hematopoietic Stem cell transplantation in mucopolysacharidosis type VI
  2564. Impact of continuous renal replacement therapy on oxygenation in children with acute lung injury after allogeneic hematopoietic Stem cell transplantation
  2565. … kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic Stem cell …
  2566. Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic Stem cell transplant recipients
  2567. Stem cell therapy doctor struck off by the GMC
  2568. High efficacy and low toxicity of short-course oral valganciclovir as pre-emptive therapy for hematopoietic Stem cell transplant cytomegalovirus infection
  2569. Hematopoietic Stem cell gene therapy as a treatment for autoimmune diseases
  2570. Allogeneic haematopoietic Stem cell transplantation as therapy for chronic granulomatous disease—single centre experience
  2571. Embryonic Stem cell therapy for osteo-degenerative diseases: methods and protocols
  2572. Autologous mesenchymal Stem cell therapy for spinal cord injury: long term safety and clinical efficacy
  2573. Immune modulation for Stem cell therapy
  2574. Thalidomide-dexamethasone as induction therapy before autologous Stem cell transplantation in patients with newly diagnosed multiple myeloma and renal …
  2575. Cardiac Stem cell therapy for the treatment of chronic stable angina refractory to conventional therapy. State of the art and current clinical experience of the San …
  2576. Randomized clinical trials in Stem cell therapy for the heart-old and new types of cells for cardiovascular repair
  2577. Human cytomegalovirus (HCMV) replication kinetics in Stem cell transplant recipients following anti-HCMV therapy
  2578. listening to the messages of patients and stakeholders: where Stem cell therapy, spinal cord injury and neuroethics meet
  2579. Nonviral gene delivery to mesenchymal Stem cells using cationic liposomes for gene and cell therapy
  2580. Immunological monitoring for guidance of preemptive antiviral therapy for active cytomegalovirus infection in allogeneic Stem–cell transplant recipients: a pilot …
  2581. From cell therapy to organ regeneration therapy: generation of functional organs from pluripotent Stem cells
  2582. Effect of immunoglobulin therapy on the rate of infections in multiple myeloma patients undergoing autologous Stem cell transplantation or treated with …
  2583. Role of substrates in diabetes therapy: Stem cell differentiation and islet transplantation
  2584. R-CHOP/R-DHAP compared to R-CHOP induction followed by high dose therapy with autologous Stem cell transplantation induces higher rates of molecular …
  2585. SyStemic therapies for mucopolysaccharidosis: ocular changes following haematopoietic Stem cell transplantation or enzyme replacement therapy–a review
  2586. Human pluripotent Stem cells: from biology to cell therapy
  2587. Embryonic Stem cell therapy for intractable epilepsy
  2588. Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with Stem cell …
  2589. High-dose therapy/autologous hematopoietic Stem cell transplantation in relapsed or refractory marginal zone non-Hodgkin lymphoma
  2590. Stem cell therapy for myocardial regeneration: the Chinese experience
  2591. Prospects of Stem cell therapy for Autism Spectrum Disorders
  2592. Topical Stem and progenitor cell therapy for diabetic foot ulcers
  2593. Repeated application of autologous bone marrow derived Stem cell therapy in patients with severe Buerger’s disease
  2594. High rate of Stem cell mobilization failure after thalidomide and oral cyclophosphamide induction therapy for multiple myeloma
  2595. Primary CNS lymphoma—radiation-free salvage therapy by second autologous Stem cell transplantation
  2596. Gene therapy for canine leukocyte adhesion deficiency with lentiviral vectors using the murine Stem cell virus and human phosphoglycerate kinase promoters
  2597. A phase III PETHEMA/GEM study of induction therapy prior autologous Stem cell transplantation (ASCT) in multiple myeloma: superiority of VTD (bortezomib …
  2598. … pulmonary computed tomography predict the higher response rate of empirical antifungal therapy in patients undergoing allogeneic hematopoietic Stem cell …
  2599. cell therapy for the treatment of metabolic liver disease: an update on the umbilical cord derived Stem cells candidates
  2600. Two cases of Stem cell therapy for pulmonary hypertension: A clinical report
  2601. New cell therapy using bone marrow-derived Stem cells/endothelial progenitor cells to accelerate neovascularization in healing of experimental ulcerative colitis
  2602. Structure of neuromuscular junctions and differentiation of striated muscle fibers in mdx mice after bone-marrow Stem cell therapy
  2603. Prospects for neural Stem cell therapy of alzheimer disease
  2604. Role of maintenance therapy after autologous Stem cell transplant for multiple myeloma: lessons for cancer therapy
  2605. Iron overload and iron chelation therapy in patients with myelodysplastic syndrome treated by allogeneic Stem‐cell transplantation: Report from the working …
  2606. Artificial cell microencapsulated Stem cells in regenerative medicine, tissue engineering and cell therapy
  2607. Stromal Stem cell therapy for Prophylaxis of Acute GVHD: Preliminary Results From a Phase 1 Trial
  2608. Adult Stem cell therapy in the twitcher mouse model of Krabbe’s disease utilizing mesenchymal lineage Stem cells
  2609. Adipobiology of Stem cell-based therapy: secretome insight
  2610. Muscle-derived Stem cells: a model for Stem cell therapy in regenerative medicine
  2611. Emerging candidates in breast cancer Stem cell maintenance, therapy resistance and relapse
  2612. The ongoing challenge of hematopoietic Stem cell-based gene therapy for β-thalassemia
  2613. Adipose-derived Stem and stromal cells for cell-based therapy: current status of preclinical studies and clinical trials.
  2614. Stem cell therapy in orthopaedics
  2615. A randomized trial of preemptive therapy for prevention of cytomegalovirus disease after allogeneic hematopoietic Stem cell transplantation
  2616. Prospects for Induced Pluripotent Stem cell-Derived Hepatocytes in cell therapy
  2617. Perinatal Stem cell therapy
  2618. Frontline therapy with bortezomib, lenalidomide, and dexamethasone (VRD) induction followed by autologous Stem cell transplantation, VRD consolidation …
  2619. Stem cell therapy in Myocardial Infarction Clinical Point of View and the Results of the REANIMA Study (REgenerAtion of Myocardium with boNe Marrow …
  2620. The National Stem cell therapy Patient Registry of Malaysia—Measuring Clinical Outcomes of Stem cell therapy
  2621. Stem cell therapy doctor exploited desperate patients, GMC finds
  2622. Functional improvement of injured retina following the adjuvant Stem cell-based therapy. Preliminary report
  2623. Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic Stem cell transplant
  2624. Perspectives of clinical Stem cell therapy in the treatment of musculoskeletal diseases in Germany
  2625. ThaDD plus high dose therapy and autologous Stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo …
  2626. Back to the bench: The rejuvenation of Stem cell therapy—the therapeutic potential of CD133+ progenitor cells
  2627. Stem cell therapy: the expectations, considerations, and clinical research issues
  2628. Paradoxical rising cytomegalovirus antigenemia during preemptive ganciclovir therapy in hematopoietic Stem cell transplant recipients: incidence, risk factors, and …
  2629. In vivo differentiation of magnetically labeled mesenchymal Stem cells into hepatocytes for cell therapy to repair damaged liver
  2630. S1-5: Modulation of Cancer and Stem cell Biomarkers by the Notch Inhibitor MK-0752 Added to Endocrine therapy for Early Stage ER+ Breast Cancer.
  2631. Tandem versus single autologous peripheral blood Stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in …
  2632. Stem cell therapy for blindness: new developments and implications for the future
  2633. Surveillance investigations after high-dose therapy with Stem cell rescue for recurrent follicular lymphoma have no impact on management
  2634. Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic Stem cell transplant recipients
  2635. Microstructural signatures of ischemia and Stem cell therapy in the myocardium revealed with serial diffusion tensor MRI and tractography of the mouse heart in vivo
  2636. Stem cell therapy for congestive heart failure
  2637. First-in-man cell therapy clinical trial for heart failure-AutoLogous human cardic-derived Stem cell to treat ischemic cardiomyopathy (ALCADIA)
  2638. Non-myeloablative autologous haematopoietic Stem cell transplantation with consolidation therapy using mitoxantrone as a treatment option in multiple …
  2639. cell therapy for diabetes: Stem cells, progenitors or beta-cell replication?
  2640. Perspectives of Stem cell therapy in type 2 diabetes mellitus
  2641. Homologous recombination in human embryonic Stem cells: a tool for advancing cell therapy and understanding and treating human disease
  2642. Interventional, intramyocardial Stem cell therapy in ischemic cardiomyopathy: update 2010
  2643. Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated …
  2644. Stem cell transplant: an effective salvage therapy for multiple myeloma
  2645. cellular therapy following allogeneic Stem–cell transplantation
  2646. Promising cell-based therapy for bone regeneration using Stem cells from deciduous teeth, dental pulp, and bone marrow
  2647. Molecular diagnostics, targeted therapy, and the indication for allogeneic Stem cell transplantation in acute lymphoblastic leukemia
  2648. H1N1 infection in a cohort of hematopoietic Stem cell transplant recipients: prompt antiviral therapy might be life saving
  2649. Efficacy of hormone therapy for osteoporosis in adolescent girls after hematopoietic Stem cell transplantation: a longitudinal study
  2650. Stem cell transplantation as a biological therapy for peripheral T-cell lymphomas
  2651. Contrast echocardiography: finding its place in Stem cell therapy.
  2652. Pilot assessment of HIV gene therapy-hematopoietic Stem cell clinical trial acceptability among minority patients and their advisors
  2653. In vivo T-cell dynamics during immune reconstitution after hematopoietic Stem cell gene therapy in adenosine deaminase severe combined immune deficiency
  2654. Long-Term Follow-Up of Stem cell therapy after Acute Myocardial Infarction
  2655. Bortezomib-based induction therapy followed by autologous Stem cell transplantation and maintenance therapy with bortezomib improves outcome in …
  2656. Second transplantation for graft failure after allogeneic hematopoietic Stem cell transplantation–a retrospective survey by Kanto Study Group for cell therapy
  2657. Should eligible patients with T-cell lymphoma receive high-dose therapy and autologous Stem cell transplant in the upfront setting?
  2658. Stem cell-based hepatic differentiation for cell therapy of liver diseases
  2659. Tandem autologous hematopoietic Stem cell transplants (AuHCT) with or without maintenance therapy (auto-auto) versus single AuHCT followed by HLA …
  2660. Low-dose valganciclovir as preemptive therapy for cytomegalovirus infection occurring in allogeneic Stem cell transplant recipients
  2661. A syStematic review of autologous Stem cell therapy in female stress urinary incontinence
  2662. Adipose tissue-derived Stem cells for cell therapy of airway allergic diseases in mouse
  2663. Stem cells and cell therapy: Popular Belief?
  2664. Oral ribavirin therapy for lower respiratory tract infection of respiratory syncytial virus complicating bronchiolitis obliterans after allogeneic hematopoietic Stem cell …
  2665. First stroke patient is recruited to take part in “milestone” UK trial of Stem cell therapy
  2666. … Rhizopus microsporus infection cured by salvage allogeneic hematopoietic Stem cell transplantation, antifungal combination therapy, and surgical resection
  2667. Stem cell therapy in no-option critical limb ischemia patients
  2668. The cancer Stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon α-2b therapy against advanced hepatocellular carcinoma
  2669. Acceleration of Wound Healing Using Adipose-derived Stem cell therapy with Platelet Concentrates: Plateletrich Plasma (PRP) vs. Platelet-rich Fibrin (PRF)
  2670. Ethical and scientific issues in gene therapy and Stem cell research
  2671. Autologous Stem cell transplantation (ASCT) as upfront or salvage therapy for noncutaneous T-cell lymphoma (TCL): The University of Texas MD Anderson Cancer …
  2672. Total ischemic time is an independent predictor of response to Stem cell therapy in patients with StemI
  2673. Peripheral blood Stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage …
  2674. MRI strain analysis as a novel modality for the assessment of myocardial function following Stem cell therapy-results from Amorcyte trial
  2675. Keynote address—Working Toward Mesenchymal Stem cell therapy for HD
  2676. 90Y-ibritumomab tiuxetan as consolidation therapy after autologous Stem cell transplantation in aggressive non-Hodgkin lymphoma
  2677. Stem cells and cell therapy: on the eve of scientific approach
  2678. … (auto-auto) with or without maintenance therapy versus single autologous transplant followed by HLA-matched sibling non-myeloablative allogeneic Stem cell …
  2679. Cardiac Magnetic Resonance for evaluating early outcomes of Stem cell therapy in non-ischemic dilated cardiomyopathy
  2680. Characteristics and outcomes after autologous Stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab …
  2681. Dual CT and MRI in vivo tracking of Stem cell therapy in peripheral artery disease
  2682. Cardiac Stem cell therapy for infarcted rat hearts
  2683. Combination of IFN-α/Gm-CSF as a maintenance therapy for multiple myeloma patients after autologous Stem cell transplantation (ASCT): a prospective phase II study
  2684. Long-term follow-up of tandem high-dose therapy with autologous Stem cell support for adults with high-risk age-adjusted international prognostic index …
  2685. Rituximab purging and maintenance therapy combined with autologous Stem cell transplantation in patients with diffuse large B-cell lymphoma
  2686. High-dose therapy and autologous peripheral blood Stem cell transplantation in patients with multiple myeloma
  2687. Case of relapsed AIDS-related plasmablastic lymphoma treated with autologous Stem cell transplantation and highly active antiretroviral therapy
  2688. Pre-Stem cell transplant induction therapy does not affect post-transplant survival in light chain (AL) amyloidosis
  2689. Effects of Dual Stem cell therapy (g-csf+ sitagliptin) On Cardiac Levels of Micrornas After Myocardial Infarction
  2690. Regenerative medicine for severe congenital skin disorders: restoration of deficient skin component proteins by Stem cell therapy
  2691. Valganciclovir for pre-emptive therapy of cytomegalovirus viraemia after hematopoietic Stem cell transplantation: a prospective multi-center trial
  2692. … at two years following Stem cell transplant in syStemic light-chain amyloidosis (AL) using short-course bortezomib and dexamethasone consolidation therapy
  2693. A dose‐intensive approach (NB96) for induction therapy utilizing sequential high‐dose chemotherapy and Stem cell rescue in high‐risk neuroblastoma in children …
  2694. … /ZK 222584 in a phase II study of post-transplant maintenance therapy in patients with multiple myeloma following high-dose chemotherapy and autologous Stem cell …
  2695. Haploidentical allogeneic haematopoietic Stem cell transplantation as salvage therapy for engraftment failure after unrelated and autologous Stem cell transplantation …
  2696. Potential application of induced pluripotent Stem cells in cell replacement therapy for Parkinson’s disease
  2697. The Science and Politics of Umbelical Stem cell therapy
  2698. Promising therapy of neural Stem cell transplantation for FASD model–neural network reconstruction and behavior recovery
  2699. Stem cell therapy does not improve visual function or structure in children with optic nerve hypoplasia (septo-optic dysplasia)
  2700. Stem cell therapy. Evaluation of risk factors
  2701. Successful treatment of high-risk and refractory acute myeloid leukemia with haploidentical Stem cell transplantation plus NK cell therapy
  2702. Impact on relapse of corticosteroid therapy after allogeneic hematopoietic Stem cell transplantation for acute myeloid leukemia
  2703. Hematopoietic Stem cell transplantation for therapy-related myelodysplastic syndrome and acute leukemia: a single-center analysis of 47 patients
  2704. Stem cell transplantation and renal replacement therapy: new predictors of outcome
  2705. Standard chemotherapy is superior to high-dose chemotherapy with autologous Stem cell transplantation on overall survival as the first-line therapy for patients with …
  2706. Combining gene and Stem cell therapy in the treatment of disferlinopaties
  2707. Ethical Considerations in Stem cell therapy Studies.
  2708. Regenerative Stem cell therapy
  2709. Fiber-modified adenovirus can mediate human adipose tissue-derived mesenchymal Stem cell-based anti-angiogenic gene therapy
  2710. Nurses’ Attitudes toward Stem cell therapy
  2711. Haploidentical Stem cell transplantation as a salvage therapy for cord blood engraftment failure in a patient with Fanconi anemia
  2712. Stem cell therapy FOR E RAIN TU MORS
  2713. Stem cells and cell therapy: on the eve of scientific approach
  2714. Autologous Stem cell Transplantation as First-Line therapy in Peripheral T-cell Lymphomas.
  2715. Clinical applications of a Stem cell-based therapy for oral bone reconstruction
  2716. A feasibility of useful cell-based therapy by bone regeneration with deciduous tooth Stem cells, dental pulp Stem cells, or bone-marrow-derived mesenchymal Stem …
  2717. Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic Stem cell transplantation from HLA-matched or …
  2718. Opportunities and Challenges of Stem cell therapy: Is there a Role in AMI?
  2719. Status of Stem cell therapy in type-1 diabetics
  2720. … vitro trans-differentiation of human umbilical cord derived hematopoietic Stem cells into hepatocyte like cells using combination of growth factors for cell based therapy
  2721. Stem cell therapy for neurological disorders
  2722. Special aspects of Stem cell therapy in patients with MLD
  2723. Stem cell therapy: Promising and Controversial!
  2724. ETHICAL ISSUES IN Stem cell RESEARCH AND cell therapy
  2725. Stem and progenitor cell-based therapy in ischaemic heart disease: promise, uncertainties, and challenges
  2726. Cardiovascular Regeneration and Stem cell therapy
  2727. Stem cell therapy for Cardiovascular Disease
  2728. Stem cell therapy in Orthopaedic Surgery.
  2729. Mesenchymal Stem cells at the intersection of cell and gene therapy
  2730. The mechanism of mesenchymal Stem cell therapy for diabets
  2731. … reversibility of renal dysfunction associated to light chain deposition disease with bortezomib and dexamethasone and high dose therapy and autologous Stem cell …
  2732. Correction of Wiskott-Aldrich syndrome by hematopoietic Stem cell gene therapy
  2733. Challenges in Stem cell therapy: Bench-To-Bedside
  2734. Embryonic Stem cell therapy; A novel cell delivery method
  2735. Inotuzumab ozogamicin (IO) is an effective salvage therapy that allows for allogeneic hematopoietic Stem cell transplantation (HSCT) in remission in patients with …
  2736. Stem cell therapy for cardiovascular disorders-our clinical experience.
  2737. Inner ear cell therapy for hereditary deafness with multipotent Stem cells
  2738. Mesenchymal Stem–cell-based therapy for the older patient
  2739. Successful allogeneic Stem cell transplantation in two patients with acute myelogenous leukaemia and invasive aspergillosis by antifungal combination therapy
  2740. General Overview of the Sixth International Symposium on Stem cell therapy and Cardiovascular Innovations
  2741. … bortezomib-thalidomide-dexamethasone (VTD) versus thalidomide-dexamethasone (TD) as consolidation therapy after autologous Stem–cell transplantation (ASCT) in …
  2742. Meeting Report: The First Midwest Conference on Stem cell Biology and therapy (SCBT)
  2743. … of front-line therapy with either high-dose therapy and autologous Stem cell rescue (HDT/ASCR) or dose-intensive therapy (R-Hypercvad) on outcome in mantle cell …
  2744. Stem cell therapy for the treatment of diabetes
  2745. Vascular and Cardiac Adult Stem cell therapy Center
  2746. Keynote address—FDA Regulation of Stem cell therapy
  2747. AGING AND Stem cell therapy: A REVIEW AND HIGHLIGHTS OF CURRENT CONTROVERSIES
  2748. Application of Stem cell therapy and magnetic resonance imaging in experimental models of cardiovascular diseases
  2749. Pulmonary Hypertension and Stem cell therapy
  2750. Adult Stem cell-Based therapy for the Heart
  2751. Repetitive busulfan administration after hematopoietic Stem cell gene therapy associated with a dominant HDAC7 clone in a nonhuman primate
  2752. Experimental myocardial regeneration with Stem cell therapy
  2753. Update cardiac Stem cell therapy
  2754. Mesenchymal Stem cells for cell therapy and Tissue Regeneration in Urology
  2755. Stem cell Research & therapy marks its first anniversary
  2756. 15 Opportunities and Challenges of Stem cell therapy: Is there
  2757. Prospects of Stem cell therapy in Diabetes-Introduction to the RDS Special Issue
  2758. Long-term IL-2 therapy after transplantation of T cell depleted Stem cells from alternative donors in children
  2759. Stem cell therapy IN DIABETES MELLITUS: CURRENT TRENDS
  2760. Stem cell AND REGENERATIVE MEDICINE: P-130: ETHICAL CONSIDERATIONS IN Stem cell therapy
  2761. Development of human Stem cell culture conditions for clinical cell therapy
  2762. Advances of reporter gene monitoring Stem cell therapy
  2763. Stem cell therapy in Cardiology: Current Concepts and The Road Ahead
  2764. The immune barriers of cell therapy with allogenic Stem cells of embryonic origin
  2765. Advances in induced Pluripotent Stem cell therapy for neurological diseases
  2766. Stem cell therapy for brain disorders: Why results are discordant
  2767. Potential Confounds in Stem cell therapy: A Case Study of Mesenchymal Stem cells and Cancer Stem cells
  2768. Stem cell therapy IN SPINE SURGERY, CURRENT STATUS AND ETHICAL CONSIDERATION
  2769. Preclinical experience in Stem cell therapy for digestive tract diseases
  2770. Cancer Stem cell: a big hurdle in cancer therapy
  2771. Feasibility of combination allogeneic Stem cell therapy for spinal cord injury: a case report
  2772. Peripheral arterial disease and Stem cell therapy: Critical appraisal
  2773. A General Review of the Current Knowledge of Stem cell therapy for Lung Disorders
  2774. One decade of Stem cell therapy for bone marrow: what is missing?
  2775. Advances of reporter gene imaging monitoring Stem cell therapy
  2776. Stem cell therapy for Patients with Chronic Liver Disease
  2777. Prospects for Induced Pluripotent Stem cell therapy for Diabetes
  2778. Stem cell therapy restores athlete to former glory
  2779. Cardiac Stem cell therapy: An Overview
  2780. Stem cell therapy for critical limb ischemia
  2781. Gene-modified Stem cell therapy for ischemic heart disease
  2782. Experimental Stem cell-Based therapy in Pediatrics: A Fictional Case Study
  2783. Stem cell therapy in diabetic foot patients: where are we now?
  2784. Stem cell therapy Works (in Mice Models of Emphysema)!
  2785. Stem cell therapy Against Oxidative Stress and Hypoxia
  2786. Stem cell therapy for cardiovascular disease: answering basic questions regarding cell behavior
  2787. Re: Stem cell therapy for Stress Urinary Incontinence
  2788. Stem cell therapy for refractory angina
  2789. Stem cell therapy in Ocular Surface Disease
  2790. From immunological tolerance to Stem cell therapy and back: an interview with Irving Weissman
  2791. Human induced pluripotent Stem cells for Stem cell therapy in stroke
  2792. Induced Pluripotent Stem cell therapy for Human Diseases: Are We There Yet?
  2793. Nanobiodevice based single cell imaging for cancer diagnosis and in vivo imaging for Stem cell therapy
  2794. Embryonic Stem cell therapy for Osteo-Degenerative Diseases
  2795. Echo and Stem cell therapy: more than just an ejection fraction
  2796. Stem cell therapy for acute myocardial infarction and subsequent heart failure
  2797. Induction therapy followed by allogeneic Stem cell transplant for MPN blast phase: outcomes from Mayo Clinic in Arizona
  2798. Vascular and Cardiac Adult Stem cell therapy Center (VC-CAST)
  2799. Heart Failure: Will There be Any Light at the End of the Tunnel with Stem cell therapy?
  2800. A New Paradigm for Stem cell therapy: Stem cell Mobilization for Tissue Repair
  2801. Stem cell therapy applications in amyotrophic lateral sclerosis
  2802. Quantitative cardiac imaging to evaluate Stem cell therapy of myocardial infarction
  2803. Consolidative proton therapy following high-dose chemotherapy and autologous Stem cell transplant in an adolescent with relapsed Hodgkin lymphoma
  2804. Relapsed pulmonary lymphomatoid granulomatosis grade III: curative treatment with radioimmune therapy and autologous Stem cell transplantation
  2805. Mesenchymal Stem cell (MSC) therapy To Prevent Ischemia-Reperfusion Injury in Lung Transplantation (145.24)
  2806. Stem/precursor cell-based CNS therapy: the importance of circumventing immune suppression by transplanting autologous cells
  2807. EVALUATION OF CLINICAL TRIALS OF Stem cell therapy FOR LIVER DISEASES IN IRAN
  2808. Flavopiridol is an effective therapy to bridge patients with chronic lymphocytic leukemia (CLL) to reduced-intensity conditioning allogeneic Stem cell transplant
  2809. IMMUNOLOGICAL BASIS FOR ALLOGENEIC MESENCHYMAL Stem cell therapy
  2810. Recent advance in Stem cell therapy for ischemic stroke and clinical concerns
  2811. Stem cell therapy for type 1 diabetes: Can it be an effective clinical scheme?
  2812. Commercialization of Stem cell therapy for the Treatment of Diabetic Retinopathy
  2813. Design of a Large-Scale Clinical Trial for the Treatment of Spinal Cord Pain Using Stem cell therapy
  2814. BONE MARROW-DERIVED Stem cell therapy IN ACUTE MYOCARDIAL INFARCTION
  2815. Embryonic Stem cell therapy for osteo-degenerative diseases-Methods and protocols
  2816. Stem cell therapy for Heart Failure Using Cord Blood
  2817. Chemical Delay of Flaps through Endogenous Stem cell therapy
  2818. CLINICAL RELEVANCE OF ISCHEMIC LARGE ANIMAL MODELS IN Stem cell therapy; AN OVERVIEW AND META-ANALYSIS.
  2819. P4. 52 Combining gene and Stem cell therapy in the treatment of dysferlinophaties
  2820. 81: Stem cell therapy IMPROVES BONY HEALING
  2821. Review of” Research Warning: Non-Host Origin Tumors Resulting From Stem cell therapy“
  2822. INVITED SPEAKERS: I-1: MESENCHYMAL Stem cell therapy
  2823. Molecular Imaging of a Preclinical Model of Stroke: Functional Evaluation and Stem cell therapy
  2824. Editorial [Hot Topic: Stem cell therapy for Cardiovascular Diseases: Are We Still at the Beginning of A Long Road?(Guest Editor: Lino M Goncalves)
  2825. Editorial [Hot Topic: Advances and Perspectives on Stem cell therapy for Human Neurodegenerative Diseases (Guest Editor: Liang-Wei Chen)]
  2826. Stem cell therapy for Vertebral Bone Tissue Engineering
  2827. Neuroprotection and gene-Stem cell therapy for ischemic stroke
  2828. Limbal Stem–cell therapy and long-term corneal regeneration.[5YIF: 54.39; Citations: 301]
  2829. Nanobiodevice based single molecule and cell sensing for cancer diagnosis and in vivo imaging for Stem cell therapy
  2830. Muscle-derived Stem cells: isolation, characterization, differentiation, and application in cell and gene therapy
  2831. New Stem cell therapy may someday cure AMD: non-embryonic human Stem cells appear promising for retinal regeneration
  2832. Improved survival for multiple myeloma in Denmark based on autologous Stem cell transplantation and novel drug therapy in collaborative trials: analysis of accrual …
  2833. Stem cell therapy: resetting autoimmunity or postponing the inevitable?
  2834. Bone Marrow Stem–cell therapy for Idiopathic Dilated Cardiomyopathy
  2835. Arsenic trioxide and Stem cell transplantation is an effective salvage therapy in patients with relapsed APL
  2836. Embryonic Stem cell-derived neurons for inner ear therapy
  2837. Acoustic radiation force for vascular Stem cell therapy: An in vitro validation
  2838. A severe haematologic adverse reaction after high dosage radioiodine therapy following blood Stem cell mobilization with growth factors
  2839. Medulloblastoma with myogenic differentiation: long-term survival in a patient treated with aggressive combination therapy and autologous Stem cell transplantation
  2840. … Salvage therapy in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Relapsing After Allogeneic Hematopoietic Stem cell …
  2841. Monitoring of early Epstein-Barr virus reactivation and preemptive therapy after allogeneic hematopoietic Stem cell transplantation
  2842. … Safety And Pharmacokinetics Of Palifermin In Pediatric Subjects With Acute Leukemias Undergoing Myeloablative therapy And Allogeneic Hematopoietic Stem cell …
  2843. Reduced mitochondrial respiration and improved coupling in infarcted heart following Stem cell therapy
  2844. Dual Stem cell therapy After Myocardial Infarction Acts Specifically by the Cxcr4-sdf1 Axis
  2845. P04 Lentivirus-mediated Stem cell therapy for Duchenne muscular dystrophy
  2846. A novel X-ray-visible microencapsuled mesenchymal Stem cell therapy for peripheral arterial disease
  2847. On the evolution of high-dose immunosuppressive therapy with autologous Stem cell transplantation in multiple sclerosis
  2848. Neuroprotection and neuroregeneration: what to expect from a Stem cell-based therapy of acute brain injury
  2849. LP39: Endogenous Stem cell therapy Improves Calvarial Bone Healing
  2850. The influence of fear appeal messages on creating awareness of Stem cell therapy in Malaysian market.
  2851. Telomere Binding Protein Antagonists for Stem cell therapy
  2852. Legal imperialism in the regulation of Stem cell research and therapy: the problem of extraterritorial jurisdiction
  2853. Restoration of fatty acid but not glucose utilization in the infarcted heart following Stem cell therapy
  2854. Dose finding study of lenalidomide as maintenance therapy in multiple myeloma after allogeneic Stem cell transplantation
  2855. (Stem) cell Based therapy for Neurological Disorders
  2856. Regenerative Stem cell therapy for multiple myeloma osteolytic bone damage
  2857. … KLINICZNE I DOŚWIADCZALNE W CHOROBACH SERCA, PŁUC I NACZYŃ A novel method for isolation of endothelial progenitor cells for cardiac Stem cell therapy
  2858. Placental Umbilical Cord Blood Transfusion for Stem cell therapy in Neurological Diseases
  2859. Development of peptide-modified hyaluronic acid hydrogels for neural Stem cell therapy
  2860. Successful nonmyeloablative allogeneic Stem cell transplantation for therapy-related acute myelogenous leukemia in a patient with preexisting visceral fungal …
  2861. Optimising Adoptive T cell therapy Following Allogeneic Hematopoietic Stem cell Transplantation
  2862. Allogeneic NK cell therapy After Autologous Stem cell Transplant: Results of a Phase I Study
  2863. Hematopoietic Stem cell therapy In Eight Patients with Metachromatic Leukodystrophy–Relevance of Post-Transplant Medication.
  2864. Adult Stem cell therapy for Injured Solid-Organ Tissue (with Emphasis on Cardiac Tissue Repair)
  2865. Mesenchymal Stem cell therapy for peripheral arterial disease: In vivo monitoring and tracking with noninvasive imaging
  2866. Intracoronary autologous Stem cell therapy for acute myocardial infarction: a syStematic review and meta-analysis of randomised controlled trials
  2867. Morphometric analysis of murine ischemic hindlimb revascularization after Stem cell therapy
  2868. Factors limiting spontaneous repair and their relevance for the efficiency of Stem cell therapy of infarcted hearts
  2869. Combination antifungal therapy and surgery for the treatment of invasive pulmonary aspergillosis after hematopoietic Stem cell transplantation
  2870. Why not” do simple things in a simple way”: Use of the Pap test as the first step in screening genetic stability for human cultured Stem cell therapy?
  2871. 761. Gene-and-Stem cell therapy for Vertebral Bone Fracture
  2872. … plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous Stem–cell transplantation in newly …
  2873. Embryonic Stem cell-Derived Multipotent Mesenchymal Stromal cell therapy Following Focal Ischemia in the Rat
  2874. A pilot study to assess perfusion recovery from mesenchymal Stem cell therapy after induction of acute myocardial infarct (AMI)
  2875. Hematopoietic Stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy
  2876. … Diffuse Large B cell Lymphomas (DLBCL) Treated in Randomized Prospective Salvage therapy, RICE or RDHAP Followed by BEAM Plus Autologous Stem cell …
  2877. Stem–cell therapy Mitigates Radiation-Induced Non-Union in Murine Mandibular Distraction Osteogenesis
  2878. Human neural Stem cell therapy in a primate model for Parkinson’s disease
  2879. What is the benefit of maintenance therapy with lenalidomide or bortezomib after autologous Stem cell transplantation in multiple myeloma and what is the risk of …
  2880. Combination therapy with BCNU/Etoposide/Melphalan (BEM) as Conditioning Regimen for Autologous Stem cell Transplant In Multiple Myeloma.
  2881. Assessment of the Microvascular Response to Stem cell therapy with Contrast Ultrasound Perfusion Imaging and Maximum Intensity Projection Angiography
  2882. Autologous peripheral blood Stem–cell (PBSC) collection is not impaired by bortezomib-thalidomide-dexamethasone (VTD) induction therapy in newly …
  2883. P3-398 DOES THE MESENCHYMAL Stem cell therapy IMPROVE THE STREPTOZOTOCIN-INDUCED NEURODEGENERATION IN RATS?
  2884. INTRACORONARY Stem cell therapy AFTER MYOCARDIAL INFARCTION-TWELVE MONTHS FOLLOW-UP OF A RANDOMIZED, RIGOROUS DOUBLE-BLIND …
  2885. Phosphodiesterase-5 Inhibition: A Novel Strategy to Improve Stem cell therapy in the Heart
  2886. Targeting the 5-Lipoxygenase as a Novel Principle of Stem cell therapy In Acute Myeloid Leukemia
  2887. … Prognostic Index Predicts Overall and Progression-Free Survival Following High-Dose therapy and Autologus Stem cell Transplant for Mantle cell …
  2888. 912. Embryonic Stem cell therapy Enhances Tendon Regeneration in a Large Animal Flexor Tendonitis Model
  2889. High-dose therapy (HDT) with hematopoietic Stem cell transplantation (HSCT) is effective therapy for patients with non-Hodgkin lymphoma (NHL) and central nervous …
  2890. Cardiac regenerative therapy: which type of cell will breast the tape?/Autologous Stem cell therapy with surgical myocardial revascularization-the Rostock University …
  2891. SELECTING OPTIMAL CULTIVATION OF HUMAN BONE MARROW MESENCHYMAL Stem cells FOR CLINICAL cell therapy
  2892. Current issues and innovations in Stem cell based therapy
  2893. Advances in Stem cell Reseach and therapy
  2894. Stem and progenitor cell-based therapy approaches: Current developments on treatment of acute myocardial infarction and chronic ischemic cardiomyopathy
  2895. Editorial [Hot Topic: Stem cell Based therapy for Autoimmunity (Guest Editor: Frank Alderuccio)]
  2896. 175 HUMAN AMNIOTIC FLUID Stem cell therapy FOR URETHRAL SPHINCTER REGENERATION
  2897. 69 Intracoronary Autologous Peripheral Stem cell therapy: A Promising Treatment for Heart Failure in Pediatric Dilated Cardiomyopathy
  2898. Influence of Permeability on the Compressive Property of Articular Cartilage: A Scaffold-Free, Stem cell-Based therapy for Cartilage Repair
  2899. … , And Montelukast (Fam) therapy In Reducing Steroid Exposure In Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoetic Stem cell Transplant (Hct)–A …
  2900. 3.09 Hollow Fiber Membrane Bioreactor Technology for Tissue Engineering and Stem cell therapy
  2901. In Situ Stem cell therapy Using Human Adipose Tissue-Derived Multi-lineage Progenitor cells Combined with HMG-CoA Reductase Inhibitor Synergistically Reduce …
  2902. T cell therapy after allogeneic Stem cell transplantation: titration of IL-2 concentration when expanding cord blood t lymphocytes with and without IL-7, in order to …
  2903. Stem cell AND REGENERATIVE MEDICINE: P-140: COMBINATION cell therapy USING OLIGODENDROCYTE PROGENITOR cells (OPC) AND BONE …
  2904. 53 Effects Of GLP-1 eluting Stem cell therapy on collagen remodelling in a porcine model of myocardial infarction
  2905. O. 9 Stem cell therapy of muscular dystrophies using exon skipping approach in GRMD dogs
  2906. … : an investigation of genomic, molecular and cellular factors in graft-versus-host disease and mesenchymal stromal cell therapy in a rat model of allogeneic Stem cell …
  2907. The Role of Time-Lapse Microscopy in Stem cell Research and therapy
  2908. Neural Stem cells for diabetes cell‐based therapy
  2909. 685 Anti-arrhythmic cell therapy for the failing heart: Mesenchymal Stem cell transplantation mitigates electrophysiological remodelling in a rat model of myocardial …
  2910. … for Developing Human Herpes Virus-6 Encephalitis and Clinical Significance of Antiviral therapy In Early Phase After Allogeneic Hematopoietic Stem cell …
  2911. … Interferon-α in Combination with Donor Lymphocyte Infusion for High Risk Acute Leukemia Patients Who Relapsed After Allogeneic Hematopoietic Stem cell …
  2912. YIA6 Effects of GLP-1 eluting Stem cell therapy on collagen remodelling, infarct size and apoptosis in a porcine model of myocardial infarction
  2913. Double knockdown of Prolyyl hydroxylase and factor inhibiting HIF with non-Viral minicircle gene therapy enhances Stem cell mobilization and angiogenesis …
  2914. The Optimal Timing for Stem cell Collection After Induction therapy for Patients with Multiple Myeloma
  2915. Embryonic Stem cell Derivatives for Cardiac therapy: Advantages, Limitations, and Long-Term Prospects
  2916. Hematopoietic Stem cell Gene therapy with Lentiviral Vector in X-Linked Adrenoleukodystrophy
  2917. Imatinib mesylate is superior to allogeneic hematopoietic Stem cell transplantation as the first-line therapy for patients with chronic myeloid leukemia in the …
  2918. Breast cancer Stem cell extinction models: implications for HER2 targeted therapy
  2919. High-dose therapy with Stem cell rescue
  2920. Favorable Outcomes of Neutropenic Enterocolitis Following Hematopoietic Stem cell Transplantation (HSCT) Using a Conservative Medical therapy …
  2921. Thiotepa (TT), Busulfan (Bu), And Clofarabine (Clo) As A Conditioning therapy For Allogeneic Hematopoetic Stem cell Transplant For Patients With High Risk …
  2922. Effects of physical therapy factors on mechanism of Stem cell regulation
  2923. Bortezomib combined with autologous peripheral blood hematopoietic Stem cell transplantation for therapy of patients with multiple myeloma
  2924. Regenerative Medicine in the Central Nervous SyStem: Stem cell-Based Gene-therapy
  2925. Embryonic Stem cell in the therapy of Neurodegenerative Diseases
  2926. Association of Cardiac Resynchronization therapy with Stem cell Transplantation for Ischemic Heart Disease
  2927. Stem cell Transplantation therapy for Heart Disease
  2928. … abnormality during lenalidomide therapy depends on the capacity of the neoplastic Stem cell to differentiate into maturing erythroid committed Stem cells
  2929. Large-Scale Expansion of Human Embryonic and Induced Pluripotent Stem cells for cell therapy Applications
  2930. cell-based therapy for myocardial repair in patients with acute myocardial infarction: rationale and study design of the SWiss multicenter Intracoronary Stem cells …
  2931. Induction therapy and the role of Stem cell transplantation in the treatment of myeloma multiplex in patients aged below 65 years
  2932. Large-scale expansion of human embryonic and induced pluripotent Stem cells for cell therapy applications
  2933. Prevention of Cytomegalovirus Infection after Hematopoietic Stem cell Transplantation: Preemptive therapy Vs Universal Prophylaxis
  2934. New Advances in Gene therapy: The Use of MGMTP140K-Mediated Stem cell Selection in Nonhuman Primates
  2935. 678. Update of Stem cell Gene therapy Clinical Trial for ADA-Deficiency in Japan
  2936. A Phase II Trial of Sequential Treatment with Cytoreductive therapy and Reduced Intensity Conditioning Allogeneic Stem cell Transplantation for Relapsed …
  2937. Response to Tyrosine Kinase Inhibitor therapy In Patients Undergoing Allogeneic Hematopoietic Stem cell Transplantation for Advanced Phase Chronic …
  2938. Current Strategies in Antifungal therapy for Invasive Aspergillosis in Immunocompromised Patients Following Hematopoietic Stem cell Transplantation.
  2939. Bortezomib-Based therapy without Autologous Stem cell Transplantation for Newly Diagnosed Multiple Myeloma Patients with t (4; 14): A Canadian National …
  2940. Reapplication of high-dose chemotherapy with melphalan followed by autologous hematopoietic Stem cell transplantation as salvage therapy for patients with …
  2941. Potent graft-versus-leukemia effect after reduced intensity (RIC) allogeneic Stem–cell transplantation (asct) as post-remission therapy for intermediate-risk de …
  2942. cellULAR therapy AND HEMATOPOIETIC Stem cell TRANSPLANTATION FOR CANCER
  2943. Using Stem cell and Gene therapy Technologies to Treat Parkinson’s Disease
  2944. Allogeneic hematopoietic Stem cell transplantation versus immunosuppressive therapy as frontline treatment for severe aplastic anaemia
  2945. Combination cellular therapy for Regenerative Medicine: The Stem cell Niche
  2946. Outcomes of a late second autologous hematopoietic Stem cell transplant compared to nontransplantation salvage therapy in relapsed multiple myeloma after upfront …
  2947. How to Overcome Myeloma Stem cell Resistance to therapy-Targeting the Stem cell Niche
  2948. … empirical antifungal therapy of intravenous itraconazole with pharmacokinetic evidence in pediatric cancer patients undergoing hematopoietic Stem cell …
  2949. Stem cell Replacement therapy in the Retina
  2950. Hormonal therapy After Stem cell Transplantation and the Risk of
  2951. … Stem cell Transplantation Significantly Improves Overall Survival After Rituximab Containing Induction therapy in Patients with High-Risk Aggressive B cell …
  2952. T cell Suicide Gene therapy Prompts Thymic Renewal in Adults After Haploidentical Hematopoietic Stem cell Transplantation in the Absence of Post-Transplant …
  2953. Mitomycin C therapy for corneal intraepithelial neoplasia masquerading as limbal Stem cell deficiency with recurrent epithelial defect
  2954. Stem cell AND REGENERATIVE MEDICINE: O-36: COMBINATION therapy OF TRAUMATIC BRAIN INJURY IN RATS WITH A Stem cell …
  2955. Imatinib combined with modified hyper-CVAD/MA followed by allogeneic hematopoietic Stem cell transplantation in CR1 as the front-line therapy for adult Ph (+) acute …
  2956. Anti-Inflammatory Gene therapy for the Promotion of Implanted Stem cell Survival in Infarcted Myocardium
  2957. Engineering bioactive scaffolds for Stem cell vascular therapy
  2958. From High-Tech to Biotech Using Stem cell and Gene therapy to Treat Hearing Loss
  2959. … /CT-guided high dose sequential induction therapy with autologous Stem cell transplantation (ASCT) does not improve outcome for poor prognosis diffuse large B-cell …
  2960. … complete response (CR) to bortezomib-thalidomide-dexamethasone (VTD) as induction therapy prior to autologous Stem–cell transplantation (ASCT) in …
  2961. Gene therapy Used for Adipose Stem cell Engineering
  2962. Transfusion support therapy for patients undergoing hematopoietic Stem cell transplantation
  2963. An eco theological reflection on Christian-ethical implications of Stem cell research and therapy
  2964. Abstract LB-155: Molecular targeted therapy of Stem cell leukemia-lymphoma induced by ZNF198-FGFR1
  2965. Muse cells: a novel type of adult human pluripotent Stem cells and their possible application to cell therapy
  2966. … Antigen Receptor Modified CD8+ T cells Derived From Virus-Specific Central Memory cells for Adoptive therapy After Allogeneic Hematopoietic Stem cell …
  2967. Diabetic treatment by Stem cell based therapy in vivo in combination with gynura procumbens extract
  2968. A 34-Year-Old Woman with 2-Year History of therapy-Resistant, Rapidly Progressive SSc Successfully Treated by Autologous Hematopoietic Stem cell …
  2969. Application of neural Stem cell transplantation to brain injury therapy
  2970. Haematopoietic Stem cell gene therapy for metachromatic leukodystrophy
  2971. Neural Stem cell gene therapy for exercise-induced spinal cord injury
  2972. Stem–cell Gene therapy for the Wiskott-Aldrich Syndrome
  2973. Stem cell Transplant Patients, Glucocorticoids and Physical therapy-How Well Do They Mix?
  2974. Human Embryonic Stem cell-derived Tissue Transplantation therapy: Clinical Hurdles
  2975. T-cell Depletion Is An Alternative Approach for Patients>/= 55 Years Undergoing Allogeneic Stem cell Transplantation as Curative therapy for Hematologic Diseases
  2976. Stem cell Replacement therapy for the Mammalian Inner Ear: A SyStematic Literature Review
  2977. Treating GM1 Gangliosidosis With Ex Vivo Hematopoietic Stem cell Gene therapy Without Using Total Body Irradiation: A Masters Thesis
  2978. Development of an embryonic Stem cell-based therapy for replacement of spiral ganglion neurons
  2979. Tissue repairing cells that exist among mesenchymal Stem cells; their potential for cell-based therapy
  2980. Clinical impact of suicide gene therapy in allogeneic hematopoietic Stem cell transplantation
  2981. Electrical competence of the infarcted heart following Stem cell based regenerative therapy, in a rat model.
  2982. Application of protein and small-molecule microarrays to study Stem cell differentiation, cancer growth, and personalized therapy
  2983. HUMAN UMBILICAL CORD BLOOD‐DERIVED MESENCHYMAL Stem cells IN THE CULTURED RABBIT INTERVERTEBRAL DISC‐A cell therapy …
  2984. Autologous Stem cell Transplantation in Multiple Myeloma in the Era of Novel Agents: Impact of Depth of Response to Induction therapy. A Single Institution …
  2985. therapy-Senescent Lymphoma cells Bear Potentially Detrimental Stem–cell Characteristics.
  2986. … Assessment of Rat Heart Force Generation: A Quantitative Approach for Predicting Outcomes From Pluripotent Stem cell-Derived therapy for Myocardial Infarction
  2987. Autologous Hematopoetic Stem cell Transplantation as An Intensive Consolidation therapy for Adult Patients in Remission from Acute Myeloid Leukemia.
  2988. Mesenchymal Stem cell infusion therapy in a carbon tetrachloride-induced liver fibrosis model affects matrix metalloproteinase expression
  2989. 315. Therapeutic Efficacy of Hematopoietic Stem cell Gene therapy for Hurler Type 1 Mucopolysaccharidosis
  2990. PATU8 Analysis of outcomes of high-dose immunosuppressive therapy with autologous Stem cell transplantation in 156 patients with multiple sclerosis
  2991. Towards Defining An Optimal Conditioning Regimen for Stem cell Gene therapy In Fanconi Anemia.
  2992. Key mechanisms underlying cancer Stem cell overpopulation in colon carcinomas: Implications for anticancer therapy.
  2993. Autologous Stem cell Transplantation (ASCT) for Multiple Myeloma (MM) in HIV Positive Patients (PTS) in the Highly Active Antiretroviral therapy (HAART) Era
  2994. Impact of Rituximab-Based therapy After Histological Transformation on High-Dose therapy and Autologous Stem cell Transplantation in Follicular …
  2995. Use Of Mechanical Ventilation And Renal Replacement therapy In The Critically Ill Hematopoietic Stem cell Transplant Patient
  2996. High Dose therapy with Autologous Stem cell Transplantation Vs Standard Dose Chemotherapy In Multiple Myeloma: A Meta-Analysis
  2997. Hematopoietic Stem cell Transplantation and Gene therapy for Primary Immune Deficiency Diseases
  2998. Autologous Stem cell Transplantation as Front Line therapy Does Not Improve the Outcome of High Risk Aggressive Non-Hodgkin’S Lymphoma: A Single Center …
  2999. Induction therapy with Novel Agents Improves Relapse-Free Survival After Autologous Stem–cell Transplantation in Multiple Myeloma
  3000. 864. Foamy Virus Vectors with MGMT-P140K Mediate Efficient Selection in a Canine Pyruvate Kinase Deficiency Model for Hematopoietic Stem cell Gene therapy
  3001. … Stem cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem cell Transplantation Following a Lenalidomide-Based Initial therapy
  3002. Ethical aspects of human embryonic Stem cell use and commercial umbilical cord blood Stem cell banking. Ethical reflections on the occasion of the regulation of the …
  3003. … Stem cell Transplantation and Chemotherapy As a Salvage therapy in Patients with Multiple Myeloma Who Relapsed After Front-Line Autologous Stem cell …
  3004. Applications for human neural Stem cell-derived motor neurons in amyotrophic lateral sclerosis: cell replacement therapy and disease modeling
  3005. … therapy with high-dose chemotherapy (HDCT) and peripheral blood Stem cell transplant (PBSCT) in patients with primary mediastinal nonseminomatous germ cell …
  3006. Decitabine as a Bridging therapy Before Allogeneic Stem cell Transplantation for Myelodysplastic Syndrome
  3007. … cells in Blood of Metastatic Breast Cancer Patients Indicates therapy Response and Provides Information on Epithelial Mesenchymal Transition and Tumor Stem cell …
  3008. Carbon Monoxide therapy Modulates Hematopoietic Stem cell Development in Heme-Oxygenase-1 Knockout Mice
  3009. A Comparative Study of the Outcome of High-Dose therapy and Autologous Hematopoietic Stem cell Transplantation in Patients with High-Risk or Standard …
  3010. Outcome after high-dose therapy with autologous Stem cell rescue with BEAM for relapsed follicular lymphoma.
  3011. Tandem Stem cell transplantation as consolidation therapy for high-risk neuroblastoma: The Children’s Healthcare of Atlanta experience.
  3012. Outcome In Follicular Lymphoma (FL) Patients (pts) Relapsing After Autologous Stem cell Transplantation (ASCT): Allografting Vs. Conventional therapy
  3013. Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic Stem cell transplant recipients
  3014. Autologous peripheral blood Stem cell transplantation with high-dose therapy for anaplastic large cell lymphoma with progressive myelofibrosis
  3015. Collapsed-Dose Versus Standard-Dose Palifermin therapy in Hematopoietic Stem cell Transplantation
  3016. The Role of High Dose Chemotherapy and Autologous Stem cell Transplantation In Patients with Multiple Myeloma Refractory to Initial Induction therapy
  3017. Prospective Use of a Triple FISH Probe to Predict sMDS/AML Following High Dose therapy with Autologous Stem cell Rescue for Lymphoma.
  3018. Peripheral Blood Stem cell Collection In Patients Undergoing Induction therapy with Lenalidomide Based Regimens: Failure Rates and Salvage Approaches
  3019. Idiotype Immunization Following High-Dose therapy and Autologous Stem cell Transplantation for Non-Hodgkin Lymphoma
  3020. Comparison of hematopoietic Stem cell transplantation from HLA identical siblings vs intensive immunosuppression therapy for severe aplastic anemia
  3021. … profound hematopoietic and mesenchymal Stem cell abnormalities involving palmar fat and skin in addition to fascia: Novel implications for pathogenesis and therapy
  3022. Allogeneic Stem cell Transplantation in Patients with therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndromes: Effect of Patient Characteristics and …
  3023. Frequency Of Allogeneic Stem cell Transplant (SCT) In Patients Presenting With Newly-Diagnosed AML Or AML At Time Of First Salvage therapy
  3024. The negative Impact of Imatinib Mesylate therapy prior to Allogeneic Hematopoietic Stem cell Transplantation in patients with chronic Myeloid Leukemia
  3025. Hepatitis C Virus-Induced Hepatocellular Carcinoma: cancer Stem cell and gene therapy
  3026. Carbon Monoxide therapy Reduces Reactive Oxygen Species Production and the Short-Term Hematopoietic Stem cell Population In Heme-Oxygenase-1 Knockout …
  3027. therapy-related myeloid neoplasm in a patient with TP53 mutation: a dilemma in allogeneic Stem cell transplant
  3028. The Novel Use of Hyperbaric Oxygen therapy to Improve Umbilical Cord Blood Stem cell Engraftment in Irradiated NOD/SCID Mice: What Did We Learn?
  3029. P4. 37 Towards hematopoietic Stem cell gene therapy for the treatment of Pompe disease
  3030. … cell Transplantation From HBsAg-Positive Donors Into HBsAg-Negative Recipients: A Safety and Practicable Regimen Under Active Prophylactic Anti-HBV therapy
  3031. Tandem versus single autologous peripheral blood Stem cell transplantation as post-remission therapy in adult acute myeloid…
  3032. Mesenchymal Stem cells therapy in Acute Renal Failure: Possible Role of Hepatocyte Growth Factor. J Stem cell Res Ther 1: 109. doi: 10.4172/2157 …
  3033. Autologous (Auto) Peripheral Blood Stem cell (SCT) As a Consolidation therapy for Patients with Acute Myeloid Leukemia (AML) in 1st Complete Remission (CR): A …
  3034. High resolution analysis of clonal pluripotent Stem cell lentiviral gene therapy in a mouse model of beta-thalassemia
  3035. High-Dose Immunosuppressive therapy (Cyclophosphamide and Campath-1H) Followed by Autologous Hematopoietic Stem cell Transplantation In the Treatment of …
  3036. Chemoresistance Can Be Reliably Overcome with High-Dose therapy and Autologous Stem cell Transplantation (HDT/ASCT) for Relapsed and Refractory …
  3037. … Rituximab As a Pre-Emptive therapy for Epstein-Barr Virus (EBV)-Associated Lymphoproliferative Disorders in 86 Adult Patients Having Allogeneic Stem cell …
  3038. Allogeneic Stem cell Transplantation for Secondary or therapy-Related Acute Myeloid Leukemia or Myelodysplastic Syndrome with Poor-Risk Cytogenetics.
  3039. … of Disease Relapse and Progression in Patients with Multiple Myeloma After First Line therapy with Autologous Stem cell Transplantation: Implications for …
  3040. … Ranimustine (MCNU), Carboplatin, Etoposide, and Cyclophosphamide (MCVC) therapy Followed by Autologous Stem cell Transplantation for Malignant …
  3041. … of glioma Stem cells: Effect of antibody-conjugated magnetic nanoparticles and proteasomal inhibitor bortezomib on GBM-derived neurospheres and glioma Stem cell …
  3042. 181 cell therapy with autologous urine-derived Stem cells for vesicoureteral reflux
  3043. … of Myocardial and Hepatic T2∗ MRI Changes in β-Thalassemia Major Hematopoietic Stem cell Transplantation Recipients and the Effect of Iron Overload therapy
  3044. Embryonic Stem cell-derived Macrophage-based Gene Replacement therapy In SOD3-deficient Mice Ameliorates LPS-induced Lung Inflammation
  3045. High Dose Oral Busulfan and Intravenous Melphalan as Conditioning therapy for Autologous Hematopoietic Stem cell Transplant (HSCT) for the Treatment of …
  3046. Does the magnitude of response to initial induction therapy impact plans for immediate autologous Stem cell transplant (ASCT) consolidation in the transplant-eligible …
  3047. … Kinase Inhibitors therapy and Donor Lymphocyte Infusion In Patients with Chronic Myelogenous Leukemia Relapsing After Allogenic Hematopoietic Stem cell …
  3048. … -Free Survival of Patients with AML Relapse After T-cell-Depleted Allogeneic Stem cell Transplantation by Re-Induction therapy and Subsequent Interferon …
  3049. … modulation by dendritic cells as a mechanism of action of extracorporeal photopheresis therapy for graft-versus-host disease after allogeneic haematopoietic Stem cell …
  3050. Maintenance therapy with Nilotinib (Tasigna) Post Allogeneic Stem cell Transplantation (AlloSCT) for Advanced (> CP1) Chronic Myeloid Leukemia (CML) and Ph+ …
  3051. … Cytomegalovirus (CMV) Serologic Status on Outcome and Survival in Patients Undergoing Allogenic Stem cell Transplantation in the Era of CMV-Preemptive therapy
  3052. … MCL-PET prognostic index and survival in patients treated with rituximab-hypercvad (R-HyCVAD) or high-dose therapy with autologous Stem cell rescue (HDT/ASCT).
  3053. … therapy Is Not Necessary In Related and Unrelated Reduced Intensity Conditioning Stem cell Transplantation Using Low Dose Alemtuzumab In Vivo T cell …
  3054. … -Based Salvage therapy in Adult Patients with T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (T-ALL/LL) Relapsing After Allogeneic Stem cell …
  3055. … versus consolidation bortezomib therapy following aggressive chemo-immunotherapy and autologous Stem cell transplant for previously untreated mantle cell …
  3056. A new humanized mouse model for studying HIV infection and antiretroviral therapeutics and human hematopoietic Stem cell-delivered gene therapy to generate anti …
  3057. … with Community-Based Parenteral Anti-Infective therapy with Intravenous Ganciclovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Stem cell …
  3058. … Lymphocyte Infusion Could Reduce Relapse and Improve Survival in Standard-Risk Acute Leukemia Patients After Allogeneic Hematopoietic Stem cell …
  3059. … of Response to therapy in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma Undergoing Salvage Chemotherapy and Autologous Stem cell …
  3060. … Present with Plasma cells Lacking Phosphorylated Retinoblastoma and/or Cyclin A Expression Benefit From High Dose therapy and Autologous Stem cell …
  3061. … Study Evaluating Busulfan and Fludarabine as Preparative therapy In Adults with Hematopoietic Disorders Undergoing Matched Unrelated Donor Stem cell …
  3062. Dual roles of mesenchymal Stem cells in spinal cord injury: cell replacement therapy and as a model syStem to understand axonal repair
  3063. Emprirical Antifungal therapy of Persistent Neutropenic Fever After Allogeneic Hematopoietic Stem cell Transplantation With Caspofungin or Liposomal Amphotericin …
  3064. Risk-adapted high-dose therapy including autologous and allogeneic Stem cell transplantation for relapsed or aggressive non-Hodgkin’s lymphoma-a phase II trial by …
  3065. … Stem cell Transplantation in HBsAg-negative and Anti-HBs-positive Patients: High Risk in Lymphoid Malignancies and Indication for Pre-emptive Antiviral therapy
  3066. CANCER AND CANCER Stem cell: O-8: COMBINING GENE therapy WITH ADENOVIRAL VECTOR ENCODING 4-1BB L, B7-1 AND P53 IN SKOV3 cell …
  3067. High-Dose therapy and Autologous Hematopoietic Stem cell Transplantation (ASCT) Has a Significant but Transient Impact on Quality of Life: Lessons From the …
  3068. … -Defined and PET/CT-Defined Complete Response (CR) to Novel Agent-Based Induction therapy and Autologous Stem–cell Transplantation (ASCT) In …
  3069. … therapy With Dose-Intensified Cyclophosphamide, Etoposide, and Cisplatin (DICEP) Re-Induction Followed by High-Dose Melphalan (HDM) and Autologous Stem …
  3070. … Blood Stem cell Collections in Multiple Myeloma Based on a Retrospective Analysis of 1,039 Patients Receiving Novel Agents As Induction therapy and …
  3071. … Leukemia (AML), Including therapy-Related AML, Associates with Worse Treatment Outcomes, Than De Novo AML Even After Hematopoietic Stem cell …
  3072. … , DEXAMETHASONE) INDUCTION FOLLOWED BY HIGH-DOSE therapy WITH AUTOLOGOUS Stem cell TRANSPLANTATION AND MAINTENANCE …
  3073. Elimination of cancer Stem cells in pancreatic cancer cell lines by a combinatorial therapy
  3074. Analytical investigation of Embryonic Stem cells propagation for cell therapy
  3075. Neural crest Stem cells from adult bone marrow: a new source for cell replacement therapy?
  3076. Vascular wall Stem cells. Selection and conditioning of progenitors useful for cell therapy. A pathological case study
  3077. cell therapy WITH HUMAN UMBILICAL CORD BLOOD‐DERIVED MESENCHYMAL Stem cells FOR INTERVERTEBRAL DISC REPAIR IN CULTURED …
  3078. An Animal Model for Assessing Cardiovascular cell therapy with Human Bone Marrow Stem cells
  3079. Application in cell therapy for Stroke: Characterization of Apoptotic Expression in Mesenchymal Stem cells
  3080. Mesenchymal Stem cells: cell-Based Reconstructive therapy in Orthopedics
  3081. cell therapy with adipose tissue-derived Stem cells for insulin-dependent diabetes mellitus in mice
  3082. cell-based therapy In Glaucoma: Co-cultures Of Neural Stem cells With Glaucomatous Retinal Explants
  3083. cell therapy Of Alkali Burned Cornea With Human Umbilical Mesenchymal Stem cells In The Mouse Model
  3084. … Purine Nucleoside Phosphorylase (PNP) Gene in Bone Marrow Derived Hematopoietic Stem cells: An In Vivo Model of Gene therapy for PNP Deficient T-cell …
  3085. Mesenchymal Stem cells for the cell-based therapy of type 1 diabetes: An experimental approach
  3086. 1-5 cell therapy OPTIONS FOR OSTEOARTHRITIS: Stem/PROGENITOR cell
  3087. … DIFFERENTIATION OF HUMAN MESENCHYMATOUS Stem cells CULTIVATED ON COLLAGEN SPONGE: PERSPECTIVES FOR GUIDED cell therapy FOR …
  3088. … umbilical blood mononuclear cell–derived mesenchymal Stem cells serve as interleukin‐21 gene delivery vehicles for epithelial ovarian cancer therapy in nude mice
  3089. Progress of research on leukemia Stem/progenitor cell targeting therapy
  3090. In Situ Expression of Gsk-3β in Mesenchymal Stem cells Phase-Dependently Affects the Efficiency of cell Based therapy for Chronic Myocardial Infarction
  3091. Proton therapy targets cancer Stem cells in treatment-resistant non-small cell lung cancer
  3092. Driving murine embryonic Stem cells toward endothelial phenotype for cell-based therapy
  3093. Use of IPs cell-derived neural Stem cells as a cellular vehicle for glioma and breast cancer therapy
  3094. Targeting the CML Stem/progenitor cell with JAK2 (BMS-911543)/ABL inhibitor combination therapy
  3095. Abstract S5-7: Estrogen Receptor Alpha Negative (ER-) Breast Cancer Stem cells in ER+ cell Lines and Primary Cancers Are Enriched by Tamoxifen therapy
  3096. … INFLUENCE OF IMMUNOSUPPRESSIVE therapy ON INFECTION RISK IN RHEUMATOID ARTHRITIS35 THE INFLUENCE OF IMMUNOSUPPRESSIVE therapy …
  3097. Stem cell therapy in treatment of different diseases
  3098. Stem cell therapy for cardiac disease
  3099. Advances in Stem cell therapy for spinal cord injury
  3100. Clinical application of Stem cell therapy in Parkinson’s disease
  3101. Challenges for heart disease Stem cell therapy
  3102. New horizons for Stem cell therapy in liver disease
  3103. Journey of mesenchymal Stem cells for homing: strategies to enhance efficacy and safety of Stem cell therapy
  3104. Stem cell therapy for cerebral ischemia: from basic science to clinical applications
  3105. Stem cell therapy for retinal disease
  3106. Key developments in Stem cell therapy in cardiology
  3107. Stem cell therapy for the spinal cord
  3108. Stem cell therapy for erectile dysfunction: a critical review
  3109. Intraoperative Stem cell therapy
  3110. Role of mesenchymal Stem cell therapy in Crohn’s disease
  3111. Stem cell therapy for stress urinary incontinence: a critical review
  3112. Stem cell therapy in chronic liver disease
  3113. Kidney protection and regeneration following acute injury: progress through Stem cell therapy
  3114. cell delivery routes for Stem cell therapy to the heart: current and future approaches
  3115. Mesenchymal Stem cell therapy for attenuation of scar formation during wound healing
  3116. Stem cell therapy in ischemic stroke: role of IV and intra-arterial therapy
  3117. Infrapatellar fat pad-derived mesenchymal Stem cell therapy for knee osteoarthritis
  3118. Autologous mesenchymal Stem cell therapy in progressive multiple sclerosis: an open label study
  3119. Stem cell therapy in oral and maxillofacial region: An overview
  3120. The potential benefit of Stem cell therapy after stroke: an update
  3121. Translational Stem cell therapy for amyotrophic lateral sclerosis
  3122. Stem cell therapy for the inner ear: recent advances and future directions
  3123. The potential of Stem cell therapy for stroke: is PISCES the sign?
  3124. Fat grafting versus adipose-derived Stem cell therapy: distinguishing indications, techniques, and outcomes
  3125. Mesenchymal Stem cell therapy for cutaneous wounds
  3126. Intervertebral disc regeneration or repair with biomaterials and Stem cell therapy-feasible or fiction?
  3127. A review and update on the current status of Stem cell therapy and the retina
  3128. Autologous Stem cell therapy in the treatment of limb ischaemia induced chronic tissue ulcers of diabetic foot patients
  3129. … -like Stem cells with maximum regenerative potential get discarded during cord blood banking and bone marrow processing for autologous Stem cell therapy
  3130. Bone morphogenetic proteins in craniofacial surgery: current techniques, clinical experiences, and the future of personalized Stem cell therapy
  3131. Mesenchymal Stem cell therapy and lung diseases
  3132. Mesenchymal Stem cell therapy prevents interstitial fibrosis and tubular atrophy in a rat kidney allograft model
  3133. Induced pluripotent Stem cell consensus genes: implication for the risk of tumorigenesis and cancers in induced pluripotent Stem cell therapy
  3134. Nano Technology and Stem cell therapy for CV Diseases: Potential Applications
  3135. Autologous intravenous mononuclear Stem cell therapy in chronic ischemic stroke
  3136. Stem cell therapy for degenerative disc disease
  3137. Stem cell therapy of tendinopathies: suggestions from veterinary medicine
  3138. Advances in Stem cell therapy
  3139. Case reports of adipose-derived Stem cell therapy for nasal skin necrosis after filler injection
  3140. Toward personalized cell therapies by using Stem cells: seven relevant topics for safety and success in Stem cell therapy
  3141. Endogenous Stem cell therapy enhances fat graft survival
  3142. Allogeneic versus autologous Stem–cell therapy
  3143. Concise review: Stem cell therapy for muscular dystrophies
  3144. Adult mesenchymal Stem cell therapy for myelin repair in multiple sclerosis
  3145. Stem cell therapy for voiding and erectile dysfunction
  3146. Stem cell therapy for diabetes
  3147. Progress in Stem cell therapy for the diabetic foot
  3148. Novel insights in basic and applied Stem cell therapy
  3149. Stem cell therapy: a novel & futuristic treatment modality for disaster injuries
  3150. … cord blood-derived mesenchymal Stem cell therapy promotes functional recovery of contused rat spinal cord through enhancement of endogenous cell …
  3151. Perspectives on Stem cell therapy for Cardiac Regeneration–Advances and Challenges–
  3152. Stem cell therapy independent of Stemness
  3153. Stem cell therapy: from bench to bedside
  3154. The impact of mesenchymal Stem cell therapy in transplant rejection and tolerance
  3155. Stem cell therapy for critical limb ischemia: what can we learn from cell therapy for chronic wounds?
  3156. Mesenchymal Stem cell therapy promotes renal repair by limiting glomerular podocyte and progenitor cell dysfunction in adriamycin-induced nephropathy
  3157. Stem cell therapy ameliorates bladder dysfunction in an animal model of Parkinson disease
  3158. The convergence of cochlear implantation with induced pluripotent Stem cell therapy
  3159. Toward personalized cell therapies by using Stem cells: seven relevant topics for safety and success in Stem cell therapy
  3160. Plasmonic photothermic and Stem cell therapy of atherosclerotic plaque as a novel nanotool for angioplasty and artery remodeling
  3161. Stem cell therapy in spinal cord injury: in vivo and postmortem tracking of bone marrow mononuclear or mesenchymal Stem cells
  3162. Development of Stem cell therapy for stress urinary incontinence
  3163. Allogeneic mesenchymal Stem cell therapy for refractory cytopenias after hematopoietic Stem cell transplantation
  3164. Allogeneic cellular and autologous Stem cell therapy for sickle cell disease:’whom, when and how’
  3165. Timeline for development of autologous bone marrow infusion (ABMi) therapy and perspective for future Stem cell therapy
  3166. Human umbilical cord mesenchymal Stem cell therapy on neuromyelitis optica
  3167. Adipose-derived Stem cell therapy for severe muscle tears in working German shepherds: two case reports
  3168. Validating intramyocardial bone marrow Stem cell therapy in combination with coronary artery bypass grafting, the PERFECT Phase III randomized multicenter …
  3169. Functional heterogeneity of mesenchymal Stem cells: implications for cell therapy
  3170. Current status of mesenchymal Stem cell therapy and bone marrow transplantation in IBD
  3171. Issues in medicine Regulatory crackdown on Stem cell therapy: what would the position be in South Africa?
  3172. Preconditioning approach in Stem cell therapy for the treatment of infarcted heart
  3173. News Commentary: human embryonic Stem cell therapy in the post-Geron era
  3174. Update on cardiac Stem cell therapy in heart failure
  3175. Autologous Bone Marrow Stem cell therapy Shows Functional Improvement in Hemorrhagic Stroke.
  3176. Acceptability of Stem cell therapy by pregnant women
  3177. Imaging Stem cell therapy for the treatment of peripheral arterial disease
  3178. Stem cell-based therapy for experimental stroke: a syStematic review and meta-analysis
  3179. Stem–cell therapy takes off in Texas: a boom in unproven procedures is worrying scientists
  3180. Carvedilol enhances mesenchymal Stem cell therapy for myocardial infarction via inhibition of caspase-3 expression
  3181. Human amniotic fluid Stem cell-derived muscle progenitor cell therapy for stress urinary incontinence
  3182. Mesenchymal Stem cell therapy following muscle trauma leads to improved muscular regeneration in both male and female rats
  3183. Mesenchymal Stem cell secreted vesicles provide novel opportunities in (Stem) cell-free therapy
  3184. Assessment of health-related quality of life in patients receiving Stem cell therapy for end-stage liver disease: an Egyptian study
  3185. Stem cell therapy for multiple sclerosis: preclinical evidence beyond all doubt?
  3186. Neural Stem cell therapy for temporal lobe epilepsy
  3187. Anti-HLA antibodies in regenerative medicine Stem cell therapy
  3188. Stem cell therapy for arterial restenosis: potential parameters contributing to the success of bone marrow-derived mesenchymal stromal cells
  3189. Neurotrophic factor‐secreting autologous muscle Stem cell therapy for the treatment of laryngeal denervation injury
  3190. Stem cell therapy: social recognition recovery in a FASD model
  3191. Mesenchymal Stem cell therapy in acute lung injury: is it time for a clinical trial?
  3192. NK cell therapy: targeting disease relapse after hematopoietic Stem cell transplantation
  3193. Effect of Stem cell therapy on induced diabetic keratopathy in albino rat
  3194. State-of-the-Art on Basic and Applied Stem cell therapy; Stem cell Research Italy–International Society for cellular therapy Europe, Joint Meeting, Montesilvano (PE …
  3195. Stem cell therapy in kidney transplantation
  3196. Autism spectrum disorders: is mesenchymal Stem cell personalized therapy the future?
  3197. The challenges of Stem cell therapy
  3198. Liposome-mediated cancer gene therapy: clinical trials and their lessons to Stem cell therapy
  3199. Mesenchymal Stem cell therapy in the sports knee: where are we in 2011?
  3200. Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic Stem cell transplantation
  3201. SPECT and PET to optimize cardiac Stem cell therapy
  3202. Societal value of Stem cell therapy in stroke–a modeling study
  3203. Prospects for Stem cell-derived therapy in stroke
  3204. Mesenchymal Stem cell 1 (MSC1)-Based therapy Attenuates Tumor Growth Whereas MSC2-Treatment Promotes Tumor Growth and Metastasis
  3205. The safety of embryonic Stem cell therapy relies on teratoma removal
  3206. Hematopoietic-Stem–cell-based gene therapy for HIV disease
  3207. Effect of Stem cell therapy on adriamycin induced tubulointerstitial injury
  3208. Stem cell therapy in animal sciences-A review
  3209. Advances in Stem cell transplantation and gene therapy in the β-hemoglobinopathies
  3210. Stem cell educator therapy and induction of immune balance
  3211. Update on gene and Stem cell therapy approaches for spinal muscular atrophy
  3212. Stem cell therapy in retinal diseases?
  3213. cell therapy using induced pluripotent Stem cells or somatic Stem cells: this is the question
  3214. Moving successful virus-specific T-cell therapy for hematopoietic Stem cell recipients to late phase clinical trials
  3215. Stem cell therapy–An Overview
  3216. Evaluating the first-in-human clinical trial of a human embryonic Stem cell-based therapy
  3217. … after bone marrow derived cell therapy in patients with acute ST elevation myocardial infarction. A 5-year follow-up from the Stem cell Transplantation in Ischaemic …
  3218. The cancer Stem–cell hypothesis: its emerging role in lung cancer biology and its relevance for future therapy
  3219. Pluripotent Stem cell–based cancer therapy: Promise and challenges
  3220. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, Stem cell accumulation, and a mesenchymal phenotype
  3221. Stem cell therapy for bone regeneration: present and future strategies.
  3222. Human amniotic fluid Stem cell injection therapy for urethral sphincter regeneration in an animal model
  3223. Human bone marrow-derived mesenchymal Stem cell: a source for cell-based therapy
  3224. Position Statement of the Chinese Diabetes Society regarding Stem cell therapy for diabetes
  3225. Stem cell based therapy-where are we going?
  3226. Mesenchymal Stem cell-based therapy for the treatment of type 1 diabetes mellitus
  3227. MicroRNA and cardiac Stem cell therapy
  3228. Effect of mesenchymal Stem cell therapy on recovery of streptozotocin-induced diabetes mellitus in adult male albino rats: a histological and immunohistochemical …
  3229. Mending the broken heart-Towards clinical application of human embryonic Stem cell therapy derivatives
  3230. Second autologous Stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival
  3231. A step-up approach for cell therapy in stroke: translational hurdles of bone marrow-derived Stem cells
  3232. Cardiac function, perfusion, metabolism, and innervation following autologous Stem cell therapy for acute ST-elevation myocardial infarction. A FINcell …
  3233. Rituximab maintenance therapy after autologous Stem–cell transplantation in patients with relapsed CD20+ diffuse large B-cell lymphoma: final analysis of the …
  3234. … of autologous Stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin’s lymphoma responding to prior salvage therapy
  3235. Mesenchymal Stem cell therapy in a rat model of osteoarthritis
  3236. Stem cell therapy for male infertility takes a step forward
  3237. Retinal regeneration and Stem cell therapy in retinitis pigmentosa
  3238. RETRACTED ARTICLE: Targeted suicide gene therapy for glioma using human embryonic Stem cell-derived neural Stem cells genetically modified by …
  3239. Understanding the application of Stem cell therapy in cardiovascular diseases
  3240. Hematopoietic Stem cell and gene therapy corrects primary neuropathology and behavior in mucopolysaccharidosis IIIA mice
  3241. Role of cytotoxic therapy with hematopoietic Stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence …
  3242. Combined strategy of mesenchymal Stem cell injection with vascular endothelial growth factor gene therapy for the treatment of diabetes‐associated erectile …
  3243. Isolation and characterization of mesenchymal Stem cell-like cells from healthy and inflamed gingival tissue: potential use for clinical therapy
  3244. Human neural Stem cell replacement therapy for amyotrophic lateral sclerosis by spinal transplantation
  3245. High-dose therapy and autologous Stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data …
  3246. Stem cell implants for cancer therapy: TRAIL-expressing mesenchymal Stem cells target cancer cells in situ
  3247. Stem cell based glioblastoma gene therapy
  3248. HLA-mismatched Stem–cell microtransplantation as postremission therapy for acute myeloid leukemia: long-term follow-up
  3249. … -thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic Stem cell transplantation in patients …
  3250. Exploring the enkephalinergic differentiation potential in adult Stem cells for cell therapy and drug screening implications
  3251. Mesenchymal Stem cell-based tumor-targeted gene therapy in gastrointestinal cancer
  3252. Clinical response of 277 patients with spinal cord injury to Stem cell therapy in iraq
  3253. Corticotomy and Stem cell therapy for orthodontists and periodontists: rationale, hypotheses, and protocol
  3254. Retracted: Tumor Tropism of Intravenously Injected Human‐Induced Pluripotent Stem cell‐Derived Neural Stem cells and Their Gene therapy Application in a …
  3255. … , and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous Stem–cell transplantation: MRC Myeloma …
  3256. The role of cytotoxic therapy with hematopoietic Stem cell transplantation in the treatment of adult acute lymphoblastic leukemia: update of the 2006 evidence …
  3257. Stem cell therapy: facts and fiction
  3258. Sonic hedgehog signaling inhibition provides opportunities for targeted therapy by sulforaphane in regulating pancreatic cancer Stem cell self-renewal
  3259. Influence of Stem cell therapy on Statin-induced Myopathy of Skeletal Muscle in Female Rats.
  3260. Alginate scaffolds for mesenchymal Stem cell cardiac therapy: influence of alginate composition
  3261. Groups propose plan to accredit controversial Stem cell therapy clinics
  3262. Utility of mesenchymal Stem cell therapy in type 1 diabetes
  3263. Indications and outcomes of antifungal therapy in French patients with haematological conditions or recipients of haematopoietic Stem cell transplantation
  3264. When inner ear Stem cell therapy becomes a reality
  3265. Mesenchymal Stem cell therapy on murine model of nonalcoholic steatohepatitis
  3266. p53-Independent, normal Stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies
  3267. The Promise of Hematopoietic Stem cell therapy for Stroke: Are We There Yet?
  3268. Valproic acid enhances anti-tumor effect of mesenchymal Stem cell mediated HSV-TK gene therapy in intracranial glioma
  3269. The Editor’s Roundtable: Advances in Stem cell therapy for treatment of cardiovascular disease
  3270. Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic Stem cell transplantation improves progression‐free survival in multiple …
  3271. Challenges in vector and trial design using retroviral vectors for long-term gene correction in hematopoietic Stem cell gene therapy
  3272. Hematopoietic Stem cell mobilization for gene therapy of adult patients with severe β-thalassemia: results of clinical trials using G-CSF or plerixafor in …
  3273. High‐dose therapy with autologous Stem cell transplantation versus chemotherapy or immuno‐chemotherapy for follicular lymphoma in adults
  3274. Cancer Stem cell targeting: the next generation of cancer therapy and molecular imaging
  3275. T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic Stem cell transplantation
  3276. New directions in cardiac Stem cell therapy: An update for clinicians
  3277. Recent trends and strategies in Stem cell therapy for Alzheimer’s disease
  3278. Residual dormant cancer Stem–cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts
  3279. Embryonic Stem cell therapy for intractable epilepsy
  3280. Stem cell-based photodynamic therapy
  3281. High-dose therapy and autologous Stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era
  3282. Stem cell therapy, regenerative medicine and hematopoietic Stem cell transplantation: Recent achievements
  3283. Therapeutic alliance in telephone-administered cognitive–behavioral therapy for hematopoietic Stem cell transplant survivors.
  3284. Immunization of children receiving immunosuppressive therapy for cancer or hematopoietic Stem cell transplantation
  3285. Molecular imaging of Stem cell therapy in brain tumors: a step towards personalized medicine
  3286. Fighting HIV with Stem cell therapy: one step closer to human trials?
  3287. PAMAM Dendrimer-Baculovirus Nanocomplex for Microencapsulated Adipose Stem cell-Gene therapy: In Vitro and in Vivo Functional Assessment
  3288. Cardiac biointerventions whatever happened to Stem cell and gene therapy?
  3289. … minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood Stem cell transplantation is an …
  3290. Stem cell therapy in orthopaedics
  3291. Stem cell therapy in kidney transplantation—reply
  3292. Mesenchymal Stem cell therapy: immunomodulation and homing mechanisms
  3293. Medical nutrition therapy provided to adult hematopoietic Stem cell transplantation patients
  3294. Safety evaluation of Stem cells used for clinical cell therapy in chronic liver diseases; with emphasize on biochemical markers
  3295. Prophylactic and preemptive therapy with dasatinib after hematopoietic Stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia
  3296. … Prognostic Scoring SyStem scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic Stem cell …
  3297. Would cancer Stem cells affect the future investment in Stem cell therapy
  3298. Role of salvage radiation therapy for patients with relapsed or refractory Hodgkin lymphoma who failed autologous Stem cell transplant
  3299. Using the BLT humanized mouse as a Stem cell based gene therapy tumor model
  3300. Hematopoietic Stem cell transplantation improves the high incidence of neutralizing allo-antibodies observed in Hurler’s syndrome after pharmacological …
  3301. Quality of life in patients with coronary artery disease after Stem cell therapy
  3302. cell therapy in Hematology: Hematopoietic Stem cell Transplantations in 2012
  3303. Why CCR5 is chosen as the target for Stem cell gene therapy for HIV infection?
  3304. Evaluation of the cell viability of human Wharton’s jelly Stem cells for use in cell therapy
  3305. Mesenchymal Stem cells in drug/gene delivery: implications for cell therapy
  3306. Stem cell therapy: Dental Aspects
  3307. Stem cell therapy in amyotrophic lateral sclerosis
  3308. Novel therapy for type 1 diabetes: Autologous hematopoietic Stem cell transplantation
  3309. cellular therapy promotes endogenous Stem cell repair
  3310. Autologous Stem cell therapy to treat chronic ulcer in heifer-A case study.
  3311. T-cell therapy: a powerful tool for the management of viral infections and relapse post hematopoietic Stem cell transplantation
  3312. Consolidation of first-line therapy with busulphan and melphalan, and autologous Stem cell rescue in children with Ewing’s sarcoma
  3313. Autologous Stem cell therapy: an analysis of the South African regulatory regime
  3314. Implications of different fluid overload definitions in pediatric Stem cell transplant patients requiring continuous renal replacement therapy
  3315. Adipose tissue-derived multi-lineage progenitor cells as a promising tool for in situ Stem cell therapy
  3316. Stem cell therapy in neurodegenerative diseases: From principles to practice
  3317. Induction of antigen-specific tolerance through hematopoietic Stem cell-mediated gene therapy: the future for therapy of autoimmune disease?
  3318. … -induced cavernous hemangioma in long-term survivors who underwent hematopoietic Stem cell transplantation with radiation therapy during childhood or …
  3319. Supportive care with art therapy, for patients in isolation during Stem cell transplant
  3320. Prognostic factors influencing clinical outcome of allogeneic hematopoietic Stem cell transplantation following imatinib-based therapy in BCR–ABL-positive …
  3321. Multiple myeloma: myeloablative therapy with autologous Stem cell support versus chemotherapy: a meta-analysis
  3322. Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic Stem cell transplantation—guidelines of the Infectious …
  3323. Oral valganciclovir versus ganciclovir as delayed pre‐emptive therapy for patients after allogeneic hematopoietic Stem cell transplant: a pilot trial (04‐0274) and …
  3324. Stem cell therapy for small animal clinical use
  3325. Involved field radiation therapy following high dose chemotherapy and autologous Stem cell transplant benefits local control and survival in refractory or recurrent …
  3326. Induced pluripotent Stem (iPS) cell-based cell therapy for muscular dystrophy: current progress and future prospects
  3327. Tandem Stem cell rescue as consolidation therapy for high‐risk neuroblastoma
  3328. Improving safety of preemptive therapy with oral valganciclovir for cytomegalovirus infection after allogeneic hematopoietic Stem cell transplantation
  3329. Induced transgene expression for the treatment of solid tumors by hematopoietic Stem cell-based gene therapy
  3330. Erythroid promoter confines FGF2 expression to the marrow after hematopoietic Stem cell gene therapy and leads to enhanced endosteal bone formation
  3331. Maintenance therapy after Stem–cell transplantation for multiple myeloma with bortezomib/thalidomide vs. thalidomide vs. Alfa2b-interferon: Final results of a phase III …
  3332. Efficacy and safety of low-dose ganciclovir preemptive therapy in allogeneic haematopoietic Stem cell transplant recipients compared with conventional-dose …
  3333. The role of allogeneic hematopoietic Stem cell transplantation in the therapy of patients with acute lymphoblastic leukemia
  3334. Therapeutic strategies against ischemia–reperfusion injury: Stem cell therapy and beyond
  3335. INTRACORONARY Stem cell therapy IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION–36 MONTHS RESULTS OF A RANDOMIZED, DOUBLE-BLIND …
  3336. Cardiopoietic Stem cell therapy in heart failure: The multicenter randomized c-cure trial
  3337. Allogeneic Stem cell transplantation in therapy-related acute myeloid leukemia and myelodysplastic syndromes: impact of patient characteristics and timing of …
  3338. Stem–cell therapy in medicine–how far we came and what we can expect?
  3339. Enhancement of cancer Stem cell susceptibility to conventional treatments through complementary yoga therapy: possible cellular and molecular mechanisms
  3340. Thiotepa and melphalan based single, tandem, and triple high dose therapy and autologous Stem cell transplantation for high risk neuroblastoma
  3341. Stem cell-based therapy for α1-antitrypsin deficiency
  3342. Intracoronary autologous CD34+ Stem cell therapy for intractable angina
  3343. Stem cell therapy in spinal cord injuries: current concepts.
  3344. Researches on application of Stem cell therapy in exercise-induced spinal cord injury recovery
  3345. Recognition of glioma Stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma
  3346. Dexamethasone palmitate successfully attenuates hemophagocytic syndrome after allogeneic Stem cell transplantation: macrophage-targeted steroid therapy
  3347. Stem cells: Source for diabetes cell therapy
  3348. Stem cell therapy for Hemorrhagic Stroke: A Single Case Study Report
  3349. Stem cell therapy in Myocardial Infarction: Latest Trends
  3350. Granulocyte transfusion therapy in pediatric patients after hematopoietic Stem cell transplantation: a 5-year single tertiary care center experience
  3351. … in combination with cyclosporin a as pre-and posttransplantation immunosuppressive therapy in nonmyeloablative allogeneic hematopoietic Stem cell …
  3352. High-dose chemotherapy followed by autologous Stem cell transplantation as a first-line therapy for high-risk primary breast cancer: a meta-analysis
  3353. Adherence of Stem cell transplant recipients receiving glucocorticoid therapy to an exercise-based rehabilitation program
  3354. Stem cell therapy in the Eye: Current status and future prospects for retinal neurodegenerative disease
  3355. Stem cell application for amyotrophic lateral sclerosis: Growth factor delivery and cell therapy
  3356. Initial low-dose valganciclovir as a preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic Stem cell transplant recipients
  3357. Pseudoprogression after high-dose busulfan-thiotepa with autologous Stem cell transplantation and radiation therapy in children with brain tumors: impact on survival
  3358. Research progress of Stem cell therapy for type 1 diabetes mellitus
  3359. Stem cell therapy and amyotrophic lateral sclerosis
  3360. … Stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy
  3361. Induction therapy and Stem cell mobilization in patients with newly diagnosed multiple myeloma
  3362. 532 Priming of Stem cells With Celastrol to Enhance Survival for cell therapy
  3363. The perspectives of Stem cell-based therapy in neurological diseases
  3364. Late onset of hepatitis B virus reactivation following hematopoietic Stem cell transplantation: successful treatment with combined entecavir plus tenofovir therapy
  3365. … , thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous Stem cell transplant and consolidation therapy with bortezomib for …
  3366. Continuous renal replacement therapy in children post-hematopoietic Stem cell transplantation: The present and the future
  3367. Consolidative therapy with Stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen
  3368. The beneficial effects of cardiac Stem cell therapy on left ventricular function and structure persists for at least one year in rats with acute myocardial infarction
  3369. MRI Stem cell tracking for therapy in experimental cerebral ischemia
  3370. … of high-dose ranimustine (MCNU), carboplatin, etoposide, and cyclophosphamide (MCVC) therapy followed by autologous Stem cell transplantation for malignant …
  3371. Non-myeloablative bone marrow Stem cell transplantation for mdx mice myodystrophy therapy
  3372. … trial of Len/Dex induction followed by tandem mel140 with autologous blood Stem cell transplantation and Len maintenance versus continued therapy with Len/Dex in …
  3373. Gene and Stem cell therapy in erectile dysfunction
  3374. Stem cell therapy
  3375. Stem cell therapy in Articular Cartilage Injury
  3376. … in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for Stem–cell transplantation and as maintenance therapy
  3377. New directions in cardiac Stem cell therapy: An update for clinicians
  3378. Radiation burns and mesenchymal Stem cell therapy
  3379. Food allergy after cord blood Stem cell transplantation with tacrolimus therapy in two patients who developed veno-occlusive disease
  3380. … matrix metalloproteinase-3 or vascular endothelial growth factor transfection of aged human mesenchymal Stem cells enhances cell therapy after myocardial infarction
  3381. Adipose derived Stem cell therapy rescues delayed wound healing in chronic radiation injury
  3382. Stem cell therapy
  3383. Delivery strategies for Stem cell-based therapy
  3384. Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous Stem cell transplant salvage therapy for relapsed/refractory aggressive non …
  3385. Comment on ‘Stem–cell therapy for Peripheral Arterial Occlusive Disease’
  3386. Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral Stem cell transplantation in patients with …
  3387. New rising infection: human herpesvirus 6 is frequent in myeloma patients undergoing autologous Stem cell transplantation after induction therapy with …
  3388. Allogeneic Stem cell transplant for chronic myeloid leukemia as a still promising option in the era of the new target therapy
  3389. cell therapy for pulmonary arterial hypertension: potential efficacy of endothelial progenitor cells and mesenchymal Stem cells
  3390. Targeted delivery of vascular endothelial growth factor to enhance the Stem cell therapy in treating myocardial infarction in rats
  3391. Peripheral nerve regeneration after traumatic injury and Stem–cell therapy
  3392. Human induced pluripotent Stem cells derived hepatocytes: rising promise for disease modeling, drug development and cell therapy
  3393. Stem cell Research & therapy in 2012
  3394. Stem cell-derived microvesicles: a cell free therapy approach to the regenerative medicine
  3395. Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by high-dose melphalan and autologous Stem cell …
  3396. Long-term improvement of left ventricular function and infarct size after cardiac Stem cell therapy: 5-years follow-up of the MYSTAR study
  3397. POEMS syndrome treated with melphalan high-dose therapy and autologous blood Stem cell transplantation: a single-institution experience
  3398. 54: Early intracranial mesenchymal Stem cell therapy after a perinatal rat brain damage
  3399. Human Stem cell therapy
  3400. Safeguarding pluripotent Stem cells for cell therapy with a non-viral, non-integrating episomal suicide construct
  3401. Durable Infarct Size Reduction Due to Allogeneic Mesenchymal Stem cell therapy Regulates Whole-Chamber Left Ventricular Remodeling
  3402. 110 RAT BONE MARROW DERIVED MESENCHYMAL Stem cell therapy IN A PARKINSONIAN ANIMAL MODEL OF DETRUSOR OVERACTIVITY
  3403. Idiotype immunization following high-dose therapy and autologous Stem cell transplantation for non-Hodgkin lymphoma
  3404. Mesenchymal Stem cell therapy Comparing Bone Marrow And Adipose Tissue-Originated cells In A Murine Model Of Elastase-Induced Emphysema
  3405. I-131-Metaiodobenzylguanidine therapy with allogeneic cord blood Stem cell transplantation for recurrent neuroblastoma
  3406. Issue of transparency in Stem cell therapy
  3407. Stem cell therapy for Heart Failure
  3408. A REVIEW AND UPDATE ON THE CURRENT STATUS OF Stem cell therapy IN ROYAN INSTITUTE; INVITED SPEAKERS
  3409. Stem cell therapy for Type I Diabetes: 1811
  3410. … immune reconstitution following post-transplant cyclophosphamide and regulatory MHC cell therapy in recipients of mhc matched allogeneic hematopoietic Stem cell …
  3411. Bioethics and freedom of scientific research in gene therapy and Stem cell biology
  3412. Stem cell therapy and the Governance of Uncertainty
  3413. Stem cell therapy for nervous syStem diseases
  3414. … with R-CHOP or high dose sequential therapy with autologous Stem cell transplantation (R-HDS) for high risk diffuse large B-cell lymphomas patients: results of the …
  3415. cell therapy with adipose tissue-derived Stem/stromal cells for elastase-induced pulmonary emphysema in rats
  3416. … with Two Cycles of Induction therapy with Bortezomib and Dexamethasone Followed by Bortezomib-High Dose Melphalan Conditioning and Autologous Stem cell …
  3417. Regulatory questions in the development of blood Stem cell products for regenerative therapy
  3418. Treatment of splenic marginal zone lymphoma of the CNS with high-dose therapy and allogeneic Stem cell transplantation
  3419. Autologous Stem cell therapy for Diabetes: an exciting new frontier opens
  3420. Gap junctions, Stem cells, and cell therapy: Rhythmic/arrhythmic implications
  3421. The Use of Stem cell therapy in Treating Diabetes Mellitus
  3422. T cell and B cell immunity can be reconstituted with mismatched hematopoietic Stem cell transplantation without alkylator therapy in artemis-deficient mice …
  3423. Stem cell therapy in Parkinson’s disease.
  3424. Stem cell therapy for inflammatory bowel disease
  3425. Stem cell therapy in experimental type I diabetes in rats
  3426. Autologous hematopoietic Stem cell transplantation versus intravenous pulse therapy cyclophosphamide for severe or rapidly progressive syStemic sclerosis, the …
  3427. Omics in Stem cell therapy: The Road Ahead
  3428. Stem cell therapy: Way to new era of regenerative dentistry
  3429. Stem cell therapy in stroke: Where are we now?
  3430. Developmental Strategy for Stem cell therapy Products in Regulatory Considerations
  3431. Stem cell therapy for erectile dysfunction
  3432. 5. Stem cell therapy
  3433. Clinically relevant issues in cardiac Stem cell therapy
  3434. MRI-Guided Stem cell therapy
  3435. Umbilical cord blood Stem cell transplantation combined with mouse neural growth factor application and physical rehabilitation therapy for infantile cerebral palsy
  3436. Autologous Stem cell therapy combined with exon skipping
  3437. Do elderly myeloma patients benefit from high dose therapy (HDT) and autologous Stem cell transplant (ASCT)?: A comparative survival analysis using SEER Registry
  3438. Apelin 13: a novel approach to enhance efficacy of hypoxic preconditioned mesenchymal Stem cells for cell therapy of diabetes
  3439. Stem cell therapy and Tooth Regeneration-A Review.
  3440. Stem cell therapy in the context of chronic liver disease: Promise and pitfalls
  3441. Determining duration of HER2-targeted therapy using Stem cell extinction models
  3442. Stem cell based therapy for muscular dystrophies: cell types and environmental factors influencing their efficacy
  3443. Gene therapy and Stem cell therapy in chronic wound healing
  3444. Bone Marrow-Derived Stem cell therapy for Myocardial Infarction
  3445. Stem cell therapy Improves Critical Limb Ischemia
  3446. Stem cell therapy for Spinal Cord Repair: A Current Status Report
  3447. Is There a Role for Stem cell therapy for Overactive Bladder?
  3448. First line therapy for patients with newly diagnosed multiple myeloma ineligible for autologous Stem cell transplantation: a syStematic review and meta-analysis …
  3449. Parkinson’s disease and mesenchymal Stem cells: potential for cell-based therapy
  3450. The Medical Nutrition therapy Provided to Adult Patients Undergoing Hematopoietic Stem cell therapy
  3451. Cardiac Stem cell therapy for heart failure
  3452. Design guidelines for an umbilical cord blood Stem cell therapy quality assessment model
  3453. Stem cell therapy and Stress Response in Pancreas and Intestine
  3454. Stem cell-based cellular therapy in rheumatoid arthritis
  3455. Autologous Stem cell therapy to treat chronic ulcer in heifer-A case study
  3456. Cardiac Stem and progenitor cell biology and therapy
  3457. Development of Multi-functional Stem cell Delivery SyStems for Cardiac therapy
  3458. … in Recipients of T cell Depleted (TCD) Allogeneic Hematopoietic Stem cell Transplants (HSCT) Is Mostly Related to Viral Infections and Anti-Viral therapy.
  3459. Stem-like cells and therapy resistance in squamous cell carcinomas
  3460. Stem cell therapy IN CHRONIC ISCHEMIC CARDIOMYOPATHY: A META-ANALYSIS
  3461. A Journey into the World of Targeted therapy: A Review of Gene therapy, Stem cell therapy, and cell Reprogramming in Cardiovascular Medicine
  3462. 137 Stem cell therapy for HIV Disease
  3463. Dynamics of Myocardial Perfusion in Patients with Coronary Heart Disease and Post-infarction Cardiosclerosis After Stem cell therapy
  3464. Scepticism in medicine, organ transplantation, gene and Stem cell therapy
  3465. Clinical correlate: Stem cell therapy for craniofacial bone regeneration
  3466. Neural Stem cells derived from iPSCs represent a safe and effective source for Stem cell therapy in experimental autoimmune encephalomyelitis
  3467. … index for overall survival in patients treated with novel agents-based induction therapy and front-line autologous Stem cell transplantation, and allow the …
  3468. Response to Comment on ‘Stem–cell therapy for Peripheral Arterial Occlusive Disease’
  3469. Current Status of Stem cell therapy for Cochlear Hair Regeneration
  3470. Effects of Stem cell therapy on amiodarone-induced liver injury in albino rats
  3471. cell therapy for opportunistic infection and recurrent disease following allogeneic Stem cell transplantation
  3472. Human amniotic epithelial cells as a reliable source for diabetes Stem–cell therapy
  3473. Salvage T cell therapy for therapy Resistant Viral Diseases After Stem cell Transplantation
  3474. Effect of Stem cell therapy on amiodarone-induced liver injury in albino rats
  3475. Optimal Administration Routes for Adipose-Derived Stem cell therapy in Ischemic Flaps
  3476. Stem cells in Normal and Malignant Breast Tissue: Is P-Cadherin a Stem cell Marker and a Possible Target for Cancer Stem cell therapy?
  3477. Chemoprotection in brain tumor patients: another success for Stem cell gene therapy
  3478. Long-term outcome of second allogeneic hematopoietic Stem cell transplantation as salvage therapy for young patients after relapse or graft failure: experience …
  3479. Bone marrow mesenchymal progenitor and Stem cell biology and therapy
  3480. Stem cell therapy in Alzheimer’s Disease Models: Neurogenesis Versus Trophic Support
  3481. Dual Stem cell therapy Using Fetal Cardiac Progenitor cells with EPCs Enhances Benefit in an Acute Myocardial Infarction Model
  3482. Safety, Feasibility and Signal of Activity of Intra-carotid Allogenic Mesenchymal Stem cell therapy in a Large Animal Stoke Model
  3483. 565. Mechanisms of Stem cell therapy in Cystinosis Treatment
  3484. Diffusion Tensor Imaging Biomarkers of Stem cell therapy Efficacy in Pediatric Cerebral Palsy
  3485. Radioisotope-antibody conjugates selectively target bone marrow prior to Stem cell therapy
  3486. … infusions induce sustained clinical remissions and tumor specific immunity in a series of patients with relapsed Hodgkin lymphoma after allogeneic Stem cell …
  3487. Immune Mechanisms of Mesenchymal Stem cell therapy for Acute Graft versus Host Disease
  3488. Stem cell therapy FOR MYOCARDIAL REGENERATION OF HUMAN cells USING SPECIAL RECEPTOR MARKERS CD45, CD34
  3489. Derivation of Human Fetal Induced Pluripotent Stem (iPS) cells Using a Non-Integrating Sendai Virus Vector: Implications for Fetal Stem cell therapy
  3490. Mesenchymal Stem cell therapy Prolongs Corneal Allograft Survival in Rats
  3491. Effects of Embryonic Neural Stem cell therapy on DNA Damage Products in Urine and Tissue After Spinal Cord Injury in Rats
  3492. Survival Advantage of cell therapy Over Cytotoxic therapy Alone in Adult Patients with Relapsed AML After Allogeneic Hematopoietic Stem cell …
  3493. Lenalidomide Is Effective therapy for Relapse After Allogeneic Stem cell Transplant for Multiple Myeloma.
  3494. Mesenchymal Stem cell therapy for Nerve Regeneration and Immunomodulation after Composite Tissue Allotransplantation
  3495. MRI Monitored USPIO-Labelled Intracardial Stem cell therapy in Acute Myocardial Infarct, Imaging Features with Pathologic Correlation in Porcine Model
  3496. Immediate Mesenchymal Stem cell therapy Provides Greater Attenuation of Myocardial Injury Than Deferred Treatment in Rats After Acute Myocardial Infarction
  3497. Intra-Carotid Mesenchymal Stem cell therapy is Superior to Intravenous delivery in Rat Model of Cerebral Ischemia
  3498. … hematopoietic Stem cell transplantation for primary and secondary myelofibrosis a retrospective, multicenter study of the Kanto Study Group for cell therapy (KSGCT)
  3499. Intravenous Autologous Bone Marrow Derived Stem cell therapy for Patients with Subacute Ischemic Stroke (InVeST): A Multi-Centric Randomized Controlled Trial
  3500. Adipose Stem cell therapy in Mice on Repetitive Intratracheal Bleomycin Induced Pulmonary Fibrosis
  3501. LOP40: Allogeneic Mesenchymal Stem cell therapy Improves Burn Wound Healing via a Predominantly Paracrine Mechanism and Is Associated with Increased …
  3502. Temporal Profiling of Immune-Related Cytokines after Intravenous Administration of Mesenchymal Stem cell therapy in Cerebral Ischemia in Mice
  3503. Adipose Stem cell therapy in mice on repetitive intratracheal bleomycin induced pulmonary fibrosis
  3504. Allogeneic Stem cell transplantation for FLT3/ITD positive acute myeloid leukemia in CR1: implication for personalized therapy to prevent early relapses
  3505. Mesenchymal Stem cell therapy with Co-Stimulation Blockers Prolonged Marginal Mass of Islet Graft Survival in Allogeneic Murine Model: 2122
  3506. High-Dose therapy and Autologous Stem cell Transplantation for Extra-Nodal NK/T Lymphoma in Western Patients; A Study From the European Group for …
  3507. … related mortality after brentuximab vedotin salvage therapy followed by reduced intensity conditioning regimen allogeneic Stem cell transplantation (RIC-ALLO …
  3508. Bottlenecks of the clinical development of pluripotent Stem cell based therapy
  3509. … (allo-CST) for poor risk cytogenetic IPSS myelodysplastic syndrome (PRC-MDS): A report from the French Society of Stem cell Transplantation and cell therapy …
  3510. … therapy with interferon-α in combination with donor lymphocyte infusion for high risk acute leukemia patients who relapsed after allogeneic hematopoietic Stem cell …
  3511. Impact of pitavastatin pretreatment on survival and functional activities of mesenchymal Stem cell: possible implication for cell transplantation therapy
  3512. Lung progenitor and Stem cell biology and therapy
  3513. Intensive induction, autologous Stem cell transplantation and rituximab maintenance has changed event free survival and overall survival in mantle cell …
  3514. … , Stem cell therapy has been one of the most promising treatments for Alzheimer’s disease patients. This article aims to summarize the current progress in the Stem cell …
  3515. Biomarkers Related with Tumor Formation of Stem cell-based therapy Products using hESC
  3516. 736 Urine derived Stem cells with high telomerase activity for cell based therapy in urology
  3517. Renal progenitor and Stem cell biology and therapy
  3518. 026 Stem cell Based-therapy Using the Chitosan-Phosphorycholine Biopolymer
  3519. Allogeneic Stem cell transplantation versus conventional postremission therapy for acute myeloid leukemia in first complete remission: a matched pairs …
  3520. Stem cell replacement therapy as a potential treatment for SCA1 disease
  3521. Lentiviral Vector Mediated Haematopoietic Stem cell Gene therapy For Mucopolysaccharidosis Type IIIA
  3522. From Empirical Toward Preemptive Antifungal therapy for Patients With Hematological Malignancies and Hematopoietic Stem cell Transplant Recipients.
  3523. Adipose tissue-derived Stem cell biology and therapy
  3524. Stem cell-based gene therapy in HIV treatment
  3525. Successful autologous Stem cell collection with filgrastim and plerixafor after long-term lenalidomide therapy for multiple myeloma
  3526. Genitourinary progenitor and Stem cell biology and therapy
  3527. Auditory progenitor Stem cell biology and therapy
  3528. cell therapy Using Adipose-Derived Stem cells for Chronic Liver Injury in Mice
  3529. Prolonged hypogammaglobulinemia after rituximab therapy for post-transplant EBV-lymphoproliferative disorder following hematopoietic Stem cell …
  3530. cell-free derivatives from mesenchymal Stem cells are effective in wound therapy
  3531. Amniotic fluid Stem cells: a promising therapeutic resource for cell-based regenerative therapy
  3532. Oral cavity progenitor and Stem cell biology and therapy
  3533. Advances in Stem cell transplantation and gene therapy in the ß-hemoglobinopathies
  3534. Assessment of the Effect of Nilotinib (Tasigna) Maintenance therapy After Allogeneic Stem cell Transplantation in Patients with Advanced CML and Ph+ ALL On …
  3535. Early Consolidation with High Dose therapy and Autologous Stem cell Transplantation in HIV-Associated Non Hodgkin Lymphoma At High Risk (Aaipi 2–3) …
  3536. Stem cell-Based therapy for Lysosomal Storage Diseases
  3537. Human bone marrow-derived mesenchymal Stem cell: a source for cell-based therapy
  3538. Combination antifungal therapy in hematopoietic Stem cell transplantation patients
  3539. High-dose therapy with autologous Stem cell support for lymphoma–from experimental to standard treatment 1735–9
  3540. Salvage therapy with azacitidine increases regulatory T cells in patients with AML or MDS and early relapse after allogeneic blood Stem cell transplantation
  3541. High-dose therapy with autologous Stem cell support for lymphoma in Norway 1987–2008 1704–9
  3542. Umbilical cord blood (UCB) progenitor and Stem cell biology and therapy
  3543. Adult Stem cell-based therapy for degenerative joint diseases
  3544. Cancer Research, Molecular and cell Biology: Look at the Nanotechnology, Based Nanoparticles for Diagnostics, and therapy. Stem cell for Treatment of Cancer …
  3545. Role of Front-Line High Dose therapy with Stem cell Transplant in Peripheral T-cell Lymphomas. A Single Center Experience.
  3546. Advanced therapy: New Treatment Development Based on Cancer Stem cell Theory
  3547. Parthenogenetic embryonic Stem cells with H19 siRNA-mediated knockdown as a potential resource for cell therapy
  3548. Photodynamic therapy Triggers Expression Of Haemopoietic Stem cell Marker Cd34 Of Keratocytes
  3549. Induced Pluripotential Stem cells and the Prospects for Cardiac cell therapy
  3550. Novel method for delivery of Stem cell-derived growth factors for heart therapy applications:«In vitro» and «In vivo» analysis
  3551. A way out or a new prospect: The future development of autologons hematopoietic Stem cell transplantation in type 1 diabetes therapy
  3552. 301 THE VOMERONASAL ORGAN AS A NEW SOURCE OF Stem cells FOR cell therapy
  3553. Multicenter Study Evaluating the Impact of Hypomethylating Agents As Bridging therapy to Hematopoietic Stem cell Transplantation in Myelodysplastic Syndromes
  3554. Improved lentiviral vectors for haematopoietic Stem cell gene therapy of Mucopolysaccaridosis type IIIA
  3555. Reprogramming and Characterization of Cord Blood Derived Stem cells by Synthetic mRNAs: Potential for Cord Blood Stem cell Regenerative therapy
  3556. Neural Stem cell Proliferation Surrounding the Area of Traumatic Brain Injury: Role of Exercise therapy
  3557. Bone marrow mesenchymal Stem cell transplantation combined with gene therapy for treatment of ischemic cerebrovascular disease
  3558. Risk of Nausea and Vomiting in Patients with Lymphoma Undergoing High Dose therapy with Autologous Stem cell Rescue
  3559. … Combining Yttrium-90 Ibritumomab Tiuxetan and High Dose therapy with Stem–cell Transplantation in Poor Risk Patients with Diffuse Large B-cell …
  3560. … Collection in Adult Thalassemic Patients: Towards the Assessment of the Suitable Hematopoietic Stem cell Source for Gene therapy of Beta-Thalassemia.
  3561. Long-term follow-up of HCV infected hematopoietic Stem cell transplant patients and effects of antiviral therapy
  3562. … Stem cell-LIKE cells DETERMINE A THERAPEUTIC MODEL IN BREAST CANCER PATIENTS WHEN ANY OTHER RECOMMENDED therapy FAILED …
  3563. A Qualitative Study Utilizing Grounded Theory: themes Expressed Throughout Art therapy Interventions with Siblings of Pediatric Hematopoietic Stem cell …
  3564. … ) for Stem cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem cell Transplantation Following a Lenalidomide Based Initial therapy
  3565. Patient-derived xenografts of non small cell lung cancer: resurgence of an old model for investigation of modern concepts of tailored therapy and cancer Stem …
  3566. Long term impact of prior rituximab therapy, early lymphocyte recovery on autologous Stem cell transplant outcome for diffuse large B cell lymphoma
  3567. In Vivo Confocal Microscopy Analysis and Image-Guided therapy of Limbal Stem cell Insufficiency
  3568. Retrospective Review of Dpace therapy as a Salvage Regimen in Patients with Relapsed Multiple Myeloma Prior to Autologous Stem cell Transplant
  3569. Successful Scale-Up and Quality Assessments of Human Embryonic Stem cells for cell therapy: Challenges and Overview
  3570. Correction: High-Dose Chemotherapy Followed by Autologous Stem cell Transplantation as a First-Line therapy for High-Risk Primary Breast Cancer: A Meta …
  3571. Autologous haematopoietic Stem–cell transplantation in refractory coeliac disease type II patients unresponsive to cladribine therapy
  3572. Feasibility and Outcome of High Dose therapy Followed by Autologous Stem cell Transplantation in Relapsed/Refractory Lymphoma in the Geriatric …
  3573. Replacement of Degraded Articular Cartilage Using Stem cell-based therapy in Rabbit Model of Osteoarthritis
  3574. Human embryonic Stem cell-derived endothelial cells as cellular delivery vehicles for targeting therapy of metastatic breast cancer
  3575. Molecular Monitoring and Stepwise Preemptive therapy to Prevent Epstein-Barr Virus-Associated Diseases After Allogeneic Hematopoietic Stem cell …
  3576. Pilot study of MAGE-A3 protein vaccination and autologous Stem cell transplantation (autoSCT) as consolidation therapy for multiple myeloma (MM).
  3577. Adjuvant Stem cell‐based therapy in acute retinal injury after sodium iodate administration in mice
  3578. High-Dose therapy and Autologous Stem cell Transplantation for Multiple Myeloma: Analysis from Registry of Monoclonal Gammopathy of Czech Myeloma …
  3579. Characterization of BDNF blended chitosan scaffolds for human umbilical cord mesenchymal Stem cell transplants in TBI therapy
  3580. Enzyme replacement therapy and/or hematopoietic Stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European …
  3581. … Treatment of Low-Dose Lenalidomide Maintenance therapy Followed by Second Autologous Peripheral Blood Stem cell Transplantation in Heavily Treated …
  3582. The role of uPAR in inducing a cancer Stem cell-like phenotype in breast cancer and allowing cells to develop endocrine therapy resistance
  3583. Cidofovir Is a Highly Effective and Safe Salvage therapy in Ganciclovir Resistant Cytomegalovirus Reactivation Following Allogeneic Haematopoietic Stem cell …
  3584. Decitabine in Combination with Donor Lymphocyte Infusion as Salvage therapy for Relapsed AML Post-Allogeneic Stem cell Transplantation
  3585. Nilotinib (Tasigna) therapy Post Allogeneic Stem cell Transplantation (AlloSCT) for Advanced (> CP1) Chronic Myeloid Leukemia (CML) and Ph+ Acute …
  3586. Bortezomib-Based Induction therapy Followed by High-Dose Chemotherapy and Autologous Stem cell transplantation in Newly-Diagnosed Myeloma: Initial Report …
  3587. THE CARDIOELECTRICAL ACTIVITY STUDY FOR therapy OF SARCOPLASMIC RETICULUM CA2+-ATPASE GENE MODIFIED BONE MARROW Stem cell …
  3588. … Clofarabine Pre-Conditioning Prior to Full Intensity or Reduced Toxicity Allogeneic Stem cell Transplantation: A Promising New therapy for the Treatment of …
  3589. Cost analysis comparing intensified chemotherapy alone to myelo-ablative therapy followed by autologous Stem cell rescue in newly diagnosed patients with …
  3590. Maintenance Hypomethylating therapy Post Allogeneic Stem cell Transplantation Provides Favorable Progression Free Survival in High Risk Acute Myelogenous …
  3591. Low Dose Azacitidine Maintenance therapy Following Allogeneic Stem cell Transplantation for MDS/AML Does Not Interact with Tacrolimus Dosing or …
  3592. … Impact of Recipient and Donor CMV Serostatus in Acute Leukemia Patients After Allogeneic Stem cell Transplantation At the Era of Preemptive therapy.
  3593. … Myeloablative Allogeneic Hematopoietic Stem cell Transplantation in Patients with Multiple Myeloma Relapsing After a First High Dose therapy in the Era of …
  3594. RESIDUAL DORMANT CANCER Stem cell FOCI ARE RESPONSIBLE FOR TUMOR RELAPSE AFTER ANGIOGENIC METRONOMIC therapy IN …
  3595. … ≤ 12 Months for Early Relapsed and Refractory Follicular Lymphoma Is Predictive of Early Failures Post-High Dose therapy and Autologous Stem cell …
  3596. … Following Risk Adapted Stem cell Transplant (SCT) in SyStemic Light-Chain Amyloidosis (AL) Using Bortezomib and Dexamethasone as Consolidation therapy
  3597. Thiotepa (Tt), Busulfan (Bu), and Clofarabine (Clo) as a Conditioning therapy for Allogeneic Hematopoetic Stem cell Transplant for Patients with High Risk …
  3598. … ) Chronic Myeloid Leukemia (CML) Patients (pts) After Surviving 5 Years of Initial therapy with Interferon Alpha (IFN), Imatinib (IMA) or Allogeneic Stem cell …
  3599. … IMRT During Partial Brain Radiation therapy for High-Grade Gliomas With and Without Selective Sparing of the Hippocampus, Limbic Circuit, and Neural Stem cell …
  3600. LC, Acute: O-056; The evaluation of effectiveness and safety for new therapy with bone marrow derived autologous mesenchymal Stem cell for hepatic failure caused …
  3601. Expression of heme oxygenase-1 in cardiac Stem cells enhances the efficacy of cell therapy for attenuating left ventricular dysfunction and remodeling after myocardial …
  3602. Sarcomas as a mise en abyme of mesenchymal Stem cells: exploiting interrelationships for cell mediated anticancer therapy
  3603. Induced pluripotent Stem cells and the prospects for cardiac cell therapy.
  3604. CANINE MESENCHYMAL Stem cells FROM VISCERAL AND SUBCUTANEOUS ADIPOSE TISSUE FOR cell-BASED therapy
  3605. Hematopoietic progenitor and Stem cells circulate by surfing on intracellular Ca2+ waves: A novel target for cell-based therapy and anti-cancer treatment?
  3606. Generation of Tumor Free Induced Pluripotent Stem cells for Safe cell Based therapy
  3607. Pluripotent Stem cells for cell replacement therapy of diabetes
  3608. Human embryonic Stem cells as a source for cell replacement therapy in diabetes
  3609. cell-based therapy options for osteochondral defects. Autologous mesenchymal Stem cells compared to autologous chondrocytes
  3610. LCA Gene therapy In Somatic-cell-Derived Induced Pluripotent Stem cells
  3611. cell based gene therapy using mesenchymal Stem cells and vascular endothelial growth factor in ischemic heart disease rat model
  3612. Targeted gene correction of spinal muscular atrophy induced pluripotent Stem cells and motoneurons as cell source for therapy
  3613. Stem cell therapy market
  3614. Mesenchymal Stem cell therapy for heart disease
  3615. Progress in Stem cell therapy for major human neurological disorders
  3616. Stem cell therapy without the cells
  3617. Stem cell therapy: a clinical trial of stroke
  3618. Cardiopoietic Stem cell therapy in heart failure: the C-CURE (Cardiopoietic Stem cell therapy in heart failURE) multicenter randomized trial with lineage-specified …
  3619. Large animal models for Stem cell therapy
  3620. Progress and prospects in Stem cell therapy
  3621. Stem cell therapy to cure type 1 diabetes: from hype to hope
  3622. Cardiac Stem cell therapy and the promise of heart regeneration
  3623. Mesenchymal Stem cell therapy in skin: why and what for?
  3624. Stem cell therapy for heart failure
  3625. Advances in Stem cell therapy against gliomas
  3626. Hematopoietic Stem cell therapy for multiple sclerosis: top 10 lessons learned
  3627. Meta-analysis of Stem cell therapy in chronic ischemic cardiomyopathy
  3628. Stem cell therapy: an exercise in patience and prudence
  3629. Cardiac Stem cell therapy to modulate inflammation upon myocardial infarction
  3630. Macrophage subpopulations are essential for infarct repair with and without Stem cell therapy
  3631. The rabbit as a model for studying lung disease and Stem cell therapy
  3632. Adverse effect of high glucose concentration on Stem cell therapy
  3633. Stem cell therapy for craniofacial bone regeneration: a randomized, controlled feasibility trial
  3634. Mesenchymal Stem cell therapy in diabetes mellitus: progress and challenges
  3635. Stem cell therapy for human cartilage defects: a syStematic review
  3636. Stem cell therapy in bladder dysfunction: where are we? And where do we have to go?
  3637. Stem cell therapy for acute cerebral injury: what do we know and what will the future bring?
  3638. Human umbilical cord mesenchymal Stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy
  3639. Stem cell therapy for lower extremity diabetic ulcers: where do we stand?
  3640. Priming mesenchymal Stem cells boosts Stem cell therapy to treat myocardial infarction
  3641. Stem–cell therapy for erectile dysfunction
  3642. Mesenchymal Stem cell therapy in lung disorders: pathogenesis of lung diseases and mechanism of action of mesenchymal Stem cell
  3643. Mesenchymal Stem cell therapy for cardiac inflammation: immunomodulatory properties and the influence of toll-like receptors
  3644. Familial occurrence of pulmonary embolism after intravenous, adipose tissue-derived Stem cell therapy
  3645. Perspectives of Stem cell therapy in D uchenne muscular dystrophy
  3646. Stem cell therapy for pediatric dilated cardiomyopathy
  3647. Rationale of mesenchymal Stem cell therapy in kidney injury
  3648. Stem cell therapy in stroke: a review literature
  3649. Mesenchymal Stem cell therapy in horses: useful beyond orthopedic injuries?
Related Posts

Neuroplasticity

BCL-2

Adipocyte Dedifferentiation (the Reversal of Fat Formation)

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

0
    0
    Your Cart
    Your cart is emptyReturn to Shop
    Continue Shopping